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Abstract 
The incorporation of a propargyl group to a natural product 
target allows for a streamlined approach to the investigation of 
structure activity relationships (SARs) and target identification 
in forward chemical genetics programmes using a ‘click’-based 
approach. To this end, an efficient synthesis of O-propargylated tyrosine derivatives was 
designed, and these have been used in the construction of peptide motifs both (a) derived 
from phage display libraries and (b) found in natural products. 
The L-tyrosine derivative Y* (compound I, X=H, R=H) was incorporated into a peptide 
sequence, PTTIYY, which is known to prevent the inhibition of p53 by the AG-2 protein. Y* 
has been included as both the terminal and the internal tyrosine in the peptide sequence. 
ELISA assays were carried out to determine how the binding of PTTIYY* and PTTIY*Y to 
AG-2 compared to that of the un-marked PTTIYY sequence. The results of these assays 
allowed new conclusions to be drawn regarding the important binding features of the peptide 
and possible sites for further optimisation of the AG-2 binding properties of this peptide 
through ‘click’ functionalisation of the modified tyrosine. The binding of the peptides 
incorporating Y* was also assessed using MCF-7 breast cancer cell lysate, known to contain 
the AG-2 protein.  These results confirmed those seen for the purified AG-2 ELISA. 
The related bromo-D-tyrosine derivative (compound I, X=Br, R=Me) has been prepared and 
employed towards the synthesis of a bisebromoamide derivative. Bisebromoamide is a newly 
discovered polypeptide, and a promising anti-cancer agent. The bisebromoamide derivative 
contains a thiazole unit (Tzl), two N-methylated amino acids, and an oxopropyl pyrrolidine 
(Opp) moiety, which is unique to bisebromoamide in natural products. The activity of this 
bisebromoamide derivative will be investigated via ‘click’-based affinity chromatography 
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Chapter 1 Introduction: p53 as a Drug Target 
1.1. Chemical Genetics 
Chemical genetics is an increasingly important line of research in several areas of 
science. It spans the interface between chemistry, biology and medicine. A simple 
definition of chemical genetics describes that the function of a protein can be altered 
using a small molecule.
1,2,3
 This can be expanded to highlight the main differences 
between chemical genetics and classical genetics. Where classical genetics uses 
mutations of genes to affect changes to the proteins they express, and time is taken 
for this mutation’s effects to be seen, in chemical genetics, the effect is instant.
4
 This 
is because the protein itself is directly influenced by a small molecule, rather than the 
gene that expresses that protein.  
Chemical genetics can be used to identify which proteins regulate different biological 
processes, to help understand how proteins perform their biological functions. The 
ability to change the function of a protein is vital in understanding diseases and in the 
development of new treatments and prophylaxes.  
There are two approaches, forward and reverse, to the alteration of protein function 
by chemical genetics. A comparison between forward and reverse approaches for 
chemical genetics is described in figure 1.
5
 
Forward chemical genetics can be carried out with a plate containing many wells of 
cells.
2,3,6,7
 To each well a solution of a different small molecule is added. The cells 
are then observed to see which shows the resultant phenotype of interest. The small 
molecule in the well in which this phenotype is seen is known, allowing the protein 
that it targeted to be identified. This is often an arduous process.
2,6,8
 A starting point 
for development of a new active pharmaceutical ingredient can then be developed 
based on this identification. 
Conversely, reverse chemical genetics takes one specific protein, which is then 
screened to find a suitable small molecule or ligand to bind, and then the protein-
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Figure 1. Comparison of Forward and Reverse Chemical Genetics. 
5 
For both forward and reverse chemical and classical genetics to affect these changes 
in the proteins, they require a variety of small molecules to be synthesised. 
 
1.2. Library Strategies for Chemical Genetics Screens 
1.2.1. Library Synthesis 
Small molecule library synthesis is a well used general protocol for making a large 
number of often similar molecules. It is frequently carried out to screen for activity 
of the molecules for a desired target gene product alteration. Once the molecule 
Tyrosine Derivatives and their Anti-Cancer Applications 
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within the library which caused the effect, the “hit”, has been identified, a commonly 
challenging deconvolution process of re-synthesis can follow for the effective library 
member and molecular probe to be successfully and efficiently synthesised (Figure 2, 
Step 5).
9
 The structure of the molecular probe will be based on the active library 
member with a tag incorporated. The tag will usually allow incorporation of a biotin 
moiety or a photo- or radio-active label to allow visualisation of the site of 
interaction of the library member with the biological target, which can then also be 
identified. 
Once the molecular probe has been synthesised, it must then be re-screened to ensure 
the library member is still active with the incorporated tag (Figure 2, Step 6).
9
 Often 
it is the case that the synthesis to include the tag has altered the molecule’s 
properties, so that it is no longer active, so the design of the molecular probe must 
begin again. It is clear that this process can be quite laborious. 
 
 
Figure 2. Traditional Approach to Chemical Library Synthesis.
9
 
As a result of these challenges there are currently very few published successful 
target identifications for chemical genetics screens, despite many research groups 
working in this area. The Hulme group has experienced these difficulties in recent 
work whilst trying to screen for activity of anisomycin and a small library of its 




Tyrosine Derivatives and their Anti-Cancer Applications 
Introduction: p53 as a Drug Target 
   
4 
1.2.2. “Marked” Libraries 
Synthesising a marked library of small molecules offers an accelerated method to 
identify “hit” compounds. If the library members can all be synthesised to include a 
small bio-compatible marker, a tag with a complementary functional group can then 




Figure 3. Marked Approach to Chemical Library Synthesis.
9 
This approach would allow the dynamic identification of the “hit” compound, the 
biological target, and cut out the time-consuming molecular probe synthesis step. As 
shown in the timeline from the American National Institutes of Health (NIH) (Figure 
4), this has the potential to reduce the drug development process by approximately 
one year.
10
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Figure 4. NIH Drug Development Timeline.
10
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This “marked” approach is quite new for the generation of small molecule libraries. 
However, it has been shown to work well for several kinds of biomolecules.
7,11
 
Marked sugars and amino acids have been successfully synthesised and incorporated 
into carbohydrates and peptides, which have then been fluorescently tagged via the 
marker. Markers used have included various functional groups which allow 
convenient complementary function on a fluorescent portion, making use of the 





1.2.3. Anisomycin Precedent 
There are very many fermentation products obtained from various Streptomyces 
species.
15
 One compound which has been of particular interest to the Hulme group is 
anisomycin. It has been shown to have a wide range of roles within organisms. These 
roles include acting as an antibiotic,
16
 an antifungal agent,
17





 and as a tool for the activation of the stress activated protein 
kinase (SAPK) pathway.
9
 It is this latter activity which the Hulme group has 
concerned some of its research with.
19
 The target by which anisomycin activates the 
SAPK pathway is as yet unknown. A small library of anisomycin derivatives were 
synthesized, many containing markers that might be used in biological studies to find 
binding partners.
20
 Two examples are shown in figure 5. 
 
Figure 5. Anisomycin Derivatives from Hulme Group Marked-Anisomycin Library.
20
 
These marked library members have been shown to have equal activity in the SAPK 
pathway compared to anisomycin itself.
19
 This demonstrates that a natural product 
can be marked successfully, whilst retaining biological activity, and the concept can 
be further pursued. 
Tyrosine Derivatives and their Anti-Cancer Applications 
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1.3. Choosing a Bioorthogonal Marker 
Tagged, or marked amino acids and sugars have been previously synthesised and 
successfully incorporated into peptides, glycans and lipids.
7
 Generally, markers are 
required to be small so the risk of them causing steric hindrance to the binding of the 
biomolecule is minimised. Other requirements are that they are very selective 
chemically to avoid unintended side reactions of the marker, and that they are stable 
under physiological conditions to avoid decomposition. There are several main 
examples of functional groups which have been successfully utilised in this way, 





































Table 1. Common Choices for Bio-Orthogonal Markers.
7
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1.3.1. Aldehydes and Ketones 
Aldehydes and ketones have been commonly used in marking proteins and 
glycans.
7
 These functional groups contain few atoms and are mildly electrophilic. 
They are non-native to proteins and glycans, yet can easily be introduced into these 
and other macromolecules, and are inert in these surroundings. It might be expected 
that the carbonyl function of the aldehyde or ketone could react with any primary 
amine present, and form a Schiff base. A primary amine could be present on the side 
chain of any protein present in a cell, for example, proteins containing asparagine, 
glutamine, lysine or arginine. However, an equilibrium exists between the carbonyl 
group and Schiff base, and in aqueous conditions, as it would be inside a cell, this 
equilibrium favours the carbonyl form. 
Aldehydes and ketones are useful as markers when carrying out in vitro 
investigations, however, it is somewhat more complicated for in vivo studies. The 
optimum pH for them to be attached to their complimentary tagging partners is lower 
than physiological pH, and is often impossible to achieve in cells whilst maintaining 
life. When using whole organisms for trials the physiology is much more 
complicated. Aldehydes and ketones are often seen as products of metabolism, 
therefore where these compounds are used as tags, they may be excreted before they 
can carry out their intended function. 
Ketones were successfully used by Sadamoto’s group, to mark bacterial cell wall 
precursors, and then coupled a hydrazine containing fluorophore for visualisation.
26
 
Aldehydes and ketones can therefore be very effective as reporters for some large 
biomolecules, but they should be selected when studying extracellular environments 
or proteins and glycans involved in cell surfaces to avoid issues of metabolism and 
pH. 
 
1.3.2. Azides and Phosphines 
Azides are much more suitable as general markers. They have been used as tags in 
three classes of biomolecules; proteins, glycans and lipids, they are not present in 
these biomolecules, and they have not been found present in any living thing to date, 
Tyrosine Derivatives and their Anti-Cancer Applications 
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except one kind of algae.
7
 Azides are kinetically stable, but due to the large amount 
of energy harboured in their structure, they can be conveniently reacted with other 
bioorthogonal compounds in selective labelling of biomolecules. Like aldehydes and 
ketones, azides are mildly electrophilic, but in contrast they require soft nucleophiles 
and harsh conditions in order to react, which is highly unlikely to be supportable 
within a cell, unless catalysed by some component already present. In certain forms, 
azides can be toxic, but as an organic azide, and under the mild physiological 
conditions of a cell, they have been shown to be safe, and are even present in some 
drug molecules such as azido-thymidine, AZT (Figure 6), a nucleoside reverse 
transcriptase inhibitor (NRTI). AZT is an inhibitor of HIV-1, delaying the 




Figure 6. Structure of HIV-1 Inhibitor, AZT.
28
  
The complimentary partners most often used with azides are either phosphines or 
alkynes. Both of these functional groups are foreign to the physiological 
environment, but generally stable under these conditions, and will react with the 
azide. Phosphines can react with azides via Staudinger ligation to form a stable 
amide linked product as shown in scheme 1, and this can take place at physiological 
pH.
29
 This approach was discovered by Bertozzi and co-workers in 2000. An azide 
was attached to sialic acid, which was then incorporated into the cell surface of 
interest. The azide reacted selectively with a biotinylated triarylphosphine the group 
had synthesised, allowing visualisation of the cell. 
 
 
Scheme 1. Staudinger Ligation. 
Tyrosine Derivatives and their Anti-Cancer Applications 
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One potential drawback of using a phosphine as the complimentary marker is that it 
would be susceptible to oxidation by enzymes or just in the presence of air. With this 
in mind, it would require an excess amount of the phosphine-probe to ensure that 





1.3.3. Azides and Alkynes 
Activated alkynes can be employed as the reactive partner for an azide tag via the 
Huisgen 1,3-dipolar cycloaddition reaction. The azide and alkyne react together to 
form a stable 1,2,3-triazole ring. All three of these species are unusual in a cellular 
environment, yet biocompatible.
7
 This reaction used to require high temperature and 
pressure, but recent catalytic developments, activating the alkyne, have enabled its 
progress under milder conditions. These developments have included the use of a 
copper(I) catalyst
30
 to give the 1,4-regioisomer (1) selectively or ruthenium(II) 
catalyst
31
 to give the 1,5-regioisomer (2) selectively when using a terminal alkyne 
(Scheme 2).  
 
Scheme 2. Formation of 1,4 or 1,5-Triazole Regioisomers. 
Even more recently, a method for producing sulfonyl triazoles without metal 
catalysts has been developed.
32
 However, it proceeds selectively with n-BuLi at 
−78ºC, which is not suitable for a cellular environment.  
Alkynyl Grignards reacting with organic azides followed by trapping with an 
electrophile can give the 1,5-disubstituted triazole product (2) selectively, but this 
reaction does not support a wide scope of reagents.
33
 Ruthenium(II) catalysts, such as 
Cp*RuCl(PPh3)2 have been used to selectively produce the 1,5-disubstituted triazole 
product (2) with a wider scope, such as primary, secondary and aromatic azides, but 
not tertiary or aryl azides, where low yields are observed and often several different 
Tyrosine Derivatives and their Anti-Cancer Applications 
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 Whereas the Copper Catalyzed Azide-Alkyne Cycloaddition 
(CuAAC) reaction is only successful for terminal alkynes, internal alkynes are 
tolerated for the RuAAC reaction, which can give 1,4,5-trisubstituted 1,2,3-triazole 
products (3a & 3b) (Scheme 3).  
 
Scheme 3. Formation of 1,4,5-Triazole Regioisomers. 
However, in a cellular environment, the presence of the 1,4-triazole regioisomer (1) 
is preferred over the 1,5- (2) or 1,4,5-triazoles (3a & 3b) due its bio-orthogonality 




A triazole ring is relatively planar, and has a strong dipole moment. A triazole ring 
and amide are similar in their electron distribution and positioning of atoms, and both 
are capable of H-bonding. The triazole ring can be included in cells without 
disrupting normal cellular function, and unlike amides, they will not be hydrolysed, 
making them stable in that environment. This is an excellent trait when looking for a 
simple way to attach different groups, such as fluorescent tags, to various compounds 
of interest, such as proteins, via a side chain marker. The compatibility of triazole 
rings in modified peptides, successfully mimicking amides and allowing continuation 





Figure 7. Similarities Between a Peptide Bond and Triazole Ring.
39  
Using the “click” reaction to tag biomolecules has been successful, however, the 
metals used to catalyse the reaction would be toxic to cells, so investigations are 
ongoing into further effective catalysts which are not cytotoxic. There are alternative 
Tyrosine Derivatives and their Anti-Cancer Applications 
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ways to activate the alkyne, allowing less harsh conditions for the “click” reaction 
without the use of catalysts. One alternative to a terminal alkyne which requires no 
activation is to use a cyclooctyne. The reaction between the azide and cyclooctyne is 
strain-promoted and occurs at room temperature. This bulky group, although not 
toxic to cells, is more likely to cause disruption to biological activity than the 
sterically undemanding terminal alkyne. In addition, the reaction between azide and 
cyclooctyne is slower than the Staudinger ligation and for these reasons the 
azide/alkyne partnership still appears preferable. A further alternative to catalytically 
activating the alkyne would be to include an electron withdrawing group in the 
structure. However, in a cellular environment an electron withdrawing group such as 
an ester is likely to undergo nucleophilic attack, so this strategy is not likely to be a 
useful alternative for these biological applications. 
 
 
Figure 8. Cravatt’s successful demonstration of in vitro “click” based ABPP.
40
 Nucleophilic group on 
enzyme reacts with PS-N3, which undergoes “click” reaction with Tag‒≡, forming triazole product; 
fluorescently labelled enzyme in vitro.   (PS = phenylsulfonate ester, TCEP = 
tris(carboxyethyl)phosphines). 
The azide-alkyne cycloaddition reaction has been successfully used to label enzymes 
in complex proteomes, both in vitro and in vivo.
40,41
 Cravatt and co-workers 
demonstrated the application of azide and alkyne tags in activity-based protein 
profiling (ABPP). They proved that an alkyne rhodamine species (Rho−≡ or Tag-≡) 
could react with an azide-sulfonate ester (PS-N3) bound to its target, distributed 
throughout several different proteomes (Figure 8), whilst showing comparable 
sensitivity to that with standard ABPP methods employing a rhodamine-sulfonate 
ester (PS-Rho). This proved that the concept of using the tagged molecules was as 
effective as the pre-synthesised fluorescent-sulfonate ester (PS-Rho). Cravatt also 
showed that the distribution of the azide-sulfonate ester, bound to its target, 
Tyrosine Derivatives and their Anti-Cancer Applications 
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throughout the proteome was more extensive than for the rhodamine-sulfonate ester. 
This confirmed that the pre-synthesised PS-Rho movement around the cell was 
inhibited by the steric bulk of the rhodamine function attached. This principle was 
also tested in mice, and these in vivo results matched the in vitro ones, confirming 
that the azide and alkyne can work effectively in such applications (Figure 9). 
 
Figure 9. Effective Use of Azide and Alkyne Tags in vitro and in vivo by Cravatt and Co-workers.
40
  
Cos cells expressing GSTO 1-1 take up PS-N3, 1 hour later cells are homogenised, and reacted with 
Tag‒≡. Strong fluorescent signal for GSTO 1-1 shows successful labelling with rhodamine. PS-N3 
was injected into mice, 1 hour later, cells were homogenised, and reacted with Tag‒≡. PS-N3 target 
ECH-1 showed strong fluorescent signal, proving successful labelling in vivo. (GSTO 1-1 = 
glutathione S-transferase omega class enzyme target, ECH-1 = enoyl CoA hydratase-1 enzyme 
target). 
The azide/alkyne tagging approach has advantages over the azide/phosphine 
approach. The catalysed “click” reaction is much faster than the Staudinger ligation. 
The azide and alkyne functionalities could also easily be reversed so that the alkyne 
could be the biomarker, and the azide the complimentary function to attach a 
fluorescent tag for example. They provide excellent tools for in vitro investigations, 
and if an alternative catalyst can also be found, then their applications for in vivo 
experiments will be very extensive. For these reasons, and particularly for their ease 
of incorporation into amino acids, the azide and alkyne tags are often the first choice 
for peptide-based library syntheses. Their use as tags will be investigated in the 
specific peptide-protein interaction discussed in section 1.4. 
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1.4. p53 and AG-2 in Cancer Cells 
p53, or transcription factor 53, is a well known protein which is present in all multi-
cellular organisms.
42
 It is a protein which runs to 53 kDa by SDS-PAGE, hence its 
name, although from its structure elucidation, it has a molecular mass of 43.7 kDa.
43
 
The reason for this discrepancy derives from the abundance of proline residues in the 
protein sequence, which are known to slow down protein migration by SDS-PAGE. 
p53 is expressed by the anti-oncogene TP53.
44
 It has been shown that of all human 
tumours, around half have been linked to a deficit of effective p53. 
When p53 was first discovered, it was considered to be a cancer causing protein as it 
was found in cancerous cells. However, Vogelstein discovered its true function in 
cell cycle regulation in 1989.
45
 p53 plays an essential role in maintaining healthy 
cells. If a cell is damaged, the cell can detect that there is a problem during its 
checkpoint stages of the cell cycle and can increase the stimulation of TP53, leading 
to increased production of p53.
44
 p53 will then relocate to the cell nucleus and ensure 
integrity of cellular and genetic stability by one of two main routes.
46
 If the damage 
can be repaired, p53 will cause the arrest of the cell cycle, allowing DNA to be 
repaired before the cell cycle recommences. This ensures that damaged DNA is not 
replicated, and therefore not passed on to future generations of cells. If the damage 
cannot be repaired, programmed cell death, apoptosis, will be initiated to eliminate 
damaged cells. Due to these roles within an organism, preventing the production 




Anterior Gradient-2 (AG-2) is also a protein. It is an androgen inducible secreting 
protein, regulating the release of the sex hormones; testosterone and oestrogen. AG-2 
has been found present in some cancer cells, particularly associated with prostate and 
breast cancer, as well as Barrett’s epithelium, which can lead to oesophageal 
cancer.
47
 More recently, AG-2 has especially been associated with metastatic 
cancers. Hamburger and co-workers have discovered ErbB3 binding protein 1 
(EBP1) which can reduce the expression of AG-2 and as a result, metastatic 
behaviour is also reduced.
48
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In addition, the use of monoclonal antibodies to detect levels of AG-2 present in 
cancer cells has been described in the patent literature. This will allow more detailed 
diagnosis as to the extent of the metastatic behaviour of the cancer, which can help 
practitioners to decide on the most effective mode of treatment.
47
 AG-2 levels also 
indicate the level of urgency of treatment, and likely length of survival period. This 
method of detection is much more sensitive than previous diagnoses of metastatic 










Figure 10. AG-2 is known to inhibit p53, thus reducing cellular and genetic stability. 
AG-2 has been shown to inhibit p53 (Figure 10), preventing cell cycle regulation and 
allowing the proliferation of damaged cells, which can explain the reported presence 
of AG-2 in cancer cells.
49
 However, the mode of action by which AG-2 affects p53 is 
not yet known. In fact, very little is currently known about AG-2. It has been 
sequenced
50
 however, the 3D structure is as yet unknown, which makes it more 
challenging to begin designing inhibitory compounds based on binding pocket 
information and computer simulations. It is possible that AG-2 binds directly to p53, 
or causes degradation of the protein, or perhaps it acts by inducing defect formation 
in the TP53 gene, preventing normal expression of p53. Mutation of TP53 is the 
most common gene mutation to find in human cancers.
44
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Figure 11 shows the latest available data for cancer incidence rates in the UK 
according to survey results presented by Cancer Research UK.
51
 It shows that breast 
cancer is currently the most commonly diagnosed cancer in the UK. In men, the most 
commonly diagnosed cancer is prostate cancer, and this is the fourth most commonly 
diagnosed cancer in the UK. These figures alone show the importance of learning 
more about AG-2 and discovering how it is interacting with p53 in the propagation 
of cancer cells; if AG-2 can be inhibited, allowing p53 to be effective in facilitating 













*Colorectum including anus (C18-C21) 




1.5. Identifying AG-2 Binding Partners 
The Hupp group have been investigating the AG-2 protein for several years. One of 
their aims has been the development of a method for diagnostic detection of AG-2 
from a clinical biopsy, through affinity chromatography.
49
 This requires finding a 
selective binding partner to facilitate the development of biomarker assays that 
would allow the selective detection of AG-2 from a complex mixture of cellular 
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components. Through the use of combinatorial peptide libraries and phage display 
techniques, Hupp and co-workers have successfully identified a peptide sequence 
which has a strong binding affinity for AG-2. In addition, when this peptide is 
present in a cell, it prevents the inhibition of p53, presumably by binding to and 
inhibiting AG-2 and thereby preventing cancer cell formation, making this peptide a 
potential candidate as an anti-cancer drug. The peptide identified has the amino acid 
sequence PTTIYY (4) (Figure 12). 
 
Figure 12. Structure of PTTIYY Peptide (4). 
An alanine scan provided further information, that xTxIYY are the amino acids in 
this sequence, which are essential for binding to AG-2.
49
 When the proline was 
replaced by alanine, the peptide sequence remained active, but when the proline was 
removed, and the resulting pentamer was tested, the binding was greatly reduced. 
Although the proline in the sequence is not essential, it is essential that there is an 
amino acid in that position. 
 
1.6. Tagged Peptide Design 
We wanted to synthesis a marked derivative of this peptide to allow further 
investigation of the relationship between p53 and AG-2, for example by fluorescent 
tagging. In order to achieve this, we looked for amino acids in the peptide sequence 
that could be modified to carry a marker that could then be reacted with a 
complimentary tag carrying a fluorescent species. Ideally, an amino acid side chain 
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could be functionalised with the marker on the side chain so that neither the N- or C-
terminus of the amino acid would be blocked by a tag. This would allow the amino 
acid to be anywhere in the sequence, and would also allow the investigation of cyclic 
peptides.  
Tyrosine (6a) is the biosynthetic and chemical starting point for the synthesis of 
many different important compounds, such as adrenaline, morphine, dopamine and 
various hormones,
52
 and has been shown to be the origin of the pyrrolidine core of 
anisomycin (5).
53
 Similarities between tyrosine and anisomycin have been 
highlighted in figure 13. 
 
Figure 13. Anisomycin (5) Showing its Similarities to Tyrosine (6a) in Blue. 
Due to tyrosine’s biological significance and the convenience of tagging the side 
chain, it is believed that tyrosine derivatives could provide a good origin for 
investigations into marked library syntheses for chemical genetics screens. The 
tyrosine compound could easily be tagged with a terminal alkyne on the phenol side 
chain or even on the nitrogen, and still allow coupling to further amino acids. 
Marked tyrosine derivatives therefore have great potential. They could also be very 
useful to mark the PTTIYY peptide, which has shown promise as an anticancer 
agent, as well as the potential to make various tyrosine-containing natural product 
marked derivatives. A tagged tyrosine-containing molecule could then be quickly 
further investigated by attaching complimentary azide-tagged fluorescent species 
using the CuAAC reaction, or other functional groups for structure-activity 
relationship (SAR) studies. In addition, any tyrosine-containing compound could be 
tagged in this way and by affinity chromatography its target molecule binding 
investigated. For these reasons, the initial target of this research was to design an 
efficient synthesis towards a propargyl-tagged tyrosine derivative. 
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Chapter 2 Results and Discussion: AG-2 Inhibition Studies 
2.1. Proposed Synthesis of “Marked” Amino Acid; Route 1 
After consideration of the merits of propargyl tagged tyrosine derivatives and their 
potential for investigating biological activity or biological processes, (discussed in 




Figure 14. Target Propargyl-Tagged Tyrosine Derivative. 
In order to propargylate the phenol of the tyrosine starting material selectively, it was 
required to protect the amine and acid functionalities. With a view to preparing the 
amino acid for subsequent peptide coupling using a Rink amide linker onto solid 
support, it would be ideal to use the 9-fluorenylmethylcarbamate (Fmoc) protecting 
group for amine protection throughout (Scheme 4).
54
 Using Rink amide linkers 
usually involves alcohol side chains being protected as the tert-butyl ether, which can 
be cleaved under the same acidic conditions as cleavage of the final peptide from the 
solid support. The amine of an amino acid is protected with Fmoc during its coupling 
to the chain, as this can then be cleaved by base to free the amine ready for coupling 
of the next amino acid, without disrupting the attachment of the chain to the solid 
support. 
 
Scheme 4. Proposed Synthesis of Propargyl-Tagged Tyrosine Derivative. 
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2.1.1. Protection of the Acid and Amine Groups 
The acid (6a) was successfully protected as the methyl ester under reflux for three 
hours with acetyl chloride and methanol. After recrystallisation, the desired product 
was recovered as the white crystalline amine hydrochloride salt (8a) in a quantitative 
yield. The amine was then protected using Fmoc-succinimide ester and sodium 
carbonate stirring at room temperature overnight. Initially this was carried out in a 
mixture of 1,4-dioxane and water. However, due to difficulties in removing the 
solvent even after extended periods under reduced pressure, and the compound’s 
instability on silica during purification by column chromatography,
†
 the reaction was 
instead carried out in methanol. Carrying out the reaction in methanol afforded a 
sticky off-white film-like crude product, which was difficult to handle, but could be 
precipitated from minimal ethyl acetate with excess hexane. This gave a clean 
colourless solid (9) in an 88% yield. 
 
2.1.2. Propargylation of the Phenol 
There was some precedence of propargylation of anisomycin (5) in the Hulme group 
(Figure 15),
55
 including the synthesis of an O-propargyl derivative (11) and N-
propargyl derivative (12). These compounds were synthesised as “marked” library 
members which could be used to investigate the role of anisomycin in the stress 
activated protein kinase (SAPK) pathways. 
 
Figure 15. Anisomycin (5) and Propargylated Derivatives (11 and 12).
55
 
Conditions employed to synthesise the O-propargyl derivative (11) were propargyl 
bromide with dry potassium carbonate in DMF, stirred overnight at room 
                                                 
†
 NMR analysis indicated that the decomposition process which occurred on silica involved cleavage 
of the Fmoc group, and formation of an unknown impurity. 
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 For the N-propargyl derivative (12) propargyl bromide was used with 
piperidinomethyl resin in DCM. It is well known that the Fmoc protecting group is 
cleaved under basic conditions, but it was thought that potassium carbonate is 
sufficiently weak as a base, that the Fmoc group would not be cleaved from 9 during 
propargylation.
56 
However, the yield of the desired product was disappointing, and 
the 
1
H NMR spectrum showed the integrals of the propargyl protons to be double 
that expected, and the shifts more consistent with a propargylated amine than a 
propargyl ether.  It is likely that instead of propargylating the alcohol, the Fmoc 




Scheme 5. Formation of Unwanted Doubly Propargylated Product. 
It was decided to investigate different bases and dry solvents to see if the mono-
propargylation reaction could be successful on Fmoc-Tyr-OMe (9) (Table 2). Using 
adaptations of the method previously employed in the Hulme group with propargyl 
bromide and potassium carbonate, the solvent was changed to see if any 
improvement was made. Butan-2-one, acetone and toluene (Table 2, Entries 2–4) all 
gave results with no improvement from DMF. Different bases were used with DMF, 
such as potassium tert-butoxide and caesium carbonate (Table 2, Entries 5 & 6). 
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Table 2.  Attempted Phenolic-Propargylation Conditions. 
 
Entry Base Solvent Additive Result
a 
Reference 
1 K2CO3 DMF  45% crude product, 55% (14) Inverarity
55
 
2 K2CO3 Butan-2-one  35% crude product, 65% (14) Adapted from
55
 
3 K2CO3 Acetone  30% crude product, 70% (14) Adapted from
55
 
4 K2CO3 Toluene  35% crude product, 65% (14) Adapted from
55
 
5 KOt-Bu DMF  35% crude product, 55% Tyr-OMe Adapted from
55
 
6 CsCO3 DMF  50% (14), 50% Tyr-OMe Adapted from
55
 
7 NaH THF  10% (14) Xiong
58
 
8 NaH DMF  30% (14) Adapted from
58
 
9 NaH DMF LiI 70% (14) Adapted from
58
 
10 Imidazole DCM  20% crude product, 5% Tyr-OMe, 75% SM Maryanoff
59
 
Reagents and Conditions: 9 (1 eq.), propargyl bromide (3.6 eq.), additive (1 eq.), base (1.3 eq.), 
solvent. 
a
 All yields approximate, based on 
1
H NMR analysis of crude product. (SM = Starting 
Material). 
 
Propargylation was also attempted, despite the strong base, using the procedure 
published by Xiong,
58
 using sodium hydride in THF or in DMF (Table 2, Entries 7 & 
8). THF was not polar enough for the reagents to dissolve, and neither of the solvents 
gave a successful reaction, although when lithium iodide (Entry 9) was used to try to 
activate the propargyl bromide, 70% of the doubly propargylated material (14) was 
observed. 
Finally, the propargylation was attempted using imidazole in DCM (Table 2, Entry 
10), which Fmoc had shown to be tolerant to when used in silyl protection of an 
alcohol by Maryanoff.
59
 This was also unsuccessful, and NMR spectra showed ~20% 
of the desired propargylated product, but mainly starting material. 
To confirm that the conditions would work on a simpler more tolerant substrate, 
propargylation was attempted using the original conditions (Table 2, Entry 1) on 4-
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chloro-phenol. The reaction gave the expected propargyl ether product, as confirmed 
by NMR spectra, showing the conditions are effective when the substrate is not too 
sensitive. 
A final attempt at making the propargyl ether on Fmoc-Tyr-OMe (9) was made using 




Scheme 6. Attempt at Forming Propargyl Ether Under Mitsunobu Conditions. 
This procedure was partially successful in that by NMR analysis, the product could 
be seen, but as expected, with large amounts of triphenylphosphine oxide. The 
triphenylphosphine oxide was found to be very difficult to remove, especially as the 
desired compound (10) was not stable to column chromatography. This Mitsunobu 
approach might be more effective using solid-supported triphenylphosphine oxide, 
but the cost of this reagent was considered to be prohibitive for large scale synthesis. 
Due to these challenges, a different route to the target tyrosine derivative was sought. 
 
2.2. Route 2: via Boc-Tyr-OMe 
In a second approach, the widely used, base stable, tert-butyloxycarbonyl (Boc) 
protecting group was used instead of the Fmoc, to investigate its suitability for 
protecting the amine (8a) during propargylation. 
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Scheme 7. Route 2 to Desired Tagged-Tyrosine Derivative 7. 
Tyr-OMe (8a) was Boc protected using tert-butyloxycarbonyl anhydride in ethanol 
with sodium bicarbonate.
55
 The reaction was found to be complete after six hours at 
room temperature. The protected compound (15a) was purified by column 
chromatography, and obtained in a 93% yield. Propargylation was then attempted 
with propargyl bromide and potassium carbonate in DMF, giving Boc-
Tyr(CH2C≡CH)-OMe (16) in 95% yield. 
Shortly after having synthesised this compound (16) it was published as a new 
compound by a group in France.
61
 Their starting material had been commercially 
available Boc protected L-Tyrosine (19a), which they reacted to form both the 
propargyl ether and ester in 91% yield as reported by Schultz.
62
 The propargyl ester 
was hydrolysed before forming the methyl ester with a 42% yield over three steps 
(Scheme 8). The synthesis developed here (Steps 1-3, Scheme 7), from the cheaper 
starting material L-tyrosine, has a much higher overall yield of 88% over the three 
steps. 
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Scheme 8. The Srivastava Group Route to 16.
61
 
Having successfully made Boc-Tyr(CH2C≡CH)-OMe (16), the Boc group was 
cleaved with TFA in DCM to free the amine in 81% yield; then the methyl ester was 
hydrolysed using sodium hydroxide in water and methanol. During the work up for 
this reaction, the pH was adjusted to 7, then water was added and the reaction 
mixture held at 4
o
C overnight to promote crystallisation of Tyr(CH2C≡CH)-OH (18). 
Although this procedure was initially successful, allowing the isolation of 
Tyr(CH2C≡CH)-OH (18), it was difficult to reproduce.  To adjust the pH to exactly 7 
required the use of dilute acid, but a large volume was then needed, and it was more 
difficult to promote crystallisation.  If concentrated acid was used, it was not possible 
to fine tune the pH to 7.  It was decided to use DOWEX 50W-X8 100-200 mesh ion 
exchange resin in its proton form to adjust the pH to 7. This would allow simple 
filtration to remove the resin, then methanol removal under reduced pressure. 
Crystallisation of 18 from the aqueous solution overnight at 4°C, resulted in a good 
yield (89%). It was found to be necessary to record the NMR spectra of 18 at pH 14 
in deuterium oxide, as at neutral pH, and in a vast range of deuterated solvents, the 
compound was insoluble. 
The nitrogen of Tyr(CH2C≡CH)-OH (18) was then re-protected with the Fmoc group 
using Fmoc-succinimide ester and sodium hydrogen carbonate in methanol (85%). 
This was successful and allowed the completion of the synthesis of Fmoc-
Tyr(CH2C≡CH)-OH (7) in an overall yield of 54% over six steps. 
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2.3. Alternative Routes to Fmoc-Tyr-(CH2C≡CH)-OH 
Synthesis of the target compound (7) had been achieved, but it was felt that it could 
be improved by using more convenient protecting groups, for example using acid and 
amine protecting groups that could be cleaved under the same conditions to remove 
one step, improving efficiency.  
Two further alternative routes were designed, one where the acid was protected as 
the tert-butyl ester (Section 2.3.1). Tertiary butyl esters are often cleaved with acidic 
reagents, such as TFA,
63
 which is also used to cleave the Boc protecting group, 
allowing efficient simultaneous deprotection of both acid and amine groups. The 
other new proposed route involves using a trifluoroacetyl group to protect the amine 
(Section 2.3.2).
64
 This group can be cleaved by base hydrolysis,
65
 and would 
therefore be an efficient group to use alongside the methyl ester protected acid, as 
both could be cleaved simultaneously. 
 
2.3.1. Route 3: via Boc-Tyr-Ot-Bu 
 
Scheme 9. Route 3 to Target Propargylated Tyrosine Derivative, 7. 
The starting material for the first revised route (Scheme 9) was commercially 
available L-Tyr-Ot-Bu (22), which was subjected to standard Boc protection 
conditions with Boc2O and NaHCO3 to give Boc-Tyr-Ot-Bu (23) in a quantitative 
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yield. Propargylation was successfully achieved in a 92% yield. Simultaneous 
cleavage of both the Boc group and tert-butyl ester groups was attempted by stirring 
24 overnight with TFA in DCM at room temperature. Cleavage of the Boc group was 
achieved, to give Tyr(CH2C≡CH)-Ot-Bu, but the ester remained intact. Further 
attempts to cleave both the t-Bu ester and Boc group simultaneously, using neat TFA 
or TFA and DCM were both tried at room temperature and at reflux. All attempts 
were unsuccessful. It was assumed that the tert-butyl carbocation produced during 
the cleavage was attacked by any free acid, resulting in reformation of the tert-butyl 
ester. A detailed literature search found some precedent for this, which could be 
rectified by employing a scavenger.
66
 1,3-Dimethoxybenzene was used in addition to 
the TFA in DCM, and the mixture stirred for 1.5 h. The crude NMR spectrum 
revealed that the global deprotection had been successful. It was challenging to 
isolate the pure product Tyr(CH2C≡CH)-OH (18), but precipitation using minimal 
ethyl acetate and excess hexane gave at best a yield of 78%, though this was not 
easily reproduced. Fmoc protection was carried out as discussed in section 2.2 to 
achieve the final compound over four steps in a maximum overall yield of 60%. 
Route 3 has a slightly higher yield than route 2, and involves one less step. However, 
it also involves a much more expensive starting material. 
 
2.3.2. Route 4: via CF3CO-Tyr-OMe 
A final alternative route (Scheme 10) using the trifluoroacetyl (COCF3) protecting 
group, was also attempted. 
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Scheme 10. Route 4 to Target Propargylated Tyrosine Derivative, 7. 
Initial attempts to form CF3CO-Tyr-OMe (25) from ester (8a) began with synthesis 
of a (trifluoroacetyl)benzotriazole reagent (27) from trifluoroacetic anhydride and  
benzotriazole  in  dry  THF (Scheme 11, Route A).
67
 Despite reports that the reagent 
was easily formed and stable, in our hands this reagent could not be synthesised in 
sufficient quantity, neither at room temperature nor with mild heating, in a number of 
different solvents, or even after prolonged periods. Having failed at this first hurdle, 
a different method was sought. This time, trifluoroacetic anhydride was used with 
triethylamine to react with the tyrosine methyl ester (Scheme 11, Route B), a 
procedure reported by Castro and co-workers.
68
 However, once again, this proved 
unsuccessful. Finally, the amine was protected as the trifluoroacetamide using ethyl  
trifluoroacetate and potassium methoxide (Scheme 11, Route C), as adapted from a 
literature procedure.
64
 This appeared to be very successful with an excellent yield of 
98%; product identification was confirmed by NMR analysis and mass spectrometry. 
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Scheme 11. Methods attempted towards N-trifluoroacetylation of 13. 
Although the yield for this reaction was initially excellent, it was found to be quite 
variable due to difficulties in isolating the product. It did however prove to be 
effective as a protecting group, allowing O-propargylation to give CF3CO-
Tyr(CH2C≡CH)-OMe (26) in an excellent yield (97%), before successful global 
deprotection under basic conditions (65%). Fmoc protection of Tyr(CH2C≡CH)-OH 
(18) gave the desired final compound (7) in an overall yield of 49% over five steps. 
Route 4 has been successful in achieving the target tagged-tyrosine derivative, and 
with the cheap L-tyrosine starting material. However, the yields for both route 2 and 
3 were higher. 
Considering the merits of each of these three successful routes to the desired 
propargyl-tagged tyrosine derivative (7), it was decided to proceed with route 2; via 
Boc-Tyr-OMe. Although the overall yield was very slightly lower than that for route 
3 using Boc-Tyr-Ot-Bu, it was extremely reliable, producing consistent high yields 
for each step. 
Having successfully produced gram quantities of the desired amino acid derivative, it 
was incorporated into peptides to determine if the desired explorations could be 
executed with this new tool. 
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2.4. Peptide Synthesis 
With the tagged-amino acid derivative in hand, the synthesis of the hexamer peptide, 
which has been shown to prevent AG-2 from inhibiting p53 (Section 1.4 – 1.5), was 
started. 
The PTTIYY peptide (4) contains two tyrosine amino acids. It was decided to work 
towards two derivatives of PTTIYY, where in turn either of the two tyrosines was 
substituted for the new tagged tyrosine derivative (Figure 16). This may indicate 
which features of each of the tyrosine moieties are important for binding to the AG-2 
protein, depending on whether the propargyl group disrupts the binding compared to 
the original hexamer or not. 
 
 
Figure 16. The Two Tagged PTTIYY Derivatives to be Synthesised. 
These two peptides were synthesised manually on solid support using SPE tubes and 
agitation by a Stuart Scientific shaker. Standard Rink amide resin procedures were 
mostly used (Scheme 12), with a 3-fold excess of Fmoc monomers and coupling 
agents, HOBt and DIC, compared to the loading of the resin. Excesses were used for 
the Fmoc-deprotection step with piperidine in DMF, and for the simultaneous 
cleavage and global deprotection step with TFA in DCM. 
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Scheme 12. General Peptide Synthesis Procedure on Rink Amide Resin. 
After each step throughout the peptide syntheses the Kaïser test was performed to 
determine whether each coupling or deprotection had been successful. The Kaïser 
test involves ninhydrin based solutions which change colour depending on the 
terminal functional group. After coupling an amino acid to the resin, the terminus of 
the chain should be an Fmoc-protected, secondary amine and this is indicated by the 
Kaïser test solution and beads turning yellow on heating. After deprotection the 
terminus should be a free, 1º amine, and the solution and beads should be deep blue. 
If any test is not the expected colour, it indicates that coupling or deprotection was 
incomplete, and the reaction can be repeated. Some coupling reactions are 
notoriously challenging, and it is common to require a repeat, for example, initial 
coupling to resin with a bulky amino acid, such as tyrosine, or coupling to a 
secondary amine, such as on proline, or N-derivatised amino acids.
69 
Not surprisingly, for the syntheses of PTTIYX (28) and PTTIXY (29), the first 
tyrosine residue and the final proline residue required double couplings in order to 
achieve completion. 
For the simultaneous cleavage from the resin and global deprotection of side chains, 
the resin was suspended and shaken in TFA:DCM (1:1) for three hours. The deep red 
solution was filtered, collected and evaporated to near dryness. Ether was added, 
causing precipitation of the peptide, a colourless solid, which was dried under 
reduced pressure to give the peptide PTTIYX (28). 
This procedure was repeated for the second peptide, PTTIXY (29). The resultant 
peptides were analysed by MALDI-TOF mass spectrometry, confirming the expected 
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mass. The samples were shown to be 98% (28) and 96% (29) pure by reverse phase 



















Figure 17. Spectral Analysis of PTTIYX. (a) MALDI-TOF mass spectral analysis. Exact Mass of 
PTTIYX is 793.40 MALDI Peak found for [M+Na]
+
 at 816.1. (b) Reverse phase HPLC trace, 
showing 98% purity. 
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These procedures proved that the peptides could be successfully synthesised 
incorporating the propargyl group in either of the tyrosine side chain positions. 
Following this, investigations into whether the propargyl-derivatised peptides 
maintain their affinity for AG-2 compared to the normal peptide were carried out. In 
order to do this, enzyme-linked immunosorbent assay (ELISA) techniques were 
employed (Section 2.5.1, Figure 19), and required the synthesis of a biotinylated 




Figure 18. Target Biotinylated Peptide Structures. [Black and grey used to clearly indicate the 
different amino acid residues]. 
The biotin moiety is required to take advantage of its strong specific affinity for 
binding to streptavidin.
70
 This relationship is exploited in ELISAs where a multi-well 
plate is used. Each of the wells on the plate is coated with streptavidin, and then 
incubated with the biotinylated compound, before further incubations with other 
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specific compounds which will allow quantification of the binding of the compounds 
of interest (Figure 19). The target structures include an SGSG “spacer” unit to ensure 
that the entire peptide is displayed and available for binding to AG-2, to avoid steric 
interference from the biotin or streptavidin anchor. 
 
BiotinSGSGPTTIYY and derivatives were synthesised manually on Rink amide 
resin using the same method as shown in figure 12. The first tyrosine residue and the 
proline residue required double couplings again for each of the peptides, in order to 
achieve completion. After each of the amino acids had been attached, and whilst the 
peptide was still attached to the resin, biotin was added to the N-terminus of the 
peptide by its free acid in another coupling reaction under the same conditions 
(HOBt, DIC in DMF). Again, simultaneous cleavage from the resin and global 
deprotection was carried out using TFA/DCM (1:1). The colourless solids (30, 31, 
32) were analysed by HPLC and MALDI-TOF mass spectrometry, confirming the 
expected masses (Appendix 2). The samples were 70%, 81% and 89% pure by 
HPLC, respectively. Repeated attempts were made to purify the peptides by 
preparative HPLC, but these were made very difficult due to extreme lack of 
solubility, thus further attempts were abandoned. Although several commercial 
sources
71
 recommend >90% purity for quantitative assessment of protein binding, 
precedent exists of using >70% pure peptides in ELISAs.
72
 Personal communication 
with a colleague at the Edinburgh Cancer Research Centre indicated that 80% purity 
was sufficient for the intended ELISAs.
73
 Although 30 fell below 80% purity, a 
commercial sample of the same peptide was available, and was used for ELISA 
alongside the synthetic 31 and 32. 
 
2.5. Biological Investigations 
Having successfully synthesised the three required biotinylated peptide-derivatives, it 
was time to determine their effectiveness in binding to AG-2, to prevent it from 
inhibiting the cell-cycle regulation by p53. 
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2.5.1. Binding of “Marked” Peptides to AG-2 (ELISAs) 
ELISAs were carried out to determine the level of binding of the two propargylated 
versions of the ligand, BiotinSGSGPTTIYX (31) and BiotinSGSGPTTIXY (32), 
compared to that of the parent BiotinSGSGPTTIYY peptide (30) (Figure 19). 
 
Figure 19. ELISA Process. (a) Each well on a multi-well plate was coated with streptavidin. Wells 
were then incubated with the four different biotinylated peptides (5 µg in 50 µL DMSO) in the 
arrangement shown in Figure 20. After washing, all wells were blocked by incubation with 3% bovine 
serum albumin (BSA) in phosphate buffered saline with 0.1% Triton (PBS-T) to prevent non-specific 
binding of further species to the streptavidin. (b) After washing, the wells were incubated with 
solutions of purified AG-2 protein at different relative concentrations made from a 2.5 mg mL
-1
 in 3% 
BSA in PBS-T stock solution. (c) After washing the wells were incubated with the primary antibody 
(α-AG-2 K47 rabbit poly) (d) After washing the wells were incubated with secondary antibody (swine 
anti-rabbit). (e) The wells were incubated with a luminescent probe (ECL), and (f) the relative 
luminescence (RLU) was measured, which is proportional to the level of binding in each well. A 
graph was generated displaying these measurements. 
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Figure 20. ELISA Assay. (a) 96-well plate with peptide and relative concentration arrangements (b) 
Average RLU Measurement Values (over 2 measurements). 
The negative control was a random biotinylated peptide chosen for its lack of affinity 
for AG-2. This would act as an indicator of the level of non-specific binding to other 
species present in the wells. The positive control was BiotinSGSGPTTIYY (30) with 
non-derivatised tyrosines. This ELISA procedure was performed in duplicate for 
each peptide, and the results are shown as averages (Figure 20b) (Raw data can be 
found in Appendix 3). 
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Figure 21. ELISA assay results of peptides’, 30, 31 and 32, relative binding [proportional to relative 
luminescence (RLU)] at different concentrations of purified AG-2. Blue = Negative control, random 
peptide; Purple = Positive control, BiotinSGSGPTTIYY (30); Green = BiotinSGSGTTIYX (31); 
Yellow = BiotinSGSGPTTIXY (32). (X = Y–propargyl). 
The level of non-specific binding, measured by the biotinylated random peptide with 
no specific affinity for AG-2, and the affinity of the positive control, the non-
derivatised biotinSGSGPTTIYY (30) to AG-2 are displayed graphically in Figure 21. 
Relative to these two results, the level of binding of the two tagged peptides to AG-2 
can be assessed. The level of binding to AG-2 by the biotinSGSGPTTIYX peptide 
(31), with the propargylated tyrosine in the terminal position is lower than that 
shown by biotinSGSGPTTIYY (30); however, the relative affinity of 
biotinSGSGPTTIXY (32), where the internal tyrosine is propargylated, to AG-2 is at 
a comparable level. This shows that the propargyl group can be tolerated in the 
internal tyrosine position, and specific binding to AG-2 occurs from the purified AG-
2 protein solution. To further confirm these results, ELISAs were repeated by the 
same method, but using MCF-7 breast cancer cell lysate. This lysate is known to 
contain AG-2, but also a wealth of other proteins and cellular components.
74
 The 
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purpose of this ELISA was to determine if the propargylated peptides could show the 
same result, selectively binding to AG-2, even from a complex mixture. The results 
of the ELISA with the MCF-7 breast cancer cell lysate are shown in Figure 22 (Full 
results shown in Appendix 4). 
 
Figure 22. ELISA assay results of peptides, 30, 31 and 32, relative binding [proportional to relative 
luminescence (RLU)] at different concentrations of MCF-7 breast cancer cell lysate. Blue = Negative 
control, random peptide; Purple = Positive control, BiotinSGSGPTTIYY (30); Green = 
BiotinSGSGTTIYX (31); Yellow = BiotinSGSGPTTIXY (32). 
These results confirm those of the first ELISAs with the purified AG-2 protein. Here 
the levels of affinity are all comparable to those seen the first time, relative to each 
other. The overall RLU, or binding affinity appears to be much lower than before, 
but this is due to the ELISA being carried out with the complex mixture of proteins, 
rather than just the purified AG-2. 
From these results, features of the tyrosine moieties which are important for the 
binding of the peptide to AG-2 can be recognised. It was previously mentioned 
(Section 1.5) that an alanine scan of the peptide sequence showed xTxIYY to be the 
important amino acids in the sequence.
49
 For the peptide BiotinSGSGPTTIYX (31) 
the binding affinity was lower than for BiotinSGSGPTTIYY (30). This indicates that 
by converting the phenol into an ether, the binding has been disrupted, and it can be 
inferred that the terminal phenol is important for binding to the AG-2 protein, 
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perhaps by hydrogen bonding. The peptide BiotinSGSGPTTIXY (32) shows good 
levels of binding to AG-2 compared to BiotinSGSGPTTIYY (30), showing that the 
propargyl ether is tolerated, and this phenol is not essential for selective binding to 
AG-2. In this case it is more likely that the aromatic ring is involved in binding to 
AG-2, perhaps by π-π stacking. 
This information is very valuable to future investigations as it is clear that any tagged 
versions of this peptide, for fluorescent or SAR investigations, should be focused on 
the PTTIXY derivative (29). 
 
2.5.2. Further PTTIYY Biological Investigations 
To further confirm the results obtained from the ELISAs, pull-down assays could be 
performed, to determine the ability of the peptides to bind AG-2 when bound, 
through biotin, to streptavidin beads. This could again be performed with purified 
AG-2 and MCF-7 breast cancer cell lysate. 
 
2.6. Future Work 
2.6.1. Peptide Display Modes 
Affinity chromatography can be used to select targets of biologically active 
molecules, by purification from a complex biological mixture, but identifying the 
target has traditionally been challenging due to the harsh conditions often required to 
separate the target compound from the solid supported system which captured it. The 
Hulme group recently developed a new affinity chromatography linker (Figure 23),
75
 
which operates independently from the strength of interaction between the ligand and 
target. It can be cleaved under mild sodium dithionite conditions, enabling 
identification of the compound by spectroscopic techniques. 
The ligand is attached to the linker via “click” chemistry, whilst the other end of the 
linker is attached to solid support. 
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Figure 23. Cleavable Affinity Chromatography Linker Developed by the Hulme Group.
75
 
The propargylated peptides discussed in this chapter could be attached to the linker 
to investigate their binding to AG-2 and how that is affected depending on the way 
the peptide is displayed. To date, all binding between PTTIYY derivatives (31 and 
32) and AG-2 has been carried out based on the BiotinSGSG-peptide structure, with 
display of the peptide from the N-terminus (Figure 24a). These peptides could be 
displayed through side-chain linkage of the C-terminus to assess the importance of 
the SGSG spacer unit, and also to determine if the biotin has any effect on the levels 
of binding seen. For example, PTTIYX (28) or PTTIXY (29) could be attached to the 
linker via “click” chemistry and challenged with AG-2 to determine how the binding 
level to the AG-2 target might change by displaying this peptide with attachment 
from the C-terminus with a triazole
76





Figure 24. Schematics of PTTIYX displayed using (a) streptavidin-biotin affinity with SGSG spacer, 
(b) the new Hulme group cleavable affinity chromatography linker (c) Hulme group linker attached to 
affinity resin with triazole spacer to PTTIYX. 
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2.6.2. Fluorescent and SAR Investigations with Derivatised 
Tagged Peptides 
Various azido-fluorophore derivatives could be attached to the propargyl tagged 
peptide via “click” chemistry. Amino-fluorescein (33) is a known compound,
77
 and is 
an azido-fluorescein precursor, and various azido-rhodamine derivatives including 34 
exist,
78 
(Figure 25). These could be attached to allow fluorescent imaging of cells 
containing the derivatised peptide bound to the AG-2 protein. The location of AG-2 
in the cell relative to the location of p53 at various stages of the cell cycle, could give 




Figure 25. Amino/Azido-Fluorophore Structures. 
As alternatives to the azido-fluorophores, other functional groups which might 
improve the binding affinity of the peptide for AG-2 could be derivatised with an 
azide group and attached by “click” chemistry. A library of azides could be 
developed for potential in situ “click” chemistry to “grow” the ligand out from this 
propargyl side chain position, allowing extension of the fragment to cover other 
accessible sites on the AG-2 surface. Such “click”-based fragment coupling 
principles to produce modulators of protein-protein interactions has recently been 
demonstrated by Manetsch and co-workers, having used sulfo-“click” chemistry.
79
 
This could give more information on the SAR as to preferences for binding 
environments. 
This principle could, of course, be applied to any interesting tyrosine containing 
peptide or natural product, which supports the tag while maintaining its bioactivity. 
Investigations in this field are explored further in chapter 4, and could also be 
combined with the cleavable affinity chromatography linker (Section 2.6.1) to 
attempt identification of the tagged ligands’ biological targets. 
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Finally, for the particular case of the PTTIYY peptide, the threonine residues could 
be explored for their tolerance of being tagged with a propargyl group. This would 
enable similar information to be gathered about their importance towards AG-2 
affinity. It is especially likely, in light of the alanine scan showing that the middle 
threonine is not required to maintain binding, that this position might be suitable for 
derivatisation. 
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Chapter 3 Introduction: Natural Occurrence and Synthetic Utility 
of Halogenated-Tyrosine Derivatives 
 
3.1. Tyrosine-Containing Natural Products (by known 
structure/activity) 
Tyrosine is a very important compound. It is essential to our survival, although it is 
not one of the essential amino acids as it can be synthesised within the body from 
phenylalanine.
80
 Tyrosine derivatives feature in many different naturally occurring 
biologically active compounds, including hormones and neurological transmitters 
such as adrenaline
81
 (35) and dopamine
82
 (36) (Figure 26).
 
 
Figure 26. Tyrosine Related Structures of Adrenaline and Dopamine. 
In addition to these examples, tyrosine is also found in natural products isolated from 
marine sponges and bacterial fermentation, some of which have been shown to have 






 and more. 
Tyrosine found and used in the human body to make proteins and neurotransmitters 
is the natural enantiomer, L-tyrosine. Sometimes during post translational 
modifications this is converted to D-tyrosine.
83
 Both isomers are found in tyrosine 
containing secondary metabolites. 
Tyrosine oligomers are also very important compounds, and there are several 
different naturally occurring forms, such as dityrosine, isodityrosine, trityrosine and 
pulcherosine (Figure 27).
84
 These compounds are found in various surroundings, 
including plant and fungal cell wall proteins, proteins such as collagen and elastin, 
and in insect and sea urchin egg envelopes.
85,86
 These poly-tyrosine moieties are also 
associated with proteins found in various diseases such as Alzheimer’s and 
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Parkinson’s disease, as well as atherosclerosis and cystic fibrosis.
86
 It is thought that 
the cross-linking between tyrosines in these structures adds stability and strength to 
proteins. A link has been made between the level of tyrosine cross-linking and 
oxidative stress in cells. Extensive cross-linking of tyrosine moieties is used 
diagnostically as an indicator of protein and cellular damage. There are many natural 











 It is 
unclear whether these naturally occurring cross-linked functionalities are present as a 
result of two neighbouring tyrosine residues being oxidatively coupled together in 





Figure 27. Structures of Tyrosine Oligomers.
86
 
There are several feasible ways of synthesising such tyrosine derivatives, including 
Stille or Suzuki couplings, Ullmann condensations, copper-mediated biaryl coupling. 
Some of these methods require halogenated-tyrosine derivatives in order to carry out 
these transformations. Some examples of such procedures, as applied to natural 
product syntheses are described below. 
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3.1.1. Geodiamolides 
Geodiamolides are a family of cyclodepsipeptide natural products isolated from 
Geodia species of marine sponge.
90
 They have been shown to have anti-fungal 
activity against Candida albicans. Their structures (Figure 28) generally contain a 
tripeptide and a polypropionate unit. The tripeptide unit contains an unnatural ortho-
halo-N-methyl-D-tyrosine derivative. 
 
Figure 28. Structure and Retrosynthesis of the Geodiamolide Family of Compounds.
93
 
The first total synthesis of Geodiamolide B was carried out by Perez-Medrano and 
Grieco largely by peptide coupling of fragments, and by macrolactonisation to 
complete the structure of the final compound.
94
 The tyrosine derivative was 
synthesised (Scheme 13) starting with protection of the phenol (19b) as the TBDMS 
ether (44). N-methylation was conducted with tert-BuLi and methyl iodide in 71% 
yield, followed by selective mono-bromination in the ortho-position using bromine 
and mercuric acetate in carbon tetrachloride with an 80% yield. 46 was then ready 
for coupling to the two further amino acid fragments, completing the tripeptide unit 
(42) in 15% yield. 42 was coupled to the nonenoic acid successfully, and completion 
of Geodiamolide B was achieved in four further steps. 
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Scheme 13. Perez-Medrano’s Synthesis of the Tyrosine Fragment of Geodiamolide B.
94 
In 1993, the Bhandari group completed the total synthesis of Geodiamolide D.
95
 
Their approach (Scheme 14) to this compound was similar to that of Perez-
Medrano's approach to Geodiamolide B (Scheme 13). They carried out methyl ester 
protection of D-tyrosine (6b), followed by Boc protection, alcohol protection as the 
silyl ether, and N-methylation with sodium hydride and methyl iodide in DMF with a 
yield of 58% over these four steps to 47. Mono-ortho-iodination using iodine and 
mercuric acetate was performed, followed by basic ether and ester hydrolysis to give 
BocNMe-3-I-Tyr-OH (49) in an overall yield of 46% in six steps. The tyrosine 
derivative (49) was coupled to the other amino acids forming intermediate (43), 
which was coupled to the nonenoic acid fragment, ready for formation of the macro-
structure. The Bhandari group had difficulty with the final macrolactonisation, but 
achieved it with DCC/DMAP/TFA in refluxing chloroform in a 7% yield for this 
final step. 
 
Scheme 14. Bhandari Group’s Approach to the Tyrosine Feature of Geodiamolide D.
95 
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Shioiri and co-workers completed a unique approach to the synthesis of 
Geodiamolide A, focussing on three main steps which they believed to allow large 
scale production of the natural product.
96
 These main steps include synthesising the 
polypropionate unit by an asymmetric alkylation using Evans' chiral oxazolidinone 
(Scheme 15), then for the initial coupling of the tripeptide and polypropionate units, 
they used a Mitsunobu reaction, and finally macrolactamisation to complete the 
cyclic structure.  
 
Scheme 15. Evans’ Asymmetric Alkylation as Employed by Shioiri and Co-Workers.
96
 
For their synthesis of the tyrosine derivative, the Shioiri group performed N-
methylation on Boc-Tyr(P)-OH, where P is either the BzlCl2 or TBS ether, using 
sodium hydride and methyl iodide in THF.
96
 The Shioiri group then coupled together 
the three amino acids forming the tripeptide unit before carrying out selective mono-
ortho-iodination with iodine and mercuric acetate. 
 
3.1.2. Bouvardins 
Bouvardin (53) and related compounds such as deoxybouvardin (54) and RA-VII 
(55) (Figure 29) are a family of bicyclic hexapeptides which have been isolated from 
the Bouvardia ternifolia plant over the last thirty years.
97
 Bouvardin and 
deoxybouvardin were initially shown to have anti-neoplastic disease activity both in 
vitro and in vivo,
 
and have since also been shown to be exceptionally potent anti-
tumour and antibiotic agents which can inhibit protein synthesis.
92 
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Several synthetic routes towards various members of this family of natural products 
have been published, based on similar retrosynthetic approaches.
89,92,98-101
 All of the 
approaches involve cleaving the dityrosine unit from the tetrapeptide, synthesising 
the two fragments independently then forming the final bicyclic structure via 
macrolactamisation. A number of different methods have been used in order to form 
the dityrosine unit. 
All of the tyrosine units in this family of structures are N-methylated. All groups 
whose syntheses are discussed carried out this transformation using sodium hydride 




In the first total synthesis of deoxybouvardin (54) and RA-VII (55), Ogura and co-
workers decided to synthesise this biaryl unit (58) by a thallium trinitrate (TTN) 
intramolecular oxidative coupling (Scheme 16).
98
 They did successfully achieve the 
isodityrosine unit by this method (5% yield), and complete the coupling to the 
tetrapeptide unit to synthesise deoxybouvardin and RA-VII, but in very poor overall 
yields (<1%).  
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Scheme 16. Ogura and Co-workers’ TTN Approach to the Cyclo Dityrosine Fragment.
98 
The Boger group undertook various studies towards the total synthesis of these 
bouvardin structures, and they focused on forming the 14-membered cyclo dityrosine 
unit by employing an Ullmann type reaction in order to achieve the cyclisation by 
intramolecular condensation (Scheme 17).
99
 This was more successful than the TTN 
approach previously used, as it achieved higher yields and the starting materials used 
were more common amino acids, rather than di-halo derivatives. From a previously 
reported L-Dopa-type tyrosine derivative
102
 coupled via amide bond to the Cbz-
protected methyl ester of 4-iodo-phenylalanine, the intramolecular Ullmann 
condensation was completed as shown in scheme 17 in 24-30% yield.
99
 It was then 
coupled to the tetrapeptide fragment with appropriate protecting group manipulations 
to afford the target deoxybouvardin (54) or RA-VII (55) compounds. The overall 
yield (2%) was an improvement on the TTN method, but still not very remarkable. 
 
Scheme 17. Ullmann Biaryl Coupling Approach to the Key Cyclo Dityrosine Fragment, Used by 
Boger and Co-Workers.
99 
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A few years later, the Boger group had managed to make significant progress in this 
respect, and achieved a moderate (54%) yield of 60, in closure of this 14-membered 
isodityrosine unit.
89
 They employed a 4-fluoro-3-nitro-phenylalanine substrate (65) 
that the Zhu group used in the synthesis of Chloropeptin I and  RP 66453
103
 (Scheme 
18). The nitro group could be removed later by reduction, then elimination.
  
 
Scheme 18. Synthesis of 4-Fluoro-3-Nitro-Phenylalanine Fragment.
103 
This substrate was N-methylated using NaH in THF, in a 95% yield, and then they 
formed the isodityrosine unit with a simple intramolecular nucleophilic aromatic 
substitution procedure, in a yield of 50-61%. Around the same time, Zhu and co-
workers published a similar application of this previously developed procedure, also 
towards the bouvardin family structures.
100
 They reported a 54% yield for this biaryl 
unit, which in five further steps was manipulated into an intermediate (58 in Scheme 
16) used in the synthesis published by Ogura and colleagues.
98
 
Recently, Soundararajan and collaborators published an improved synthesis of the 
14-membered cyclo dityrosine ring component of deoxybouvardin (54) and RA-VII 
(55).
101
 They synthesised a 3-bromo-tyrosine derivative (67) from tyrosine with 
bromine and hydrogen bromide, and achieved mono-brominated product (66) in 95% 
yield (Scheme 19). This bromo-derivative (66) was incorporated into dityrosine 
derivative (68), which was later converted to a boronic acid (70). Copper mediated 
coupling of the dimer with Cu(OAc)2 and DMAP, selectively achieved the desired 
cyclisation product (71) in a yield of 60%, higher than any of the TTN, Ullmann, or 
nucleophilic aromatic substitution reactions previously used. 
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Scheme 19. Soundararajan Group’s Approach to Cyclo Dityrosine.
101 
The synthesis of this biaryl dityrosine unit has been the main challenge of these 
syntheses. Boger and co-workers have been working towards the syntheses of these 
compounds, and other related dityrosine compounds, for more than twenty years, 
which reflects the difficulty of achieving such units efficiently. They published a 
paper in 1988 which included investigations into the cyclisation of the core peptide 
structure, without the biaryl coupling between the two tyrosine components.
92
 They 
intended to find out if the extended efforts into this functionality were necessary for 
the bioactivity of the bouvardin family of compounds. Boger and co-workers carried 
out macrolactamisation of the hexapeptide core, carefully choosing the location for 
the final amide bond formation. They considered that the rate of amide bond 
formation would be affected by substitution at the amine, for instance it could be 
slowed down by coupling to an N-Me group, but the rate could also be increased by 
coupling to the N-terminus of a D-amino acid rather than an L-isomer. With these 
considerations in mind, they chose to close the ring between the D-alanine and L-
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tyrosine. They tried with two different groups at the C-terminus; the free acid (73), 
coupling with DPPA and NaHCO3, and also with the pentafluorophenyl ester (75) 
using pyridine to affect the cyclisation (Scheme 20). Both methods were successful, 
but the free acid/DPPA method was one step shorter and gave a higher overall yield. 
Having successfully synthesised the core structure (76) of the bouvardin family of 
natural products, Boger and colleagues tested the bioactivity of the compound and 
found that it showed no appreciable bioactivity, therefore proving that the biaryl-link 
between the two tyrosine components is essential for activity. There remains room 
for improvement for the synthesis of this biaryl unit. 
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3.1.3. Chloropeptins I and II 
Chloropeptins I (77) and II (78) (complestatin), are related molecules, extracted from 
Streptomyces species of bacteria, which have proven activity against HIV-1.
104
 They 
are remarkable because they have been shown to act in two locations against HIV, 
thereby making it much more difficult for the virus to evolve to become resistant to 
them. The two compounds differ only by the attachment of the indole to the central 
phenyl segment, ring ‘D’ (Figure 30). The left-hand macrocycle contains an N-
methyl-tyrosine derivative. 
Several syntheses exist for these two compounds; most employ a nucleophilic 
aromatic substitution to form the left hand macrocycle, and either Stille or Suzuki 
coupling, or a Larock annulation to form the right hand macrocycle.
88,104-106
 
Formation of the rest of the structure is usually based on peptide couplings. The 
focus of this section will be the generation of the tyrosine derivative and the two 
macrocycles. 
 
Figure 30. Retrosynthetic Approaches Toward the Structures of the Chloropeptin Compounds.
88,104-106
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Snapper and Hoveyda published the first synthesis of chloropeptin I, and found that 
with their chosen conditions, in order to form the desired atropisomer, they needed to 
carry out the formation of the left hand macrocycle first (Scheme 21).
105
 They 
achieved this via copper-mediated biaryl ether formation (50% yield), this then led to 
the desired atropisomer when carrying out a Stille coupling to form the phenyl-indole 
bond (40% yield, 80). 
 
Scheme 21. Snapper and Hoveyda’s Approach to Chloropeptin I.
105
 
Snapper and Hoveyda then tried a similar approach to the synthesis of chloropeptin 
II, with a Suzuki-Miyaura borylation coupling to form the phenyl-indole bond after 
the biaryl ether was in place. However, this resulted in the unnatural atropisomer of 
chloropeptin II. Further work using the Suzuki-Miyaura approach has been more 
successful towards chloropeptin II synthesis in the hands of Zhu group members.
106
 
In order for successful formation of the correct atropisomer, they formed the right 
hand macrocycle by Suzuki-Miyaura coupling in 66% yield, and later nucleophilic 
aromatic substitution (62% yield) to form the left hand macrocycle.
103
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Boger et al. carried out the first synthesis of chloropeptin II in 2009.
88
 They decided 
to take a different approach to the formation of the indole and employed an 
intramolecular Larock annulation (Scheme 22), successfully demonstrating the 
reaction’s first use in macrocyclisation with a yield of 56%. This step was carried out 
before the nucleophilic substitution to form the biaryl ether (81% yield), and 
successfully gave the desired atropisomer (83) in 4:1 selectivity, contrary to the 
selectivity shown by the Suzuki-Miyaura approach by Snapper and Hoveyda. In later 
studies by the same group, they managed to optimise the synthesis, finding that by 
forming the left hand macrocycle first, they achieved greater selectivity, 20:1, for the 
Larock annulation product (83) when forming the right hand macrocycle, achieving a 




Scheme 22. Larock Annulation Method for Right Hand Macrocycle Formation of Chloropeptin II.
88 
The tyrosine derivative appearing in the left hand macrocycle of the chloropeptin 
structures is N-methylated. This was achieved using methyl iodide and sodium 
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hydride, by all three groups discussed.
88,105,106 
However, none of the approaches used 
tyrosine as the starting material for this portion, instead they employed the method 
reported in the synthesis of the similar natural compound, teicoplanin aglycon 




It was also discovered that by treating chloropeptin II (78) with acid, it could be 
easily converted into chloropeptin I (77).
108
 This conversion was most efficient when 
using TFA at 50 ºC for five minutes. 
 
3.1.4. RP 66453 
RP 66453 (84) is a neurotensin antagonist, a cyclic peptide containing 
pulcherosine.
86
 It was first isolated from a Streptomyces species of bacteria as a 
secondary metabolite in 1998.
87








The stereochemistry of RP 66453 was determined by Zhu and co-workers during 
their total synthesis in 2003.
103
 Their approach to the formation of RP 66453 
involved solution phase coupling of the amino acids and nucleophilic aromatic 
substitution to form the 14-membered ring by ether formation using the same 4-
fluoro-3-nitro-phenylalanine type of substrate (65) approach as the group also used in 
the synthesis of chloropeptin II.
106 
This was followed by Suzuki-Miyaura borylation 
coupling of a 3-iodo-tyrosine derivative (86) to afford the 15-membered macrocycle 
in 40% yield, completing the core structure of RP 66453. Skaff and co-workers had 
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first published this tandem Suzuki-Miyaura borylation coupling method of forming 
the dityrosine, 15-membered ring section of the molecule earlier the same year.
85
 
They used iodine and silver sulfate to form the 3-iodo-tyrosine derivative (86) 
(Scheme 23), in a 90% yield, that was then used with Pd(dppf)Cl2, K2CO3 and 
bis(pinacolato)diboron in DMSO to give the biaryl compound (88) in 70% yield, 
which underwent global deprotection with H2, Pd/C to give the final dityrosine 
desired product (89). 
 
Scheme 23. Suzuki-Miyaura Borylation Biaryl Coupling to Form Dityrosine.
85
 
Stille couplings have also been successfully employed by Velay and Achab to form a 
similar bi-aryl dityrosine derivative in 56% yield for the coupling of 90 to 91 
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In October 2009, a new tyrosine containing natural product’s discovery was 
published, bisebromoamide (93).
91
 It was isolated from the Lyngbya sp. of a marine 
cyanobacterium found in Japan. It is a novel cytotoxic linear peptide based 
compound, which has sparked interest due to its anti-proliferative activity at 
nanomolar levels. Particularly interesting features of this compound include a 
thiazoline ring, which is methylated in the α-position, attached to a 4-methyl-pyrrole 
ring. It also contains a 3-bromo-D-tyrosine derivative, with two N-methyl amino 
acids, and the 2-(1-oxopropyl)pyrrolidine (Opp) moiety, which had never previously 
been seen in a natural product. 
 
Figure 32. Proposed Structure of the Natural Product Bisebromoamide.
91
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The Ye group published the first total synthesis of bisebromoamide in 2010.
110
 They 
approached the synthesis by creating four main fragments as shown in figure 33.  
 
Figure 33. Ye Group’s Retrosynthetic Approach to the Proposed Structure of Bisebromoamide, 
Showing Key Target Fragments.
110
 
The Ye group hypothesised that the thiazoline feature might be sensitive, and should 
be established late on in the synthesis, to reduce the chances of its epimerisation.
110 
The group began their synthesis by developing fragment 94 from D-tyrosine (Scheme 
25). They employed methodology published by the Boger group for the synthesis of 
the antipode (Scheme 25)
92
 to achieve compound 102. They then carried out 
selective mono-ortho-bromination using N-bromosuccinimide and para-toluene 
sulfonic acid in acetonitrile with an 87% yield.
110
 This gave compound 103 in a yield 
of 27% over seven steps from D-tyrosine. This sequence was followed by coupling to 
Boc protected L-alanine using 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-
one (DEPBT), the product (104) of which underwent base hydrolysis to give 
fragment 94. 
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Scheme 25. The Ye Group Approach to Fragment 94 of Bisebromoamide.
110
 
The group obtained the known phenylalanine derivative (105) of fragment (98)
106
  
and coupled it to Boc-D-leucine using bis(2-oxo-3-oxazolidinyl)phosphinic chloride 
(BOPCl) and triethylamine. The dipeptide product (106) was then coupled with the 
2-(1-oxopropyl)pyrrolidine (Opp) fragment (108), prepared from a literature 
procedure,
111
 using DEPBT (Scheme 26).
110
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Scheme 26. The Ye Group Approach to Fragment 98 of Bisebromoamide.
110
 
Ye and co-workers then attempted to construct the thiazoline ring from α-methyl 
serine coupled to fragment (107) and then through cyclodehydration of a β-hydroxy 
thioamide derivative of the 4-methyl pyrrole moiety.
110
 This was unsuccessful, and 
they assumed the reason was due to steric hindrance between the thioamide and the 
α-methyl serine quaternary centre. They revised their approach to involve 
cyclocondensation between a nitrile derivative of the 4-methyl pyrrole moiety (110) 
and S-α-methyl cysteine (96a) (Scheme 27). This approach was effected by 
converting Boc-(4Me)-Pro-OMe (95) to the corresponding nitrile (110) using a 
literature procedure.
112
 The Boc group was then removed, ready for coupling to Boc-
Ala-NMe-Br-Tyr-OH (94) using HATU and HOAt.
110
 The Boc group was removed 
from the resultant compound, and the free amine coupled with pivalic acid, giving 
111. The thiazoline ring was formed by reaction with S-α-methyl cysteine (96a)
110
 in 
DIPEA and EtOH at 90°C in a sealed tube. The final step of coupling 98 with 112 
was carried out employing HATU and HOAt, to afford the proposed structure of the 
bisebromoamide natural product (93). 
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Scheme 27. The Ye Group’s Formation of Bisebromoamide’s Proposed Structure.
110
 
On analysis of the experimental data, it was determined that the NMR data and 
optical rotation value of the synthetic product did not match those of the natural 
product sample.
110
 Through careful observation of that data, it was proposed that the 
quaternary centre of the thiazoline ring had been wrongly assigned. Employing the 
same methodology, but using R-α-methyl cysteine (96b), the epimer was 
synthesised, and found to match the natural product exactly. The true stereochemistry 
of bisebromoamide is shown in figure 34.  
Having synthesised two epimers of bisebromoamide, the Ye group investigated their 
bioactivity.
110
 Investigations showed that both epimers showed similar levels of 
activity, and the IC50 values of epi-bisebromoamide (113) were comparable to those 
of bisebromoamide (93) across three cancer cell lines. This result indicates that the 
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stereochemistry of the α-position of the thiazoline is not significant for the biological 
efficacy of the compound. 
 
Figure 34. Revised Structure of Bisebromoamide Natural Product.
 110
 
The Ma group completed the total synthesis of bisebromoamide in 2011.
113
 In a 
method similar to the Ye group, they decided to install the thiazoline as late as 
possible in the synthesis, due to concern over the stability of this group. Ma and co-
workers elected to form the thiazoline last, leaving two main fragments, one bearing 
a nitrile derivative of 4-methyl pyrrole (111), and the other with S-α-methyl cysteine 
(114). These two fragments could be further broken down to individual amino acid 
fragments (Figure 35). This design is convergent, and would easily allow adaptation 
of the individual amino acids to make analogues efficiently. 
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The Ma group started off synthesising the left hand fragment (111) (Scheme 28). 
Despite the very high cost, they chose the commercially available Boc-NMe-D-
Tyr(Bn)-OH as the starting point for their tyrosine derivative. They converted it to 
the methyl ester using TMSCHN2, and then achieved selective mono-ortho-
bromination with N-bromosuccinimide in DMF to give 115a in an excellent yield of 
98%. This brominated-tyrosine derivative was then Boc deprotected and coupled 
with Boc-L-Ala using HOAt and HATU, before further Boc deprotection and 
coupling with the terminal pivaloyl group. The tyrosine methyl ester (120) 
underwent base hydrolysis to give the free acid (121) ready to be coupled later. 
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Scheme 28. The Ma Group’s Approach to the Left-Hand Fragment of Bisebromoamide.
113
 
The 4-methyl pyrrole derived fragment (126) was synthesised starting from a known 
literature compound (122).
114
 This pyroglutamic acid derivative was methylated in 
the 4-position using LiHMDS then treated with methyl triflate to selectively give the 
syn diastereomer of 123, which was reduced in two steps by using LiBEt3H, and then 
Et3SiH with BF3·Et2O, affording 124 (Scheme 29).
113
 The tert-butyl ester was 
cleaved with TFA, and did not require a scavenger. The acid was converted to the 
amide (125) through coupling with ammonium hydroxide, HOBt and EDCI. 
Dehydration was then carried out with trifluoroacetic anhydride, followed by Cbz 
deprotection by hydrogenation, affording the target fragment (126). The pyrrole 
derivative was then coupled to the rest of the tyrosine containing dipeptide derivative 
(121) using HATU, HOAt and DIPEA (Scheme 28). Hydrogenation was carried out 
under Pd/C, H2 with ethyl acetate, achieving a low yield of the desired compound 
(111). If this hydrogenation step was carried out in a protic solvent, loss of the 
bromine was observed. 
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Scheme 29. The Ma Group’s Approach towards the 4-Methyl Pyrrole Fragment, 126.
113
 
In undertaking the synthesis of the right hand segment of the natural product, Ma et 
al. started from Fmoc-NMe-Phe-OAllyl (118).
113
 The Fmoc group was removed 
under basic conditions, and then the phenylalanine derivative coupled with Fmoc-D-
Leu using HATU and DIPEA to give 127 (Scheme 30). The allylic group was 
removed with Pd(PPh3)4 and NMA, before coupling the amino alcohol (128) to the 
acid with HATU, HOAt and DIPEA. The amino alcohol was prepared through 
NaBH4 reduction of the known compound 108.
115
 Having achieved 129, the Fmoc 
group was removed, followed by coupling of the free acid of Boc-S-Cys(Boc)αMe-
OH (117), again using HOAt, HATU and DIPEA, which was then oxidised to 
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Scheme 30. Synthesis of the Right Hand Fragment of Bisebromoamide by the Ma group.
113 
The Boc protecting groups were removed from the right hand segment with TFA, 
then coupling to the left hand segment took place employing sodium hydrogen 
carbonate and methanol in a pH 6 buffered solution at 70ºC.
113
 This successfully 
achieved formation of the thiazoline ring, and completed the synthesis of the 
proposed structure of bisebromoamide (93). The analytical data did not agree with 
that of the natural sample. The Ma group synthesised the compound with an epimeric 
thiazoline quaternary centre (113), and this agreed with the spectroscopic data of the 
natural product; thus supporting the conclusions of the Ye group after they 
completed their total synthesis.
110
 
Making use of the convergent nature of their synthetic route, the Ma group decided 
to investigate some of the other stereocentres in the bisebromoamide structure.
113.
 
The group made a bisebromoamide epimer containing the alternative, L-enantiomer 
of the tyrosine fragment (115b), another containing D-alanine, and another without 
the methyl group in the 4-position of the central pyrrole fragment (126). These 
isomers together with the two different thiazoline isomers (93 and 113) were all 
tested to see how their IC50 values against HeLa S3 cell lines compared. It was 
discovered that the unnatural thiazoline epimer of bisebromoamide (93) is only 
slightly less cytotoxic (IC50 165 ng mL
-1
) than the natural compound (IC50 40 ng mL
-
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1
), as is the analogue with 4Me-Pro replaced by Pro (134 ng mL
-1
), indicating that 
these features are not essential for activity. Changing the enantiomer of the tyrosine 
fragment (115b) caused the cytotoxicity to drop slightly (396 ng mL
-1
), and changing 
the enantiomer of alanine destroyed all cytotoxicity (no activity at 8 µg mL
-1
). The L-
alanine stereochemistry is therefore essential to maintaining bioactivity. 
Suenaga and co-workers have more recently published further investigations into 
bisebromoamide and some of its analogues.
116
 They have isolated 
norbisebromoamide, an analogue where the α-methyl group from the thiazoline is 
replaced by a hydrogen (Figure 36, R
1
=H). From the parent bisebromoamide 
structure (113), they have also developed several more analogues as shown in figure 
36. The Suenaga group carried out investigations to measure the derivatives’ IC50 
values against HeLa S3 cells, and found that all these analogues have cytotoxicity of 
a similar magnitude as the parent compound (40 – 91 ng mL
-1
). This information 
means that the functional groups involved in all of the analogues are not essential for 
biological activity, as changing them has not reduced the IC50 values. Figure 36 
shows a summary of all the adaptations made to create the analogues, and indicates 
the features of the molecule that can and cannot be modified in further investigations 
which might try to develop more cytotoxic analogues, or attach probes to learn more 









Figure 36. Tolerance of Biological Activity to Changing Structural Features of Bisebromoamide, as 
Shown by the Ma and Suenaga Groups.
113,116
 Green – Tolerated. Blue – Essential for Bioactivity. 
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3.2. Biological Activity of Bisebromoamide 
Further biological details were determined regarding the activity of 
bisebromoamide.
91
 When tested against a selection of human cancer cell lines, 
bisebromoamide showed an average 50% growth inhibition (GI50) value of 40 nM 
for all 39 cell lines assessed. It was also shown that the natural product could 
selectively inhibit the phosphorylation of a specific protein kinase (extracellular 
signal regulated protein kinase, ERK), and it did not show any inhibition of 
phosphorylation for other related proteins tested. Bisebromoamide therefore, is 
potentially selectively targeting the ERK signalling pathways. 
 
3.2.1. Targeting Actin Filaments 
Uesugi and co-workers have undertaken some investigations into actin filament 
stabilisers and destabilisers.
117
 Observing changes in cell morphology, they used a 
library of natural products to identify compounds which had an effect on actin 
filaments in HeLa cells. The library used consisted of 400 purified natural products, 
which were a mixture of compounds with and without known biological activity. Of 
these 400 compounds, nine were identified, at concentrations between 0.1-1000 µM, 
as “hit” molecules after the treatment of HeLa cells for one hour produced an 
observable protrusion of the cell’s nucleus. These nine compounds were cytochalasin 
D (131), mycalolide B (132), latrunculin A (133), swinholide A (134), jasplakinolide 
(135), doliculide (136), seragamide A (137), which were all previously known to 
have actin-targeted activity, plus miurenamide A (138) and of particular interest to 
our studies, bisebromoamide (113), whose activity was previously unknown (Figure 
37). 
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Of the nine marine-derived natural product “hits”, four (113, 136-138) contain ortho-
halogenated-tyrosine derivatives. It was already known that cytochalasin D (131), 
mycalolide B (132), latrunculin A (133) and swinholide A (134) are actin filament 
destabilising compounds, and that jasplakinolide, doliculide and seragamide are actin 
filament stabilising compounds. Two of the morphological changes that were 
observed with both of these classes of actin-targeting compounds, were that the area 
of cytoplasm in the cell reduced, and the centroid of the nucleus became further from 
the centroid of the whole cell upon treatment (Figure 38a-c).
117
 A graphical plot of 
the effects of each of the natural products tested on these two parameters was 
generated (Figure 38d). 
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Figure 38. Examples of the morphological changes observed in the HeLa cells on treatment with the 
library’s “hit” natural products. (a) No morphological  change  or  weak  blebbing  of  the  plasma  
membrane (b) Nuclear-protruded morphology (c) Completely  retracted  cytosol,  and  only  the  
nucleus  is  visible. (d) Extent of natural products’ effects on cell morphology. Blue = known actin 




Interestingly, the majority of the actin targeting compounds can be seen in the same 
bottom right area of the graph (Figure 38d), and the tyrosine-containing ones are 
especially close together. From the clustering of the two new natural product hits, 
bisebromoamide (113) and miuraenamide A (138), it could be estimated that they are 
actin filament stabilisers as their morphological effects are most similar to those of 
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the known actin filament stabilisers doliculide (136), jasplakinolide (135) and 
seragamide (137). In order to confirm this hypothesis, actin-polymerisation and 
depolymerisation assays were carried out for bisebromoamide (113) and 
miuraenamide A (138). These two compounds were shown to enhance 
polymerisation, and inhibit depolymerisation, which are characteristics further 
indicating that the compounds are actin filament stabilisers. This was further 
confirmed when a bisebromoamide derivative with fluorescein attached (139, Figure 
39a) via a terminal oxopropylpyrrolidine moiety derivative with linker, was observed 
within HeLa cells. It was noted that the potency reduced significantly with the linker-
fluorescein attached, presumably due to permeability problems, but it was clearly 
seen on fluorescent images that the small amount of compound that did enter the 
HeLa cells was specifically targeting the actin filaments (Figure 39b). The reduction 
in potency of bisebromoamide with fluorescein attached was confirmed to be due to 
permeability rather than loss of activity due to derivatisation, as bisebromoamide 
with the linker, without terminal fluorescein was shown to be as active 
bisebromoamide. In addition, attachment of the linker and fluorescein in this position 
showed that the terminal ketone of the bisebromoamide structure is not required for 
biological activity. 
It is still not understood how the protrusion of the cell nucleus is caused by the actin-
targeting molecules, but it is clear that these compounds have a positive effect and 
could be potential drug candidates, with their activity at nanomolar levels. This 
simple and effective newly developed assay for chemical genetics screens could be 
used in further screens as new natural compounds are discovered. Bisebromoamide 
(113) and Miuraenamide A (138) could be further explored to see if slight structure 
modifications could make them even more potent. 
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Figure 39. (a) Structure of Bisebromoamide-Fluorescein (139)
117
 (b) Targeted Actin Filaments Within 
HeLa Cells, Highlighted by 139. 
 
3.2.2. Bisebromoamide as a Target for Screening 
The Hulme group has shown an interest in tyrosine derivatives over a number of 
years.
55
 This new bisebromoamide natural product was thus identified as an excellent 
target to bring together several different projects. Previous work carried out to 
synthesise the tagged tyrosine-containing peptide, PTTIYY (Chapter 2) could be 
applied to the synthesis of the tyrosine derivative in bisebromoamide, to create a 
tagged derivative (140). This probe could then be used to investigate the biological 
targets of bisebromoamide using the new azide-based affinity chromatography linker 
developed by the group.
75
 An attempt towards a step-wise first total synthesis of 
bisebromoamide and tagged analogues was undertaken as described in Chapter 4. A 
step-wise approach would allow facile derivatisation of the natural product, including 
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the possibility of rapidly carrying out an alanine scan to determine important 
functional aspects of the natural product. 
During the course of the synthetic work discussed in this thesis, the Ye group 
completed the synthesis of bisebromoamide,
110 
and their chosen methods had some 
significant similarities to our own. 
 
Figure 40. Propargyl Tagged Bisebromoamide Derivative Target with Revised Stereochemistry. 
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Chapter 4 Results and Discussion: Towards the Synthesis of 
Bisebromoamide and Derivatives 
4.1. Retrosynthetic Analysis 
Having identified potential synthetic targets in bisebromoamide 113 and a 
propargylated analogue 140, a retrosynthetic approach was designed (Scheme 41). 
Our approach involves cleavage of the six amide bonds, creating seven amino acid-
like fragments. Of these seven fragments, three are the commercially available 
pivalic acid (142), L-alanine (143), and D-leucine (146), and the remaining four 
fragments required synthesis (144, 145, 147, 148). 
 
Figure 41. Retrosynthetic Approach Towards Bisebromoamide and Tagged-Analogues. 
This approach, creating amino acid-like fragments, allows great flexibility when 
constructing the natural product. Each amino acid can be derivatised independently, 
enabling the facile synthesis of various analogues of bisebromoamide. The amino 
acids could be coupled together on solid support using standard peptide synthesis 
procedures, allowing construction of the complete compound. 
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For synthesis on solid support protecting groups will be employed to ensure coupling 
in the desired position. Orthogonality between side chain protecting groups, C-
terminus and N-terminus protecting groups, and solid support attachment must be 
chosen carefully. For the approach to bisebromoamide, it was anticipated to begin by 
coupling the Fmoc protected phenylalanine fragment (147) to Wang resin. Sequential 
coupling of the other fragments would be continued until reaching the pivalic acid 
terminus. The peptide could then be cleaved from the resin using TFA which would 
also cleave side chain protecting groups. Cleavage from the Wang resin would result 
in the carboxylic acid at the C-terminus. The final fragment, Opp (148), could then 
be coupled in solution phase to result in the natural product. 
In previous syntheses of bisebromoamide, groups installed the thiazoline fragment 
late-on to reduce any risk of epimerisation at the 2-position of the proline,
110,113
 
although literature precedent does exist for thiazoline functionalities surviving solid 
phase synthesis.
118
 The Ye and Suenaga groups showed that the chirality at the α-
carbon in α-Me-Cys does not affect the bioactivity of the compound.
91,110
  In 
addition, the methyl group in the 4-position of the proline was shown not to affect 
the bioactivity.
113
 With these things in mind, and taking advantage of the flexible 
nature of our approach towards this natural product, it was decided to work towards 
the synthesis of another analogue, replacing the 4-Me-Pro with commercial Pro and 
the thiazoline (145) with a thiazole (150). The heteroaryl derivative might be 
expected to be less susceptible to racemisaton of the adjacent proline stereocentre, 
and would also be more straightforward for synthesis (see section 4.2.3). 
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Figure 42. Retrosynthetic Approach Toward the Thiazole Analogue of Bisebromoamide. 
4.2. Fragment Syntheses 
4.2.1. N-Methyl-Phenylalanine (NMeFmoc-Phe-OH) 
The N-methyl-phenylalanine fragment (147) required the free acid, and Fmoc-
protected amine to be compatible with solid phase synthesis using Wang resin. The 
proposed route towards this fragment (Scheme 31) was based on the chemistry 
employed in synthesising the tyrosine fragment (7) previously used for the PTTIYY 
peptide (Chapter 2), with the addition of an N-methylation step. 
 
Scheme 31. Synthetic Route Toward Phenylalanine Fragment, 147. 
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L-phenylalanine (151) was converted to the methyl ester with acetyl chloride and 
methanol at reflux in a quantitative yield, then the amine was Boc-protected with 
Boc-anhydride and sodium hydrogen carbonate in ethanol to give 152 in a 97% 
yield. 
Initial attempts to methylate the amine involved using formaldehyde and formic acid 
in DMSO in a Eschweiler-Clarke-type microwave reaction on 152 (Scheme 32).
119
 
However, no identifiable product was recovered from column chromatography. 
 
Scheme 32. Eschweiler-Clarke Type Attempt at N-Methylation.
119
 
Boger et al. had used sodium hydride and methyl iodide to N-methylate a 
phenylalanine-like compound (Scheme 33) in their syntheses of Chloropeptin I and 
II,
88
 so this method was attempted on the phenylalanine derivative (152). This 
protocol proved to be equally successful in our hands on the phenylalanine substrate, 
giving the desired product 153 in a 95% yield.  
 
Scheme 33. Boger’s N-methylation Procedure.
88 
Protecting group manipulations were then carried out to remove the Boc-protecting 
group under standard TFA conditions (89% yield), and to convert the ester to the free 
acid (155) by base hydrolysis (89% yield). The final step was then to protect the 
amine with the Fmoc group, preparing the fragment (147) for solid phase synthesis. 
The Fmoc protection was achieved with Fmoc-OSu and sodium bicarbonate in 
methanol. The product (147) was visible in the NMR analysis and confirmed by 
mass spectrometry, but purification was very challenging. Crystallisation was 
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attempted with various solvent combinations, but always resulted in an impure sticky 
oil. Column chromatography was also attempted, but despite one TLC spot being 
isolated, it quickly decomposed, becoming four spots by TLC. Since the product was 
clearly present, and the main contaminant appeared to be cleaved Fmoc, it was 
decided to proceed with the fragment in this condition. 
 
4.2.2. Ortho-Bromo-Tyrosine (NMeFmoc-Br-Tyr(t-Bu)-OH and 
NMeFmoc-Br-Tyr(Propargyl)-OH) 
In order to synthesise the natural product (113), the D-tyrosine derivative must have a 
free phenol. To maintain this group during solid phase synthesis, the alcohol requires 
protection. A tert-butyl ether was the group of choice since it can be cleaved by TFA, 
so side chain deprotection could be achieved under the same conditions as for 
cleavage of the peptide from the resin, therefore making the synthesis as efficient as 
possible. The target tyrosine derivative fragment is therefore 144 with an Fmoc-
protected methyl amine. For the same reasons as discussed in Chapter 2, the Boc 
protecting group is employed for the amine during fragment synthesis, as basic 
conditions are used for most transformations, and these would prematurely deprotect 
the amine if Fmoc was used as the initial N-protecting group. 
Much of the chemistry required to achieve the desired fragment (144) involves 
transformations already investigated and discussed in Chapter 2. In addition to these, 
the fragment required ortho-bromination, N-methylation and protection of the 
phenol.  
 
Scheme 34. Towards the Synthesis of Tyrosine Derivative Fragments. 
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By the same methodology as for the phenylalanine fragment (147), and the L-
tyrosine derivative used in peptide PTTIYY (7), D-tyrosine was converted to the 
methyl ester in quantitative yield, then Boc-protected in an excellent yield (97%). 
Bromination in the ortho-position to give the target fragment (158) was then 
attempted.
†
First attempts at mono-ortho-bromination were made using N-bromosuccinimide 
(NBS) and indium triflate (In(OTf)3) as the catalyst in acetonitrile.
120
 The reaction 
proceeded very rapidly, and di-bromination was complete in minutes. In attempts to 
slow and control the reaction, it was carried out in the dark and at 0ºC, but di-
bromination was still the main reaction taking place. 
Leykajarakul’s group published a procedure for selective mono-ortho-halogenation 
of tyrosine derivatives, with their most successful conditions reported as NBS in 
acetonitrile with para-toluene sulphonic acid (pTsOH) at room temperature for 18 
hours (Scheme 35).
121
 This reaction achieved mono-brominated 160 in 96% yield, di-
brominated 161 in 2% yield, and 2% starting material was recovered. It was decided 
to attempt this procedure on our substrate (15b). 
 
Scheme 35. Leykajarakul Group’s Bromination Procedure.
121 
In accordance with the literature procedure, 1 equivalent of pTsOH was stirred with 
15b in acetonitrile for five minutes before NBS (1 equiv.) was added, and the 
reaction mixture was stirred for 18 hours, becoming pale yellow.
121
 Mass 
spectrometric analysis of the reaction mixture after 10 minutes showed small peaks 
for di-brominated product and some starting material in addition to two very large 
peaks for the bromine isotopes of the desired mono-brominated product (158). This 
                                                 
†
 Work towards ortho-bromination of tyrosine derivatives was carried out in collaboration with project 
student Alan Healy. 
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analysis was very similar 18 hours later. The work up procedure involved extraction 
of the acetonitrile (MeCN) reaction mixture with ethyl acetate (EtOAc) from a 5% 
sodium thiosulphate solution. Unfortunately, after the work up, less than 20% crude 
material had been obtained. Further washings of the remaining aqueous layers did 
not significantly improve the recovery. It appeared that problems were arising from 
the miscibility of MeCN with water, from which it proved difficult to extract the 
product. 
This reaction was repeated, and rather than attempt work up on the reaction mixture 
in MeCN, first the solvent was removed under reduced pressure. The remaining oil 
was partitioned between ethyl acetate and 5% aqueous Na2S2O3 solution, washed 
with water and brine, but again the recovery of product was very poor. 
Concurrent attempts at bromination were made using bromine and hydrogen bromide 
in acetic acid.
122
 Although mono-ortho-bromination was initially successful on a 
small scale, it proved difficult to reproduce, and the toxicity and difficulty in 
handling bromine made it an undesirable route to proceed with. 
It was decided to persist with the NBS and pTsOH route,
121
 investigating different 
solvents in an attempt to improve the recovery of the product. 
On milligram scale, using EtOAc and pTsOH (1 equiv.) with NBS, the desired 
product was obtained over 4 hours in a 90% yield after work up, including washing 
with Na2S2O3 (5% aq. solution), water then brine. This method was repeated on 
multi-gram scale. The reaction was observed to be proceeding at a much slower rate, 
and was left overnight. After this time, a white precipitate had formed in the reaction 
mixture. The solid was removed by filtration and identified as the Boc-deprotected, 




C NMR and mass spectrometric analysis. 
The reaction was repeated again on 2 g scale, this time using 0.1 equivalents of 
pTsOH in EtOAc, to reduce the formation of the de-protected salt side product. The 
reaction proceeded more slowly again, but after 30 hours, a good yield of 85% 
mono-brominated product had been achieved. 
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Catalyst Solvent Conditions Products. 
1 NBS In(OTf)3 MeCN r.t. ~45% 162 
2 NBS In(OTf)3 MeCN Dark, r.t. ~45% 162 
3 NBS In(OTf)3 MeCN Dark, 0ºC ~45% 162 
4 NBS pTsOH (1 eq.) MeCN 18 h, r.t ~20% 158  isolated 
5 NBS pTsOH (1 eq.) MeCN r.t., Remove MeCN 
before EtOAc work 
up 
~20% 158 isolated 
6 Br2, HBr  AcOH r.t. 158, not 
reproducible. 
7 NBS pTsOH (1 eq.) EtOAc Milligram, 4 h, r.t. 90% 158 isolated 
yield. 




9 NBS pTsOH (0.1 
eq.) 
EtOAc Mutli-gram, 30 h, 
r.t. 
85% 158 
10 NBS - MeCN 15 mins, hυ, r.t. ~45% 162 
11 NBS pTsOH (0.1 
eq.) 
MeCN 40 mins, hυ, r.t. ~20% 158 isolated 
12 NBS pTsOH (0.1 
eq.) 
EtOAc 40 mins, hυ, r.t. 99% 158 isolated 
Reaction conditions: Substrate 15b in solvent with catalyst was stirred for 5 minutes before addition 
of NBS. 
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Around this time, Leykajarakul and co-workers published further results regarding 
this reaction.
123
 They proposed a mechanism for the involvement of pTsOH in the 
reaction, conjugating to the phenol, and directing bromination to the para position. 
However, if the phenol is already para-substituted, the bromination is directed to the 
ortho-position, and selectivity for mono-bromination is observed. Leykajarakul and 
Chhattise both proposed that such bromination reactions proceed via a radical 
mechanism,
123,124
 and could be accelerated using ultraviolet light (hυ). 
With our desired substrate, 15b, under hυ light, in acetonitrile with NBS, and without 
pTsOH, complete conversion to di-brominated product was observed within 15 
minutes. This method was repeated with pTsOH (0.1 equiv.), and mono-brominated 
product observed after 20 minutes. It was left stirring for an extra 20 minutes, and 
no-di-brominated product was observed. Once again, the use of acetonitrile as 
solvent caused trouble with product isolation, so the reaction was repeated replacing 
the acetonitrile solvent with EtOAc. This led to the successful recovery of a 
quantitative yield of mono-ortho-brominated product 158 after 40 minutes, which is 
a vast improvement on the initial result. 
 
Scheme 36. Successful Mono-Ortho-Bromination Conditions. 
From this point, two reaction schemes were pursued; one to form the tert-butyl ether 
tyrosine derivative, and one to form the propargyl ether derivative. 
The tert-butyl ether is required to prevent methylation of the alcohol during the N-
methylation step, or side reactions occurring during the amino acid coupling stages. 
It can be removed at the same time as cleavage from the solid support once the 
natural product peptide skeleton is complete. Protecting an alcohol as a tert-butyl 
ether used to require harsh conditions, often strongly acidic and requiring the use of 
isobutene gas.
125
 A strong acid would not be compatible with our substrate, as it 
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would be likely to cleave the Boc protecting group. In addition, the standard 
conditions used for introduction of the tert-butyl group usually leads to Friedel-




Scheme 37. Tert-Butyl Ether Formation.
126
 
Instead, an adaptation of a recent publication, using mild conditions with Boc 
anhydride (Boc2O) and scandium triflate (Sc(OTf)2) to protect alcohols including a 
range of phenols was used to protect our substrate (158).
126
 The Sambri group had 
expected that these conditions would form the tert-butyl carbonate, but instead they 
observed high yields of tert-butyl ether. In reproducing this method, it was found to 
require, extra additions of Boc2O at intervals throughout the reaction. Over time the 
Boc2O decomposed, before the reaction was complete, so 5 portions were added over 
the course of the reaction, achieving a 72-77% yield. This reaction is proposed to 
proceed via chelation of the scandium to the anhydride, forming tert-butyl alcohol, 
and forming an anhydride with the phenol, then 2 equivalents of carbon dioxide are 




Scheme 38. Proposed Mechanism for tert-Butyl Ether Formation.
126
 
The propargyl ether (164) was obtained in an excellent yield (98%) from phenol 
(158), using propargyl bromide and potassium carbonate in DMF, by the same 
method used for the tyrosine derivative in Chapter 2. 
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Scheme 39. Towards the Syntheses of Bromo-Tyrosine Derivative Fragments. 
Following ether formation, N-methylation was attempted using the same conditions 
as had been successful for forming the phenylalanine fragment. NaH with MeI again 
proved fruitful, giving 166 in an excellent yield of 99% for the propargyl ether and 
165 in 95% a yield for the tert-butyl ether. Having installed all the required 
functional groups, protecting group manipulation remained in order to prepare the 
fragments for solid phase synthesis. 
 
Scheme 40. Boc Deprotection of Propargyl Ether Tyrosine Derivative. 
For the propargyl ether (166), Boc-deprotection was carried out under standard TFA 
conditions (Scheme 40). For the tert-butyl ether, TFA could not be used, as this 
would also cleave the tert-butyl protected phenol. A literature procedure was used to 
successfully carry out the selective Boc-deprotection, using 2,6-lutidine and 
trimethylsilyl triflate to give 168 in an 86% yield (Scheme 41).
127 
 
Scheme 41. Boc Deprotection of tert-Butyl Ether Tyrosine Derivative.
127
 
This selective deprotection of the Boc group of 165, and standard Boc deprotection 
of 166, was followed by ester hydrolysis under basic conditions, to give the free 
acids (171 and 172), then Fmoc-protection of the methyl amine to afford the desired 
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target fragments (144 and 173). Unfortunately, as with the phenylalanine fragment 
(147), the final Fmoc-protected compounds were very challenging to purify. 
Crystallisation and column chromatography were unsuccessful. Having confirmed 
the presence of the products through NMR and mass spectral analysis, the impure 
final compounds were used as isolated. 
 
Scheme 42. Protecting Group Manipulations Toward Tyrosine Derivatives. 
Having successfully synthesised these fragments towards bisebromoamide and a 
propargyl-tagged derivative, the iodo equivalent fragments were also synthesised. 
The methodology used to form these iodo fragments was based on the synthetic route 
used for the bromo-derivatives. The ortho-halogenation was carried out using N-
iodosuccinimide (NIS) rather than NBS, and this reaction took longer, requiring 4 
hours. Otherwise, the route to form these fragments was the same. 
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Figure 43. Syntheses of the Four Final Tyrosine Derivatives. 
Each of the four fragments was formed over 8 steps, with an overall yield of 48% for 
NMeFmoc-3-Br-Tyr(CH2C≡CH)-OH (173), 35% for NMeFmoc-3-Br-Tyr(t-Bu)-OH 
(144), 43% for NMeFmoc-3-I-Tyr(CH2C≡CH)-OH (184) and 30% for NMeFmoc-3-
I-Tyr(t-Bu)-OH (183). 
 
4.2.3. Thiazole Fragment (Fmoc-Pro-Tzl-OH) 
The thiazole 150, was synthesised as an alternative fragment to the thiazoline, 145. 
This was due to concerns raised by the Ye and Ma groups over potential 
racemisation of the thiazoline fragment at the 2-position of the proline. The thiazole 
fragment was synthesised using literature procedures (Scheme 44).
128,129
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Scheme 44. Synthesis of Thiazole Fragment, 150.
128 
L-Prolinamide (185) was converted to the thioamide (186) in a quantitative yield, 
using the very mild and high yielding, Lawesson’s reagent under anhydrous 
conditions. In carrying out this reaction on test substrates, the Ko group found by 
HPLC analysis, that the majority of amino acid compounds converted to the 
thioamides by this procedure were achieved in >95% enantiomeric purity and in very 
good or excellent yields.
130
 
The thiazole ring was then formed according to a modified Hantzsch procedure in a 
two step reaction; using sodium hydrogen carbonate and ethylbromopyruvate to form 
the five membered ring, which was then converted to the thiazole (187) in a second 
step with triflic anhydride and 2,6-lutidine. 
Standard conditions allowed for Boc deprotection, ester hydrolysis and finally, Fmoc 
protection to afford Fmoc-Pro-Tzl-OH (150) as required for solid phase peptide 
synthesis in an overall yield of 79%. 
 
4.2.4. Thiazoline Unit (4-Me-Pro-α-Me-Tzl-OH) 
Although the thiazole has been identified as a key analogue of bisebromoamide due 
to its enhanced stability to the conditions employed in solid phase synthesis, work 
has been undertaken towards the synthesis of the parent thiazoline-containing subunit 
as outlined below. 
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The thiazoline unit of bisebromoamide can be further broken down into two amino 
acid-like fragments (Figure 43), by cleavage of the thiazoline ring, to give 4-methyl 
proline (4-Me-Pro, 190) and α-methyl cysteine (α-Me-Cys, 191), as the starting 
fragments. 
 
Figure 43. Retrosynthetic Approach Toward Thiazoline Fragment. 
 
4.2.4.1. α-Methyl Cysteine (α-Me-Cys) 
The synthesis of the α-methyl-cysteine fragment was begun according to a procedure 




Scheme 45. Route Towards α-Methyl-Cysteine by Singh et al.
131
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The above method towards α-Me-Cys was chosen for its expected ease of handling 
the crystalline intermediates, and use of commercially available reagents. Indeed, the 
first two steps were completed conveniently and efficiently; R-cysteine ethyl ester 
(192) was converted to the thiazoline (194) and used without purification. The (1S)-(-
)-2,10-camphorsultam was installed forming the amide (196), and this bulky group 
would direct the methylation, but purification became challenging at this point. 
Product isolation by column chromatography was possible, but labourious due to co-
elution of the product with an impurity. It was discovered that by repeated 
precipitation with EtOAc from a minimal amount of hexane, pure product could be 
isolated. Although it required repeated precipitations, this was more efficient than the 
challenging column chromatography otherwise required. 
The key step was then attempted, with methylation at the α-position of 196, using 
MeI, n-BuLi and HMPA. This reaction appeared to proceed successfully, achieving 
the enantioselective methylation, but purification was again very challenging. Great 
difficulty was experienced in the removal of the HMPA. At this point, due to 
concerns over this purification step, and the use of undesirable HMPA required for 
the methylation, it was decided to explore an alternative methodology for this step 
towards the α-Me-Cys, involving the use of a phase transfer catalyst, and this work 
was carried out by another member of the Hulme group. 
α-Alkyl-serine (200) had been synthesised by the Jew group, using a phase transfer 
catalyst called P2-Et (201), with TBAB and an alkyl halide using a substrate very 
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Scheme 46. Use of P2-Et Phase Transfer Catalyst for α-Alkyl-Serine Synthesis.
132
 
Heather Johnston then applied this method to our thiazoline equivalent (196), and 
successfully and rapidly afforded the desired enantiomer (197). Purification was 
achieved by column chromatography giving 197 in a 92% yield. This step was 
followed by removal of the camphorsultam by base hydrolysis, and cleavage of the 
thiazole ring using 6 N HCl at reflux. The α-Me-Cys was then purified by column 
chromatography over ion exchange resin to achieve 57% pure product, over these 3 
steps. 
The final step required was trityl protection required for the formation of the 
thiazoline fragment (191), this was carried out using triphenylmethanol and BF3-
OEt2 cooled to 0ºC with sodium acetate added, according to Cheng’s procedure.
133
 
The product was obtained by extraction, and then purified by successive hexane 
washes to achieve STrt-α-Me-Cys-OH (191) in a 94% yield. 
 
4.2.4.2. 4-Methyl Proline (4-Me-Pro) 
To achieve enantioselective methylation in the 4-position of proline was considered 
to be a challenging transformation. A literature procedure exists for producing each 
of the four stereoisomers of 4-Me-Pro selectively (Scheme 47).
134
 The reaction 
schemes published by Munro boast being concise, showing good selectivity, and 
with good overall yields. However, some of the steps do involve the use of 
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unfavourable reagents, such as chromium VI, which is highly carcinogenic, and 
titanium species which are notoriously difficult to handle. 
 
Scheme 47. Munro’s Selective Syntheses of the 4 Stereoisomers of 4-Me-Pro.
134
 
4-Me-Pro is commonly found in natural products, and prolines have been shown to 
be important for intramolecular binding for such compounds. Often prolines are key 
to the three-dimensional structure of peptides, and therefore, it is of great importance 
to be able to synthesise them effectively and efficiently. It was felt that there is room 
for improvement in terms of the synthesis of these compounds, and investigations 
into this area were initiated. 
Early strategy focussed on producing alkylated linear amines that could be cyclised 
by ring closing metathesis by a route such as that shown in Scheme 48. 
 
Scheme 48. The Hulme Group’s First Proposed Route Towards 4-Me-Pro. 
Unfortunately, this scheme failed at the first hurdle of making vinyl glycine. Despite 
several literature procedures existing for the synthesis,
135-137
 they could not be 
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reproduced. However, it was felt that the general approach towards the 4-Me-Pro 
fragment had promise, so with a re-design of the initial idea, a few routes were 
designed for further investigations (Figure 44), and work towards this aim is ongoing 
in the Hulme group. 
 
Figure 44. Revised Approaches Towards 4-Me-Pro Synthesis. 
Once 4-Me-Pro has been successfully synthesised, it will be combined with α-Me-
Cys to form the thiazoline by a literature procedure modified from forming a 








Preliminary investigations into forming the thiazoline ring have been successfully 
carried out with similar substrates (Scheme 50), showing promise for this approach 
in the future. Fmoc-Pro-OH (217) was coupled to commercially available Cys(Trt)-
OMe, followed by the use of (Ph3)3O and triflic anhydride allowed formation of the 
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simplified thiazoline ring structure. Products were confirmed as present by crude 
NMR and mass spectroscopy. 
 
Scheme 50. Thiazoline Formation Test Reactions Using Simplified Substrates. 
The successful formation of 219, has given confidence that when 4-Me-Pro (190) 
and α-Me-Cys (191) syntheses have been completed within the Hulme group, the 
steps shown in scheme 50 can be readily applied for formation of the thiazoline ring. 
After formation of the thiazoline ring (145), solid phase coupling could take place to 
attempt the synthesis of the parent compound bisebromoamide (113), and propargyl 
tagged-derivatives (140). This would then determine whether the Ye and Ma groups’ 
epimerisation concerns
110,113
 were fair, or if, as in Nicas’ work
118
, the thiazoline can 
be successfully incorporated into the natural product on solid support without 
epimerisation. 
 
4.2.5. Oxopropyl Pyrrolidine (Opp) 
The Opp fragment (148) is a unique natural product feature of bisebromoamide. The 
fragment was derived from proline according to a procedure published by De Luca 
and co-workers.
139 
L-Proline was Boc protected under standard conditions, with 
NaHCO3 and Boc anhydride in ethanol in a 93% yield (220). De Luca’s procedure 
was then employed, creating the activated ester under anhydrous conditions, and then 
reducing it to the ketone with copper and a Grignard reagent (Scheme 51). 
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Scheme 51. De Luca Route Towards Opp Fragment.
139 
The success of this procedure was found to be very dependent on the apparatus set 
up. It is essential for the conditions to be dry and under an inert atmosphere. This is 
challenging, as after the initial step forming the activated ester, a filtration is 
required. In this instance, oven-dried glassware was used, and an argon atmosphere. 
An adapter containing a sinter was used to remove the precipitate by filtration. It was 
found that using a vacuum pump introduced air into the system, and the subsequent 
step was unsuccessful. Instead, the filtrate was forced through the sinter, and into an 
attached reaction flask, using a positive pressure of argon. Copper iodide and 
Grignard reagent were then added to the filtrate. This resulted in the desired ketone 
product 148 which was purified by column chromatography (91% yield). 
Boc deprotection was successfully carried out under standard TFA conditions, giving 
a near-pure volatile product (83% crude yield). Improvement of the purity was 
attempted by column chromatography, however, the product was unstable and 
decomposed on silica. Instead, the crude de-protection product was used without 
further purification. 
 
Scheme 52. Synthesis of Boc-Opp-OProp (223) Fragment. 
A similar propargylated version of the Opp fragment was also synthesised (223). 
This fragment is the propargyl ester of L-proline. Boc-protected proline (220) was 
propargylated using propargyl bromide and potassium carbonate under the same 
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conditions as employed for the tyrosine propargyl ether derivatives. Propargylation 
was successful in a 96% yield. This compound (223) suffered similar volatility and 
decomposition issues as the Opp fragment, so Boc-deprotection using TFA was 




Having successfully synthesised all fragments required, the solid phase coupling of 
the components to form the thiazole derivative of bisebromoamide was attempted. 
Two analogues were to be attempted initially; bisebromoamide with the thiazoline 
replaced by thiazole, and with the tyrosine with a free phenol (149), the second 
analogue would be bisebromoamide with the thiazoline replaced by thiazole and with 
the propargyl-tagged tyrosine (224). 
 
Figure 45. Initial Bisebromoamide Analogue Targets. 
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The first step was to attach the first fragment, NMeFmoc-Phe-OH (147), to Wang 
resin (Scheme 53). This was achieved by shaking swelled Wang resin with 2,6-
dichlorobenzoyl chloride (DCB) with pyridine and fragment 147 in DMF for 18 
hours. This procedure was selected as despite its relatively long reaction time, 
minimal epimerisation and formation of impurities is observed.
140
 Fmoc deprotection 
of the Phe fragment (147) was carried out using 20% piperidine in DMF. The 
chloranil test was carried out to confirm the presence of a terminal secondary amine, 
with the beads turning green as a positive result. Having confirmed the successful 
deprotection, the next amino acid fragment could be coupled. Fmoc-D-Leucine-OH 
was added to the resin using HOBT, and DIC in DMF, shaken at room temperature 
for 1 hour. After this time, the chloranil test was performed, but showed some green 
beads still present, indicating the coupling was incomplete. The coupling reaction 
was repeated under the same conditions, and completed coupling was confirmed by 
the chloranil test showing colourless beads. Following Fmoc-deprotection of Leu, 
confirmed by observing dark blue beads with the Kaiser test, the thiazole fragment 
(150) was coupled, using the same conditions; HOBT and DIC in DMF. This process 
was repeated to deprotect and couple each amino acid; NMeFmoc-Br-Tyr(t-Bu)-OH 
(144), Fmoc-Ala-OH (required triple coupling), and pivalic acid, until the terminus 
was reached. After successful coupling of pivalic acid to the N-terminus, the peptide 
was cleaved from the resin using TFA:DCM (1:1), in the presence of 2.5% 
triisopropyl silane as a scavenger for the tert-butyl carbocation which formed upon 
simultaneous cleavage from the tyrosine of the tert-butyl ether side chain. 
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Scheme 53. General Protocol for Solid Supported Amino Acid Coupling on Wang Resin. 
 
This process was repeated in order to produce an analogue with a propargyl-tagged 
tyrosine side chain. The same procedure was used, double coupling was again 
required for leucine attachment, the NMeFmoc-Br-Tyr(t-Bu)-OH was replaced by 
NMeFmoc-Br-Tyr(Prop)-OH (173), and the alanine again required three couplings 
before it was complete. Cleavage of the peptide from the resin was carried out with 
TFA:DCM (1:1). 
Following cleavage, the filtrates for each peptide were collected separately, and 
evaporated to near dryness before precipitation with cold ether. The colourless solids 
were collected and analysed by mass spectrometry. 
It was with great disappointment that the thiazole bisebromoamide analogue 
precursor, with free phenol (149) was not isolated following peptide coupling. The 
product could not be identified by mass spectrometry. 
The second thiazole analogue of bisebromoamide, containing the propargyl-tag 
(224), appeared to be present by mass spectrum analysis, but in a very small quantity. 
The major peaks of the mass spectrum could not be assigned. 
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It is possible that the inability to purify the Phe and Tyr–derivatives had an effect on 
the synthesis and disrupted the amino acid coupling, however, from chloranil and 
Kaiser tests, the coupling steps appeared to proceed as expected. In order to clarify 
where the problem is arising from, it will be required to obtain more material and re-
attempt the coupling process, as well as identify the compounds which were made 
during the peptide coupling. 
One possible approach to improving the purity of Fmoc-Phe-OH and Fmoc-Tyr-OH 
derivatives could be to attempt Fmoc protection twice. Double couplings are often 
employed in peptide synthesis when a bulky, or cyclic amino acid is challenging to 
couple to. Indeed, during the coupling steps, it was seen that it was very difficult to 
couple to the tyrosine derivatives, as triple couplings were required in order to 
complete the attachment of the alanine. If repeated Fmoc-protection allowed a purer 
product to be synthesised, this may aid with efficient amino acid attachment. 
 
4.4. Biological Investigations (Future Work) 
The first attempts at the synthesis of bisebromoamide thiazole analogues, have been 
disappointing. Confidence remains that this approach can be successful, but more 
material is required in order to re-attempt the coupling of the fragments. The further 
efforts will involve repeating the process of solid supported coupling towards the 
bromo-thiazole analogues of bisebromoamide. 
The synthesis of the α-Me-Cys fragment has now been successfully completed, and 
that of 4-Me-Pro is nearing conclusion. Test reactions have been carried out to 
confirm that coupling of STrt-Cys-OMe and Fmoc-Pro-OH by the proposed method 
(Scheme 50) can be successful, and this will be applied to α-Me-cys and 4-Me-Pro 
when both are available to make the thiazoline fragment. It will then be attempted to 
use solid supported amino acid coupling to incorporate the thiazoline to the 
bisebromoamide structure without epimerisation. Ye and Ma groups did show 
concern over the stability of the stereocentres of this fragment,
110,113
 but some 
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literature precedent does exist where thiazolines have been successfully incorporated 
into peptidic structures on solid support.
118
 
If the synthesis of the natural product with the thiazoline is successful on solid 
support, the propargylated version will also be synthesised in this way. Iodo-
equivalents of the bromo-tyrosine fragments have already been synthesised, and can 
readily be incorporated into the natural product analogues for any of the thiazole or 
thiazoline structures, both for the free phenol of tyrosine, and the propargyl-tagged 
derivative as well. 
In addition, the propargyl-Opp (223) fragment has also been synthesised, and could 
also be readily incorporated into more natural product analogues. The synthesis of 
the hydrazone derivative by the Suenaga group
116
 suggests that this is a suitable point 
for attachment to resin or a fluorophore. 
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Figure 46. Potential Bisebromoamide Analogues Towards which Progress has been made. 
This will complete a small library of bisebromoamide analogues which can be 
screened against HeLa cells, to compare their bioactivity to the natural sample of the 
compound, already tested by the Suenaga group.
91
 This will lead to important 
information regarding which sites of the natural product can tolerate derivatisation, 
whilst maintaining activity. With this information in hand, propargyl-tagged 
bisebromoamide derivatives which are efficacious can be attached via “click” 
chemistry to the new cleavable affinity chromatography linker developed in the 
Hulme group,
75
 in the same manner as proposed for the PTTIYY peptide in Chapter 
2 (Section 2.6.1). This could allow for bisebromoamide binding targets to be 
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identified, allowing greater understanding of their biological activity, and their 
potential uses. 
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Chapter 5 Experimental 
5.1 General Experimental Details 
1
H nuclear magnetic resonance (NMR) spectra were recorded at 298 K or 323 K on 
Bruker AC250 (250 MHz), DPX360 (360 MHz), AVA400 (400 MHz) and AVA500 
(500 MHz) instruments. The data is presented as follows: chemical shift (in ppm 
scale relative to δTMS= 0), multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet), coupling constant (measured in Hz) and interpretation. 
13
C 
NMR spectra were recorded at 298 K or 323 K on Bruker DPX360 (90.6 MHz), 
AVA400 (100.6 MHz), AVA500 (125.8 MHz) Fourier transform instruments and 
were referenced to the solvent carbon peak or ‘spiked’ with MeOH for samples run 
in D2O. The data is presented as follows: chemical shift (in ppm on the δ scale) and 
assignment; and were confirmed by DEPT 90 and DEPT 135.
 19
F NMR spectra were 
recorded at ambient temperature on Bruker AVA400 (376.3 MHz) fourier transform 
instrument. The data is presented as follows: chemical shift (in ppm on the δ scale) 
and assignment. 
Infra-red spectra were recorded on a Shimadzu IR Affinity-1 spectrometer. The 
wavelengths of maximum absorbance (υmax) are quoted in cm
-1
.  
Melting points were determined on a Gallenkamp Electrothermal Melting Point 
apparatus and are uncorrected. 
Electrospray ionisation (ESI) mass spectra were recorded on a Finnigan LCQ or 
Micromass Platform instrument at The University of Edinburgh. The parent ion or 
relevant fragment is quoted, followed by significant fragments and their 
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percentages. MALDI-TOF mass spectra were recorded on a Voyager-DE STR 
Biospectrometry Workstation at COIL, School of Biology, University of 
Edinburgh., using α-cyano-4-hydroxycinnamic acid (CHCA) matrix. 
TLC was performed on Merck 60 F254 (0.25 mm) aluminium silica plates and 
visualised by ultraviolet (UV) light, potassium permanganate or vanillin stains.  
Flash chromatography was carried out on Fluka Kieselgel 60 under positive pressure 
by means of a hand pump. Eluent compositions are quoted as ratios. 
Optical rotations were measured on an AA-1000 polarimeter with a path length of 
1.0 dm at the sodium D line (589 nm) and are reported as follows: [α]D, 
concentration (c in g/ 100 cm
3
), and solvent. All optical rotations were measured at 
room temperature. 
Reagents were purified by standard techniques. Triethylamine (Et3N) was distilled 
from calcium hydride and stored over calcium hydride. Tetrahydrofuran (THF) and 
dichloromethane (DCM) were passed through activated alumina columns using a 
solvent purification system from Glass Contour Solvent Systems. N-
Bromosuccinimide and copper iodide were recrystallised from water. All other 
reagents were used as supplied. 
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General Reaction Procedures 
 




) was cooled to 0 ºC (ice bath) and acetyl chloride (11.3 mmol, 
3.00 eq.) was added slowly (CARE: gas evolved). The solution was stirred at 0 ºC 
for 15 minutes before carboxylic acid (3.77 mmol, 1.00 eq.) was added portion-
wise. The colourless solution was warmed to room temperature before heating to 
reflux for 3 h. 
The reaction mixture was cooled to room temperature, then the solvent evaporated 
under reduced pressure. The resultant solid was recrystallised from methanol, 
affording the colourless solid methyl ester. 
 
General Procedure B: Boc-protection 
 
Amine (6.71 mmol, 1.00 eq.) was dissolved in ethanol (25 cm
3
) with NaHCO3 (20.1 
mmol, 3.00 eq.) and Boc2O (6.71 mmol, 1.00 eq.). The colourless suspension was 
stirred at room temperature for 6 h, before vacuum filtration, and removal of the 
solvent under reduced pressure, affording the Boc-protected amine. The oil was 
purified by column chromatography. 
 
General Procedure C: Propargyl ether formation 
 
Alcohol or carboxylic acid (4.65 mmol, 1.00 eq.) was dissolved in dry DMF (30 
cm
3
) under a nitrogen atmosphere. K2CO3 (9.29 mmol, 2.00 eq.) was added, 
followed by propargyl bromide (80% in toluene, 16.7 mmol, 3.60 eq.). The reaction 
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was carried out in the dark (foil-wrapped flask), and stirred at room temperature for 
16 h. 
The reaction was quenched with water (20 cm
3
) with cooling (ice bath), and 
extracted with ether (3 × 20 cm
3
). The combined ether layers were washed with 
brine (20 cm
3
), dried (MgSO4), and the solvent removed under reduced pressure to 
afford the crude propargyl ether, which was purified by column chromatography. 
 
General Procedure D: Standard Boc-deprotection 
 
Boc-protected amine (6.49 mmol, 1.00 eq.) was dissolved in DCM (30 cm
3
) with 
TFA (64.9 mmol, 10.0 eq.). The pale yellow solution was stirred at room 
temperature for 16 h. 
The reaction mixture was quenched with NaHCO3 (30 cm
3
, sat. aq. soln.) added 
gradually, with cooling (ice bath). The mixture was left for bubbling to cease (~ 30 
minutes), then extracted with DCM (3 × 30 cm
3
), dried (MgSO4), and the solvent 
removed under reduced pressure to afford the TFA salt of the free amine. The crude 
product was purified by column chromatography. 
 
General Procedure E: Ester hydrolysis (with DOWEX) 
 
Methyl ester (11.7 mmol, 1.00 eq.) was dissolved in methanol (10 cm
3
) and water 
(40 cm
3
) with NaOH (12.2 mmol, 1.1 eq.). The pale yellow reaction mixture was 
stirred at room temperature for 3 h. 
The pH was adjusted to 7 (DOWEX ion-exchange resin, 50W-X8 100-200 mesh, 
hydrogen form), then the resin was removed by vacuum filtration, and organic 
solvent removed under reduced pressure. The residual aqueous suspension was 
cooled (4 ºC) overnight to afford the crude free acid which was removed by vacuum 
filtration. No further purification was carried out. 
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General Procedure F: Ester Hydrolysis 
 
Methyl ester (11.7 mmol, 1.00 eq.) was dissolved in methanol (10 cm
3
) and water 
(40 cm
3
) with NaOH (12.2 mmol, 1.1 eq.). The pale yellow reaction mixture was 
stirred at room temperature for 3 h. 
The pH was adjusted to 7 (1 N HCl aq.) resulting in precipitate formation. The 
colourless solid was collected by vacuum filtration. No further purification was 
carried out. 
 
General Procedure G: Fmoc-protection 
 
Amine (11.5 mmol, 1.00 eq.) was dissolved in methanol (90 cm
3
) and DMF (10 
cm
3
) with Na2CO3 (34.5 mmol, 3.00 eq.) and Fmoc-OSu (11.5 mmol, 1.00 eq.). The 
colourless suspension was stirred at room temperature for 16 h. 
The pH was adjusted to 2 (10 N HCl), and the mixture extracted with ether (3 × 50 
cm
3
), washed with brine (50 cm
3
), dried (MgSO4), and the solvent removed under 
reduced pressure to form the crude Fmoc-protected amine. 
 
General Procedure H: Global deprotection (Boc and t-Bu ester) 
 
Boc-protected amine (9.45 mmol, 1.00 eq.) was dissolved in DCM (20 cm
3
) with 
TFA (94.5 mmol, 10.0 eq.) and 1,3-dimethoxybenzene (14.2 mmol, 1.50 eq.). The 
deep red solution was stirred at room temperature for 3 h. 
The reaction mixture was quenched with NaHCO3 (30 cm
3
, sat. aq. soln.) gradually 
added with cooling (ice bath). The mixture was left for bubbling to cease (~ 30 
minutes), then extracted with DCM (3 × 30 cm
3
), dried (MgSO4), and the solvent 
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removed under reduced pressure to afford the TFA salt of the free amine. Precipitate 
formed from minimal EtOAc on addition of hexane (excess). 
 
General Procedure I: Amino Acid Attachment to Rink Amide Resin 
 
Rink amide resin (0.09 mmol, 1.00 eq.) was swollen in DCM (2 cm
3
) for 30 
minutes, then washed with DMF (3 × 3 cm
3
). The first Fmoc-protected amino acid 
residue (0.27 mmol, 3.00 eq.) was then coupled by addition of HOBt (0.27 mmol, 
3.00 eq.) and DMF (3 cm
3
), which was shaken for 10 minutes before addition of 
DIC (0.27 mmol, 3.00 eq.). The reaction mixture was shaken for 1 h at room 
temperature, before being washed (3 × shaken with DMF (3 cm
3
) then vacuum 
filtered, 3 × shaken with MeOH (3 cm
3
) then vacuum filtered, 3 × shaken with DCM 
(3 cm
3
) then vacuum filtered). The resin was then dried under reduced pressure for 2 
minutes. 
 
General Procedure J: Amino Acid Attachment to Wang Resin 
 
Wang resin (0.09 mmol, 1.00 eq.) was swollen in DCM (2 cm
3
) for 30 minutes, then 
washed with DMF (3 × 3 cm
3
). The first Fmoc-protected amino acid residue (0.45 
mmol, 5.00 eq.) was coupled to the resin by addition of pyridine (0.74 mmol, 8.25 
eq.), and shaking until completely dissolved. DCB (0.45 mmol, 5.00 eq.) was added, 
and the mixture gently shaken for 18 h. The resin was then washed (3 × shaken with 
DMF (3 cm
3
) then vacuum filtered, 3 × shaken with MeOH (3 cm
3
) then vacuum 
filtered, 3 × shaken with DCM (3 cm
3
) then vacuum filtered). The resin was then 
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General Procedure K: Amino Acid Coupling 
 
Fmoc-protected amino acid (0.27 mmol, 3.00 eq.), HOBt (0.27 mmol, 3.00 eq.) and 
DMF (3 cm
3
) were added to the resin (0.09 mmol, 1.00 eq.) and shaken at room 
temperature for 10 minutes. DIC (0.27 mmol, 3.00 eq.) was added, and the mixture 
shaken at room temperature for 1 h. It was then filtered under reduced pressure, and 
then washed (3 × shaken with DMF (3 cm
3
) then vacuum filtered, 3 × shaken with 
MeOH (3 cm
3
) then vacuum filtered, 3 × shaken with DCM (3 cm
3
) then vacuum 
filtered). The resin was then dried under reduced pressure for 2 minutes. 
 
General Procedure L: Fmoc-Deprotection 
 
The Fmoc-protected peptide on solid support was shaken in a 20% solution of 
piperidine in DMF (3 cm
3
) for 20 minutes. It was then filtered under reduced 
pressure and washed (3 × shaken with DMF (3 cm
3
) then vacuum filtered, 3 × 
shaken with MeOH (3 cm
3
) then vacuum filtered, 3 × shaken with DCM (3 cm
3
), 
before being dried under reduced pressure for 2 minutes. The Kaiser test was 
performed. If the result was yellow, deprotection was repeated, if blue, the next 
Fmoc-protected amino acid was coupled according to the above procedure. 
 
General Procedure M: Cleavage of Peptide from Resin 
 
After addition and, if necessary, Fmoc-deprotection of the final residue to the resin, 
global side-chain deprotection and cleavage from the resin was performed. 
The solid supported peptide sequence was shaken in DCM:TFA (3 cm
3
, 1:1) for 3 h. 
The deep red solution was filtered and collected, then evaporated to dryness under 
nitrogen. Ether (15 cm
3
) was added forming a colourless precipitate. The suspension 
was cooled (dry ice) to ensure complete precipitation. The suspension was 
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centrifuged (5000 rpm), and the ether poured off before fresh ether (15 cm
3
) was 
added. Sonication was used to re-mobilise the precipitate. The suspension was 
centrifuged (5000 rpm) and the ether poured off, before the colourless solid was 
dried at 40 ºC under reduced pressure to afford the free peptide sequence. Any tert-
butyl-protected side chains present were also cleaved during this procedure. 
 
General Procedure N: t-Bu ether formation 
 
Alcohol (6.24 mmol, 1.00 eq.) was dissolved in dry DCM (10 cm
3
) with Sc(OTf)3 
(0.31 mmol, 0.05 eq.) and Boc2O (74.9 mmol, 12.0 eq. added in 2 eq. portions as 
required, [indicated by absence on TLC]), under nitrogen. It was stirred at 25 ºC and 
the reaction monitored by TLC at hourly intervals, until complete (stained with 
vanillin). The reaction mixture was then cooled to room temperature, water (10 cm
3
) 
was added, then extracted with DCM (3 × 10 cm
3
), dried (MgSO4) and the solvent 
removed under reduced pressure to afford the crude tert-butyl ether which was 
purified by column chromatography. 
 
General Procedure O: N-methylation 
 
Boc-protected amine (5.50 mmol, 1.00 eq.) was dissolved in dry THF (30 cm
3
) 
under a nitrogen atmosphere at 0 ºC (ice bath). NaH (60% dispersion in mineral oil, 
8.25 mmol, 1.50 eq.) was carefully added and the suspension stirred at 0 ºC for 15 
minutes before DMF (5 cm
3
) and MeI (44.0 mmol, 8.00 eq.) were added. The pale 
yellow reaction mixture was stirred at 0 ºC for 1 h, then at room temperature for 16 
h. 
The reaction mixture was then diluted with EtOAc (30 cm
3
), and NaHCO3 (30 cm
3
 
sat. aq. soln.) was carefully added. The aqueous layer was extracted with EtOAc (3 
× 30 cm
3
). The combined organic layers were washed with brine (30 cm
3
), dried 
Tyrosine Derivatives and their Anti-Cancer Applications 
Experimental 
   
112 
(MgSO4), and the solvent removed under reduced pressure to afford the crude N-
methylated compound. The crude product was purified by column chromatography. 
 
General Procedure P: Selective Boc Deprotection 
 
Boc protected amine-tert-butyl ether (5.93 mmol, 1.00 eq.) was dissolved in DCM 
(20 cm
3
) at 0 ºC (ice bath) with 2,6-lutidine (29.6 mmol, 5.00 eq.). TMSOTf (23.7 
mmol, 4.00 eq.) was added, and the reaction mixture stirred at 0 ºC (ice bath) for 15 
minutes. The reaction mixture was warmed to room temperature, then stirred for 95 
minutes. 
The reaction mixture was again cooled to 0 ºC (ice bath), and cold NH4Cl (80 cm
3
 
sat. aq. soln.) was added. The reaction mixture was extracted with EtOAc (2 ×20 
cm
3
), washed with NaHCO3 (20 cm
3
), then brine (20 cm
3
), dried (MgSO4) and the 
solvent removed under reduced pressure. The free amine-tert-butyl ether was 
purified by column chromatography. 
 
General Procedure Q: COCF3 Protection 
 
Amine (7.30 mmol, 1.00 eq.) was dissolved in methanol (3.3 cm
3
) with KOMe (14.6 
mmol, 2.00 eq.) and then ethyl trifluoroacetate (14.6 mmol, 2.00 eq.). The reaction 
mixture was stirred at 40 ºC for 18 h. 
The solution was then cooled (ice bath), quenched into HCl (2.5 N, 10 cm
3
) and 
extracted with EtOAc (20 cm
3
). The organic phase was washed with acidic brine 
(10% brine in 1 N HCl, 50 cm
3
) and the solvent removed under reduced pressure. 
The product was used without further purification. 
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Methyl 2-amino-3-(4-hydroxyphenyl)propanoate hydrochloride (8) 
 
 
Using General Procedure A, tyrosine (49.9 g, 276 mmol) was reacted with acetyl 
chloride (58.9 cm
3
, 827 mmol) in methanol (850 cm
3
). The resultant solid was 
recrystallised from methanol, affording methyl ester 8 as a colourless solid (63.3 g, 
99%). 
 
Methyl (S)-2-amino-3-(4-hydroxyphenyl)propanoate hydrochloride (8a) 
 
 
Rf (DCM:MeOH, 99:1) = 0.00; mp 125-127 °C, (lit.
141





+28.0 (c 0.1, EtOH)]; IR (neat) 3335 (OH), 1746 (C=O, 
ester); 
1
H NMR (400 MHz, CD3OD) δ 7.08 (2H, d, J = 8.5, ArH), 6.80 (2H, d, J = 
8.5, ArH), 4.26 (1H, t, J = 6.6, CHNH2), 3.80 (3H, s, OCH3), 3.18 (1H, dd, J = 14.5, 
6.1, CHAHBAr), 3.11 (1H, dd, J = 14.5, 7.1, CHAHBAr); 
13
C NMR δ (125.8 MHz, 
CD3OD) 170.6 (C=O), 158.4 (C), 131.5 (2 ×CH), 125.6 (C), 116.9 (2 × CH), 55.4 
(CH), 53.6 (CH3), 36.6 (CH2); m/z (ESI+, MeOH) 391 ([2M+H]
+





Methyl (R)-2-amino-3-(4-hydroxyphenyl)propanoate hydrochloride (8b) 
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Rf (DCM:MeOH, 99:1) = 0.00; mp 175-177 °C, (lit.
142





−27.7 (c 0.1, EtOH)]; IR (neat) 3335 (OH), 1746 (C=O, 
ester); 
1
H NMR (400 MHz, CD3OD) δ 7.08 (2H, d, J = 8.5, ArH), 6.80 (2H, d, J = 
8.5, ArH), 4.26 (1H, t, J = 6.6, CHNH2), 3.80 (3H, s, OCH3), 3.18 (1H, dd, J = 14.5, 
6.1, CHAHBAr), 3.11 (1H, dd, J = 14.5, 7.1, CHAHBAr); 
13
C NMR δ (125.8 MHz, 
CD3OD) 170.6 (C=O), 158.4 (C), 131.5 (2 × CH), 125.6 (C), 116.9 (2 × CH), 55.4 
(CH), 53.6 (CH3), 36.6 (CH2); m/z (ESI+, MeOH) 391 ([2M+H]
+














Using General Procedure G, amine 8a (0.500 g, 2.16 mmol) was reacted with 
Fmoc-OSu (0.728 g, 2.16 mmol) to give 9 as a colourless solid (0.793 g, 88%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.09; mp 122-125 ºC, (lit.
143





−19 (c 5.0, DMF)]; IR (neat) 3318 (OH), 1724 (C=O, 
ester), 1688 (C=O, carbamate); 
1
H NMR δ (360 MHz, CDCl3) 7.76 (2H, d, J = 7.5, 
ArH), 7.56 (2H, dd, J = 7.3, 3.0, ArH), 7.40 (2H, t, J = 7.4, ArH), 7.30 (2H, td, J = 
7.4, 1.0, ArH), 6.95 – 6.80 (2H, m, ArH), 6.74 – 6.68 (2H, m, ArH), 6.00 (1H, br s, 
OH), 5.35 (1H, d, J = 8.3, NH), 4.64 (1H, q, J = 14.1, 5.9, CHNH), 4.43 – 4.36 (2H, 
m, OCH2), 4.20 (1H, t, J = 7.0, CH2CHAr), 3.73 (3H, s, OCH3), 3.04 (2H, qd, J = 
14.1, 6.0, ArCH2CH); 
13
C NMR δ (90.6 MHz, CDCl3) 172.4 (C), 156.0 (C), 155.3 
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(C), 144.0 (2 × C), 141.5 (2 × C), 130.6 (2 × CH), 127.9 (2 × CH), 127.5 (2 × CH), 
127.3 (2 × CH), 125.3 (2 × CH), 120.2 (2 × CH), 115.7 (2 × CH), 67.2 (CH2), 55.2 
(CH), 52.6 (CH3), 47.3 (CH), 37.6 (CH2); m/z (ESI+, MeOH) 418.6 ([M+H]
+
, 1%), 
166 (61), 165 (84), 91 (100). 
 





Methyl (S)-2-(di(prop-2-ynyl)amino)-3-(4-hydroxyphenyl)propanoate (14) 
 
Amino carbamate 9 (0.304 g, 0.902 mmol) was dissolved in DMF (10 cm
3
) with 
NaH (60% mineral oil dispersion, 0.028 g, 1.17 mmol), LiI (0.121 g, 0.902 mmol) 
and propargyl bromide (80% in toluene, 0.362 cm
3
, 3.25 mmol). The reaction was 
carried out in the dark (foil-wrapped flask) and stirred at room temperature for 16 h. 
The reaction was quenched with water (20 cm
3
) with cooling (ice bath), and 
extracted with ether (3 × 20 cm
3
). The combined ether layers were washed with 
brine (20 cm
3
), dried (MgSO4), and the solvent removed under reduced pressure to 
afford crude 14 (70% crude yield by NMR analysis). 
 
1
H NMR δ (360 MHz, CDCl3) 7.08 (2H, d, J = 7.5, ArH), 6.78 (2H, d, J = 7.5, 
ArH), 3.90 (1H, t, J = 6.4, CHCH2Ar), 3.72 (3H, s, OCH3), 3.28 (1H, dd, J = 13.2, 
6.4, CHAHBAr), 3.17 (1H, dd, J = 13.2, 6.4, CHAHBAr), 3.35 (2H, s, NCH2), 3.34 
(2H, s, NCH2), 2.59 (1H, s, HC≡C), 2.56 (1H, s, HC≡C); 
13
C NMR δ (90.6 MHz, 
CDCl3) 171.3 (C=O), 157.8 (C), 131.9 (2 × CH), 129.6 (C), 116.3 (2 × CH), 77.4 
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(C), 77.3 (C), 73.5 (CH), 73.2 (CH), 67.8 (CH), 52.5 (CH3), 39.8 (CH2), 39.7 (CH2), 
34.9 (CH); m/z (ESI‒, MeOH) 270.2 ([M‒H]
‒
, 36%), 416 (16), 207 (24), 183 (70). 
 
 
Methyl 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanoate (15) 
 
 
Using General Procedure B, amine hydrochloride 8 (63.2 g, 324 mmol) was 
reacted with Boc2O (70.7 g, 324 mmol) and NaHCO3 (81.6 g, 971 mmol) in ethanol 
(800 cm
3
). The off-white solid was purified by column chromatography 
(Hexane:EtOAc, 9:1 to 3:2) to give Boc protected amine 15 as a colourless 
crystalline solid (78.0 g, 97%). 
 
Methyl (S)-2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanoate (15a) 
 
Rf (Hexane:EtOAc, 3:1) = 0.17; mp 107-109 ºC, (lit.
144
 106-107 °C); [α]D = +57.3 
(c 1.10, CHCl3), [lit.
145
 [α]D +51.4 (c 1.0, CHCl3)]; IR (neat) 3368 (OH), 1738 
(C=O, ester), 1688 (C=O, carbamate); 
1
H NMR (400 MHz, CDCl3, 323 K) δ 6.99 
(2H, d, J = 8.5, ArH), 6.74 (2H, d, J = 8.5, ArH), 4.94 (1H, s, NHCH), 4.52 (1H, s, 
CHNH), 3.71 (3H, s, OCH3), 3.04 (1H, dd, J = 13.9, 5.8, CHAHBAr), 2.96 (1H, dd, J 
= 13.9, 6.0, CHAHBAr), 1.43 (9H, s, OC(CH3)3); 
13
C NMR (125.8 MHz, CDCl3, 298 
K) δ 172.7 (C=O), 155.4 (C=O), 155.0 (C), 130.6 (2 × CH), 128.0 (C), 115.6 (2 
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Rf (Hexane:EtOAc, 3:1) = 0.17; mp 107-108 ºC, (lit.
146
 102-109 °C); [α]D = −59.5 
(c 1.08, CHCl3), [lit.
147
 [α]D −52.6 (c 1.0, CHCl3)]; IR (neat) 3368 (OH), 1738 
(C=O, ester), 1688 (C=O, carbamate); 
1
H NMR (400 MHz, CDCl3, 323 K) δ 6.99 
(2H, d, J = 8.5, ArH), 6.74 (2H, d, J = 8.5, ArH), 4.94 (1H, s, NHCH), 4.52 (1H, s, 
CHNH), 3.71 (3H, s, OCH3), 3.04 (1H, dd, J = 13.9, 5.8, CHAHBAr), 2.96 (1H, dd, J 
= 13.9, 6.0, CHAHBAr), 1.43 (9H, s, OC(CH3)3); 
13
C NMR (125.8 MHz, CDCl3, 298 
K) δ 172.7 (C=O), 155.4 (C=O), 155.0 (C), 130.6 (2 × CH), 128.0 (C), 115.6 (2 














Using General Procedure C, phenol 15a (1.50 g, 5.08 mmol) was reacted with 
propargyl bromide (2.04 cm
3
, 18.3 mmol) and potassium carbonate (1.40 g, 10.2 
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mmol) in DMF (40 cm
3
). The resultant yellow oil was purified by column 
chromatography (Hexane:EtOAc, 3:1) to give propargyl ether 16 as a pale yellow 
oil (1.62 g, 95%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.11; [α]D = +36.4 (c 1.10, DCM), [lit
148
 +35.7 (c 1.00, 
DCM)]; IR (neat) 3291 (NH), 1711 (C=O, carbamate); 
1
H NMR (500 MHz, CDCl3) 
δ 7.05 (2H, d, J = 7.0, ArH), 6.90 (2H, d, J = 7.0, ArH), 5.03 (1H br s, NH), 4.67 – 
4.62 (2H, m, CH2C≡ CH), 4.58-4.49 (1H, m, CHNH), 3.70 (3H, s, CH3), 3.08-2.94 
(2H, m, CH2Ar), 2.53-2.52 (1H, m, HC≡ CCH2), 1.41 (9H, s, C(CH3)3); 
13
C NMR 
(125.8 MHz, CDCl3) δ 172.4 (C), 156.7 (C), 155.5 (C), 130.3 (2 × CH), 129.0 (C), 
115.0 (2 × CH), 80.0 (C), 78.6 (C), 75.5 (CH), 55.8 (CH2), 54.2 (CH), 52.3 (CH3), 
37.4 (CH2), 28.3 (3 × CH3); m/z (ESI+, MeOH/DCM) 689 ([2M+Na]
+
, 100%), 667 
([2M+H]
+
, 5), 356.0 ([M+Na]
+













Using General Procedure D, Boc protected amine 16 (0.360 g, 1.06 mmol) was 
reacted with TFA (0.790 cm
3
, 10.6 mmol) to give amine 17 as a pale yellow 
crystalline solid (0.200 g, 81%). 
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Rf (Hexane:EtOAc, 3:1) = 0.78; mp 57-59 ºC; [α]D = -27.0 (c 1.01, MeOH); IR 
(neat) 3285 (NH); 
1
H NMR δ (250 MHz, CDCl3) 7.09 (2H, d, J = 8.6, ArH), 6.89 
(2H, d, J = 8.6, ArH), 4.64 (2H, d, J = 2.4, HC≡CCH2), 3.68 (3H, s, OCH3), 3.37 - 
3.65 (1H, m, CHNH2), 3.00 (1H, dd, J = 10.8, 4.1, CHAHBAr), 2.79 (1H, dd, J = 
10.8, 6.1, CHAHBAr), 2.50 (1H, t, J = 2.4, HC≡C), 1.71 (2H, br s, NH2); 
13
C NMR δ 
(62.9 MHz, CDCl3) 176.4 (C), 157.5 (C), 131.3 (2 × CH), 131.2 (C), 116.0 (2 × 
CH), 79.6 (C), 76.5 (CH), 56.2 (CH), 56.1 (CH2), 53.0 (CH3), 41.1 (CH2); m/z 
(ESI+, MeOH) 234.1 ([M+H]
+
, 69%), 149 (100); HRMS (ESI+, MeOH) [M+H]
+
 
found 234.1124, C13H16O3N requires 234.1125. 
 
 
(S)-2-Amino-3-[4-(prop-2-ynyloxy)phenyl]propanoic acid (18) 
 
 
Using General Procedure E, methyl ester 17 (0.500 g, 2.14 mmol) was reacted 
with NaOH (94.3 mg, 2.36 mmol) in MeOH (10 cm
3
) and water (10 cm
3
) to afford 
carboxylic acid 18 as colourless precipitate (0.419 g, 89%). 
 
Using General Procedure H, Boc protected amine, tert-butyl ester 24 (0.500 g, 
2.14 mmol) was reacted with TFA (1.59 cm
3
, 21.4 mmol) and 1,3-
dimethoxybenzene (0.42 cm
3
, 3.21 mmol) in DCM (5 cm
3
) to afford carboxylic acid 
18 as colourless precipitate (0.367 g, 78%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.00; mp 202 ºC (dec.); [α]D = +24.4 (c 1.00, aq. NaOH); 
IR (neat) 3285 (OH), 2122(C≡C), 1725 (C=O, carboxylic acid); 
1
H NMR δ (360 
MHz, CDCl3) 7.20 (2H, d, J = 8.4, ArH), 6.93 (2H, d, J = 8.3, ArH), 4.78 (2H, d, J 
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= 2.0, CH2C≡CH), 3.60 (1H, d, J = 14.6, CHNH), 3.11 (2H, dd, J = 14.3, 3.6, 
ArCH2), 2.82 (1H, q, J = 14.2, 8.1, C≡CH); 
13
C NMR δ (90.6 MHz, CDCl3) 176.8 
(C), 157.4 (C), 131.8 (2 × CH), 131.7 (C), 116.1 (2 × CH), 80.9 (C), 79.6 (CH), 57.1 














Using General Procedure G, amine 18 (0.300 g, 1.37 mmol) was reacted with 
Fmoc-OSu (0.462 g, 1.37 mmol) to give Fmoc protected amine 7 as a colourless 
solid (0.513 g, 85%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.30; mp 128-132 ºC; [α]D = +7.96 (c 1.01, EtOH); IR 
(neat) 3285 (OH), 2122 (C≡C); 
1
H NMR δ (360 MHz, CDCl3) 7.77 (2H, d, J = 7.6, 
ArH), 7.56 (2H, dd, J = 6.8, 4.4, ArH), 7.40 (2H, t, J = 7.2, ArH), 7.35 – 7.29 (2H, 
m, ArH), 7.07 (2H, d, J = 8.4, ArH), 6.90 (2H, d, J = 8.4, ArH), 5.24 (1H, d, J = 8.1, 
NH), 4.51 (2H, d, J = 2.2, CH2C≡CH), 4.45 (1H, d, J = 7.1, CHNH), 4.21 (1H, t, J = 
6.7, CHAr), 3.12 (2H, qd, J = 32.1, 14.0, 5.6, ArCH2) 2.49 (1H, t, J = 5.6, C≡CH); 
13
C NMR δ (90.6 MHz, CDCl3) 176.0 (C), 157.3 (C), 156.3 (C), 144.2 (2 × C), 
141.9 (2 × C), 131.0 (2 × CH), 129.1 (C), 128.3 (2 × CH), 127.9 (2 × CH), 125.6 (2 
× CH), 120.6 (2 × CH), 115.6 (2 × CH), 79.1 (C), 76.1 (CH), 67.6 (CH2), 56.4 
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tert-Butyl (S)-2-tert-butoxycarbonylamino-3-(4-hydroxyphenyl)propanoate (23) 
 
 
Using General Procedure B, amine 22 (2.00 g, 8.43 mmol) was reacted with 
Boc2O (1.84 g, 8.43 mmol) and NaHCO3 (2.13 g, 25.3 mmol) in ethanol (30 cm
3
) to 
give Boc-protected amine 23 as a colourless solid (2.82 g, 99%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.34; mp 111-113 °C, (lit.
150
 113 ºC); [α]D = +7.33 (c 
0.96, EtOH), [lit.
150
 +8.00 (c 1.00, EtOH)]; IR (neat) 3360 (OH), 1693 (C=O, 
carbamate); 
1
H NMR (360 MHz, CDCl3) δ 7.01 (2H, d, J  =  8.1, ArH), 6.73 (2H, d, 
J  = 8.2, ArH), 5.92 (1H, br s, OH), 5.02 (1 H, d, J = 8.2, NH), 4.40 (1H, dd, J = 
13.8, 5.9, CHNH), 2.96 (2H, m, CH2Ar), 1.43 (9H, s, C(CH3)3) 1.40 (9H, s, 
C(CH3)3); 
13
C NMR δ (125.8 MHz, CDCl3) 171.3 (C), 155.4 (C), 155.1 (C), 130.6 
(2 × CH), 127.8 (C), 115.3 (2 × CH), 82.2 (C), 80.0 (C), 55.1 (CH), 37.7 (CH2), 28.4 
(3 × CH3), 28.0 (3 × CH3); m/z (ESI-, MeOH) 336.2 ([M-H]
-
, 31%), 218 (66), 105 
(100). 
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Using General Procedure C, phenol 23 (560 mg, 1.66 mmol) was reacted with 
propargyl bromide (711 mg, 5.97 mmol) and potassium carbonate (459 mg, 3.32 
mmol) in DMF (15 cm
3
) to give propargyl ether 24 as a pale yellow oil (575 mg 
92%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.55; [α]D = +6.25 (c 1.12, EtOH); IR (neat) 1709 (C=O, 
ester), 1610 (C=O, carbamate); 
1
H NMR (360 MHz, CDCl3) δ 7.07 (2H, d, J = 8.6, 
ArH), 6.87 (2H, d, J = 8.5, ArH), 4.95 (1H, d, J = 7.7, NH), 4.64 (2H, d, J = 2.4, 
HC≡ CCH2), 4.38 (1H, dd, J = 7.7, 6.1, CHNH), 3.03-2.90 (2H, m, CH2Ar), 2.48 
(1H, t, J = 2.4, HC≡ CCH2), 1.39 (9H, s, C(CH3)3), 1.37 (9H, s, C(CH3)3); 
13
C NMR 
(125.8 MHz, CDCl3) δ 171.0 (C), 156.5 (C), 155.1 (C), 130.0 (2 × CH), 129.4 (C), 
114.8 (2 × CH), 82.0 (C), 79.6 (C), 78.6 (C), 75.5 (CH), 55.8 (CH2), 54.9 (CH), 37.7 
(CH2), 28.3 (3 × CH3), 28.0 (3 × CH3); m/z (ESI+, MeOH) 376 ([M+H]
+
, 62%), 259 
(55), 146 (100). 
 
 
Methyl (S)-3-(4-hydroxy-phenyl)-2-(2,2,2-trifluoroacetylamido)propanoate (25)  
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Using General Procedure Q, amine 8 (1.43 g, 7.30 mmol) was reacted with 
potassium methoxide (1.02 g, 14.6 mmol) in methanol (3.3 cm
3
) and ethyl 
trifluoroacetate (8.32 cm
3
, 14.6 mmol) to afford trifluoroacetamide 25 as a 
colourless solid (2.08 g, 98%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.08; mp 144-147 °C, (lit.
151
 141-143 ºC); [α]D = -37.3 (c 
0.97, CDCl3); IR (neat) 3279 (OH), 1697 (C=O, carbamate); 
1
H NMR (400 MHz, 
MeOD) δ 7.01 (2H, d, J = 8.6, ArH), 6.71 (2H, d, J = 8.6, ArH), 4.63 (1H, td, J = 
9.9, 5.0, CHN), 3.72 (3H, s, OCH3), 3.17 (1H, dd, J = 14.0, 5.3, CHAHBAr), 2.92 
(1H, dd, J = 14.0, 9.8, CHAHBAr); 
13
C NMR δ (125.8 MHz, CDCl3) 174.2 (C), 
159.1 (q, J = 37.3, C), 156.3 (C), 132.0 (2 × CH), 129.6 (C), 118.2 (q, J = 286.7, 
CF3), 117.7 (2 × CH), 56.6 (CH), 52.6 (CH3), 37.8 (CH2); 
19
F NMR (376.3 MHz, 
CDCl3) δ -77.2 (3F, s, C); m/z (ESI-, MeOH) 290 ([M-H]
-
, 86%), 276 (100). 
 









Using General Procedure C, phenol 25 (1.00 g, 3.43 mmol) was reacted with 
propargyl bromide (1.38 g, 12.4 mmol) and potassium carbonate (0.95 g, 6.87 
mmol) in DMF (30 cm
3
), to afford propargyl ether 26 as a pale yellow oil (1.10 g, 
97%). 
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Rf (Hexane:EtOAc, 3:1) = 0.37; [α]D = -87.7 (c 1.43, EtOH); IR (neat)1746 (C=O, 
ester), 1699 (C=O, carbamate); 
1
H NMR (500 MHz, CDCl3) δ 7.18-7.10 (2H, m, 
ArH), 7.01– 6.89 (2H, m, ArH), 4.86-4.70 (1H, m, NH), 4.67 (2H, d, J = 2.4, HC≡ 
CCH2), 4.51 – 4.25 (1H, m, CHNH), 3.75 (3H, s, CH3), 3.45 – 3.24 (2H, m, CH2Ar), 
2.51 (1H, t, J = 2.4, HC≡ CCH2); 
13
C NMR (100.6 MHz, CDCl3) δ 171.2 (C), 156.7 
(C), 156.4 (q, J = 44.5, C), 130.1 (2 × CH), 129.7 (C), 115.8 (q, J = 287.9, CF3), 
115.2 (2 × CH), 78.4 (C), 76.0 (CH), 62.3 (C), 60.4 (CH2), 55.9 (CH), 53.0 (CH3), 
33.2 (CH2); 
19










Phenol 15b (3.00 g, 10.2 mmol) was dissolved in ethyl acetate (100 cm
3
) with p-
TsOH (0.193 g, 1.02 mmol) under UV radiation (365 nm) at room temperature. N-
Bromosuccinimide (1.81 g, 10.2 mmol) was added, and the very pale yellow 
solution was stirred for 40 minutes. The reaction mixture was washed with Na2S2O3 
(5% aq., 3 × 200 cm
3
), water (3 × 200 cm
3
), brine (200 cm
3
), dried (MgSO4) and the 
solvent removed under reduced pressure. The dark orange oil was purified by 
column chromatography (Hexane:EtOAc, 95:5) to give ortho-bromo-phenol 158 as 
a colourless crystalline solid (3.42 g, 90%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.12; mp 121-123 ºC; [α]D = −58.6 (c 1.11, CHCl3); IR 
(neat) 3360 (OH), 1742 (C=O, ester), 1688 (C=O, carbamate); 
1
H NMR (400 MHz, 
CDCl3, 323 K) δ 7.24 (1H, d, J = 2.0, ArH), 6.98 (1H, dd, J = 8.3, 2.0, ArH), 6.92 
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(1H, d, J = 8.3, ArH), 5.52 (1H, s, OH), 4.96 (1H, br s, NHCH), 4.50 (1H, br s, 
CHNH), 3.72 (3H, s, OCH3), 3.04 (1H, dd, J = 13.8, 5.8, CHAHBAr), 2.94 (1H, dd, J 
= 13.8, 5.8, CHAHBAr), 1.43 (9H, s, OC(CH3)3); 
13
C NMR (125.8 MHz, CDCl3, 298 
K) δ 172.3 (C=O), 155.2 (C=O), 151.6 (C), 132.9 (CH), 130.5 (C), 130.1 (CH), 
116.3 (CH), 110.2 (CBr), 80.3 (C), 54.6 (CH), 52.5 (CH3), 37.3 (CH2), 28.4 (3 × 








, 100), 342 







Using General Procedure C, phenol 158 (2.29 g, 6.12 mmol) was reacted with 
K2CO3 (1.69 g, 12.2 mmol) and propargyl bromide (2.5 cm
3
, 22.0 mmol) in DMF 
(40 cm
3
). The crude product was purified by column chromatography 
(Hexane:EtOAc, 90:10) to afford propargyl ether 164 as a colourless solid (2.47 g, 
98%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.29; mp 66 ºC; [α]D = -41.1 (c 1.24, CHCl3); IR (neat) 
3435 (NH), 3304 (C≡C−H), 2122 (C≡C), 1738 (C=O, ester), 1708 (C=O, 
carbamate); 
1
H NMR δ (400 MHz, CDCl3, 323 K) 7.32 (1H, d, J = 2.1, ArH), 7.03 
(1H, dd, J = 8.4, 2.1, ArH), 6.97 (1H, d, J = 8.4, ArH), 4.97 (1H, br s, NHCH), 4.72 
(2H, d, J = 2.4, HC≡CCH2), 4.50 (1H, br s, CHNH), 3.70 (3H, s, OCH3), 3.05 (1H, 
dd, J = 13.8, 5.8, CHAHBAr), 2.93 (1H, dd, J = 13.8, 5.8, CHAHBAr), 2.51 (1H, t, J = 
2.4, HC≡CCH2) 1.41 (9H, s, OC(CH3)3); 
13
C NMR δ (125.8 MHz, CDCl3, 298 K) 
172.1 (C=O), 155.1 (C=O), 153.2 (C), 134.4 (C), 130.9 (CH), 129.2 (CH), 114.2 
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(CH), 112.3 (CBr), 80.1 (C), 78.0 (C), 76.3 (CH), 57.0 (CH2), 54.5 (CH), 52.4 
























Using General Procedure O, Boc protected amine 164 (2.08 g, 5.05 mmol) was 
reacted with NaH (60% mineral oil dispersion, 0.303 g, 7.58 mmol) in dry THF (25 
cm
3
) and DMF (6 cm
3
) with MeI (2.5 cm
3
, 40.4 mmol). The crude product was 
purified by column chromatography (Hexane:EtOAc, 100:0 to 85:15) to afford Boc 
protected methyl amine 166 as a colourless oil (2.13 g, 99%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.20; [α]D = +23.5 (c 1.02, CHCl3); IR (neat) 3292 
(C≡C−H), 2122 (C≡C), 1740 (C=O, ester), 1688 (C=O, carbamate); 
1
H NMR δ 
(500 MHz, CDCl3, 298 K) 7.39 (1H, d, J = 4.7, ArH), 7.09 (1H, dd, J = 8.2, 4.7, 
ArH), 6.98 (1H, d, J = 8.2, ArH), 4.85 (0.44H, dd, J = 10.5, 5.3, NCH3CH), 4.74 
(2H, s, HC≡CCH2), 4.54 (0.56H, dd, J = 10.5, 4.3, NCH3CH), 3.75 (1.68H, s, 
OCH3), 3.73 (1.32H, s, OCH3), 3.22 (1.12H, m, CH2Ar), 2.94 (0.88H, m, CH2Ar), 
2.73 (1.68H, s, NCH3CH), 2.70 (1.32H, s, NCH3CH), 2.51 (1H, t, J = 2.4, 
HC≡CCH2), 1.39 (3.96H, s, OC(CH3)3), 1.34 (5.04H, s, OC(CH3)3); 
13
C NMR δ 
(125.8 MHz, CDCl3, 298 K) major rotamer (56%) 171.4 (C=O), 155.0 (C=O), 153.0 
(C), 134.0 (CH), 132.6 (C), 129.1 (CH), 114.3 (CH), 112.5 (CBr), 80.6 (C), 78.0 
(C), 76.3 (CH), 61.4 (CH), 57.1 (CH2), 52.4 (CH3), 34.5 (CH2), 32.2 (CH3), 28.3 (3 
× CH3), minor rotamer (44%) 171.7 (C=O), 155.9 (C=O), 152.9 (C), 134.0 (CH), 
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132.4 (C), 128.9 (CH), 114.3 (CH), 112.3 (CBr), 80.4 (C), 78.0 (C), 76.2 (CH), 59.6 









, 100), 394 (52), 392 (55); 














Using General Procedure D, Boc protected methyl amine 166 (4.45 g, 10.4 mmol) 
was reacted with TFA (8.00 cm
3
, 104 mmol) in DCM (50 cm
3
). The crude product 
was purified by column chromatography (DCM) to give methyl amine 167 as a 
colourless solid (3.06 g, 90%). 
 
Rf (DCM:MeOH, 99:1) = 0.11; mp 80-82 ºC; [α]D = +14.3 (c 1.05, CHCl3); IR 
(neat) 3291 (C≡C−H), 2122 (C≡C), 1732 (C=O, ester); 
1
H NMR δ (500 MHz, 
CDCl3) 7.35 (1H, d, J = 2.1, ArH), 7.05 (1H, dd, J = 8.4, 2.1, ArH), 6.95 (1H, d, J = 
8.4, ArH), 4.71 (2H, d, J = 2.4, HC≡CCH2), 3.65 (3H, s, OCH3), 3.37 (1H, t, J = 6.8, 
CHNH), 2.86 (1H, dd, J = 12.9, 5.6, CHAHBAr), 2.82 (1H, dd, J = 12.9, 6.1, 
CHAHBAr), 2.52 (1H, t, J = 2.4, HC≡CCH2), 2.33 (3H, s, NHCH3); 
13
C NMR δ 
(125.8 MHz, CDCl3) 174.7 (C=O), 152.9 (C), 134.1 (CH), 132.1 (C), 129.1 (CH), 
114.1 (CH), 112.3 (CBr), 78.1 (C), 76.2 (CH), 64.5 (CH), 57.0 (CH2), 51.8 (CH3), 






















 found 326.0386, C14H17
79
BrNO3 requires 326.0386. 
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Using General Procedure F, methyl ester 167 (4.33 g, 13.3 mmol) was reacted 
with NaOH (0.585 g, 14.6 mmol) in H2O (54 cm
3
) and MeOH (12 cm
3
) to afford 
carboxylic acid 172 as a colourless solid (3.69 g, 89%). 
 
Rf (DCM:MeOH, 99:1) = 0.00; mp 204-206 ºC (subl.); [α]D = −14.0 (c 0.93, aq. 
NaOH); IR (neat) 3437 (OH); 
1
H NMR δ (400 MHz, D2O, pD 14) 7.35 (1H, d, J = 
1.8, ArH), 7.07 (1H, dd, J = 8.5, 1.8, ArH), 6.99 (1H, d, J = 8.5, ArH), 4.71 (2H, s, 
HC≡CCH2), 3.05 (1H, t, J = 6.8, CHNH), 2.72-2.66 (2H, m, CH2Ar), 2.12 (3H, s, 
NHCH3); 
13
C NMR δ (125.8 MHz, D2O, pD 14) 181.7 (C=O), 152.5 (C), 134.5 
(CH), 134.3 (C), 130.2 (CH), 115.4 (CH), 112.0 (CBr), 78.6 (C), 67.5 (CH), 67.4 



































 found 310.0085, 
C13H14
79




methylamino]propanoic acid (173) 
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Using General Procedure G, 3-(3-Bromo-4-prop-2-ynyloxy-phenyl)-2-
methylamino-propionic acid 172 (3.68 g, 11.8 mmol) was reacted with Fmoc-OSu 
(3.98 g, 11.8 mmol) and Na2CO3 (3.75 g, 35.4 mmol) in MeOH (90 cm
3
) and DMF 
(20 cm
3
) to afford Fmoc-protected amine 173 as a yellow oil (4.53 g, 72%), which 
was used without further purification. 
 
Rf (Hexane:EtOAc, 3:1) = 0.05; 
1
H NMR δ (400 MHz, CDCl3) 7.58-7.52 (2H, m, 
ArH), 7.37-7.32 (2H, m, ArH), 7.27-7.25 (2H, m, ArH), 7.25-7.17 (3H, m, ArH), 
7.12-7.08 (2H, m, ArH), 4.83-4.55 (1H, m, CHNMe), 4.55-4.53 (2H, m, 
CH2C≡CH), 4.53-4.52 (1H, m, CH2CHAr), 4.46-4.45 (2H, m, CH2O), 3.24 (3H, s, 
NCH3), 3.04-2.86 (2H, m, CH2NH), 2.86 (1H, s, C≡CH); 
13
C NMR δ (100.6 MHz, 
CDCl3) 172.4 (C=O), 155.2 (C=O), 154.8 (C), 145.0 (2 × C), 138.7 (2 × C), 134.2 
(CH), 132.7 (C), 129.9 (CH), 128.8 (2 × CH), 127.1 (2 × CH), 124.1 (2 × CH), 
122.9 (2 × CH), 114.7 (CH), 112.7 (CBr), 80.2 (C), 78.6 (CH), 67.7 (CH2), 59.8 
























, 92), 1709 (43), 1142 (41), 622 (57), 
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Phenol 15b (3.00 g, 10.2 mmol) was dissolved in ethyl acetate (100 cm
3
) with p-
TsOH (0.193 g, 1.02 mmol) under UV radiation (365 nm) at room temperature. N-
Iodosuccinimide (2.29 g, 10.2 mmol) was added, and the very pale yellow solution 
was stirred for 11 hours. The reaction mixture was washed with Na2S2O3 (5% aq. 
soln., 3 × 200 cm
3
), water (3 × 200 cm
3
), brine (200 cm
3
), dried (MgSO4) and the 
solvent removed under reduced pressure. The dark orange oil was purified by 
column chromatography (Hexane:EtOAc, 95:5) to give ortho-iodo-phenol 174 as a 
colourless crystalline solid (3.59 g, 84%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.13; mp 112-114 ºC, (lit.
152
 110-112 °C); [α]D = −49.1 
(c 1.14, CHCl3), [lit.
152
 (for (S)-enantiomer) [α]D +48.8 (c 0.57, CHCl3)]; IR (neat) 
3368 (OH), 1738 (C=O, ester), 1686 (C=O, carbamate); 
1
H NMR δ (400 MHz, 
CDCl3, 323 K) 7.43 (1H, d, J = 2.0, ArH), 7.00 (1H, dd, J = 8.3, 2.0, ArH), 6.89 
(1H, d, J = 8.3, ArH), 5.30 (1H, s, OH), 4.96 (1H, br s, NHCH), 4.50 (1H, br s, 
CHNH), 3.72 (3H, s, OCH3), 3.03 (1H, dd, J = 13.9, 5.8, CHAHBAr), 2.92 (1H, dd, J 
= 13.9, 5.8, CHAHBAr), 1.43 (9H, s, OC(CH3)3); 
13
C NMR δ (125.8 MHz, CDCl3, 
323 K) 172.3 (C=O), 155.2 (C=O), 154.3 (C), 139.1 (CH), 131.2 (CH), 130.4 (C), 
115.2 (CH), 85.6 (CI), 80.3 (C), 54.8 (CH), 52.4 (CH3), 37.3 (CH2), 28.5 (3 × CH3); 
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Using General Procedure C, phenol 174 (2.54 g, 6.03 mmol) was reacted with 
K2CO3 (1.67 g, 12.1 mmol) and propargyl bromide (2.4 cm
3
, 21.7 mmol) in DMF 
(40 cm
3
). The crude product was purified by column chromatography 
(Hexane:EtOAc, 90:10) to afford propargyl ether 176 as a colourless solid (2.58 g, 
93%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.26; mp 73-75 ºC; [α]D = −50.7 (c 1.01, CHCl3); IR 
(neat) 3377 (NH), 3292 (C≡C−H), 2122 (C≡C), 1742 (C=O, ester), 1709 (C=O, 
carbamate); 
1
H NMR δ (500 MHz, CDCl3, 323 K) 7.55 (1H, d, J = 2.1, ArH), 7.07 
(1H, dd, J = 8.4, 2.1, ArH), 6.90 (1H, d, J = 8.4, ArH), 4.97 (1H, br s, NHCH), 4.71 
(2H, d, J = 2.4, HC≡CCH2), 4.50 (1H, br s, CHNH), 3.71 (3H, s, OCH3), 3.03 (1H, 
dd, J = 13.9, 5.8, CHAHBAr), 2.93 (1H, m, CHAHBAr), 2.51 (1H, t, J = 2.4, 
HC≡CCH2), 1.42 (9H, s, OC(CH3)3); 
13
C NMR δ (125.8 MHz, CDCl3, 323 K) 172.1 
(C=O), 155.8 (C=O), 155.1 (C), 140.6 (CH), 131.7 (C), 130.3 (CH), 113.3 (CH), 
86.8 (CI), 80.2 (C), 78.2 (C), 76.2 (CH), 57.3 (CH2), 54.7 (CH), 52.3 (CH3), 37.2 
(CH2), 28.5 (3 × CH3); m/z (ESI+, MeOH) 482 ([M+Na]
+
, 100%), 426 (53), 359 
(28), 356 (49), 300 (27); HRMS (ESI+, MeOH) [M+Na]
+
 found 482.0432, 








Using General Procedure O, Boc protected amine 176 (3.30 g, 7.12 mmol) was 
reacted with NaH (60% mineral oil dispersion, 0.431 g, 10.8 mmol) in dry THF (35 
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) and DMF (8 cm
3
) with MeI (3.6 cm
3
, 57.5 mmol). The crude product was 
purified by column chromatography (Hexane:EtOAc, 100:0 to 85:15) to afford Boc 
protected methyl amine 178 as a colourless oil (3.16 g, 93%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.21; [α]D = +38.9 (c 1.24, CHCl3); IR (neat) 3291 
(C≡C−H), 2122 (C≡C), 1740 (C=O, ester), 1688 (C=O, carbamate); 
1
H NMR δ 
(400 MHz, CDCl3, 323 K) 7.63 (1H, d, J = 1.9, ArH), 7.12 (1H, br s, ArH), 6.91 
(1H, d, J = 8.4, ArH), 4.82 (0.45H, br s, CHNCH3), 4.72 (1.1H, s, HC≡CCH2), 4.71 
(0.9H, s, HC≡CCH2), 4.53 (0.55H, br s, CHNCH3), 3.74 (3H, s, OCH3), 3.20 (1H, 
dd, J = 14.5, 5.1, CHAHBAr), 2.93 (1H, m, CHAHBAr), 2.73 (3H, br s, CHNCH3), 
2.50 (1H, t, J = 2.4, HC≡CCH2), 1.38 (9H, br s, OC(CH3)3); 
13
C NMR δ (125.8 
MHz, CDCl3, 298 K) major rotamer (55%) 171.5 (C=O), 155.3 (C=O), 155.0 (C), 
140.1 (CH), 133.0 (C), 130.2 (CH), 113.1 (CH), 86.8 (CI), 80.6 (C), 78.1 (C), 76.3 
(CH), 61.4 (CH), 57.1 (CH2), 52.4 (CH3), 34.3 (CH2), 32.2 (CH3), 28.4 (3 × CH3), 
minor rotamer (45%) 171.7 (C=O), 155.9 (C=O), 155.3 (C), 140.1 (CH), 132.8 (C), 
130.0 (CH), 113.1 (CH), 86.5 (CI), 80.3 (C), 78.2 (C), 76.2 (CH), 59.6 (CH), 57.1 
(CH2), 52.4 (CH3), 33.8 (CH2), 32.4 (CH3), 28.4 (3 × CH3); m/z (ESI+, MeOH) 496 
([M+Na]
+
, 100%), 440 (73), 374 (27); HRMS (ESI+, MeOH) [M+Na]
+
 found 
496.0596, C19H24INNaO5 requires 496.0602. 
 
 




Using General Procedure D, Boc protected methyl amine 178 (2.61 g, 5.51 mmol) 
was reacted with TFA (4.2 cm
3
, 55.1 mmol) in DCM (25 cm
3
). The crude product 
was purified by column chromatography (DCM) to give methyl amine 180 as a 
colourless solid (1.71 g, 83%). 
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Rf (DCM:MeOH, 99:1) = 0.09; mp 93-94 °C; [α]D = −27.6 (c 1.09, CHCl3); IR 
(neat) 3294 (C≡C−H), 2122 (C≡C), 1732 (C=O, ester); 
1
H NMR δ (500 MHz, 
CDCl3) 7.60 (1H, d, J = 2.2, ArH), 7.11 (1H, dd, J = 8.4, 2.2, ArH), 6.90 (1H, d, J = 
8.4, ArH), 4.72 (2H, t, J = 2.4, HC≡CCH2), 3.68 (3H, s, OCH3), 3.38 (1H, t, J = 6.8, 
CHNH), 2.86 (1H, dd, J = 12.7, 5.6, CHAHBAr), 2.83 (1H, dd, J = 12.7, 5.6, 
CHAHBAr), 2.52 (1H, t, J = 2.4, HC≡CCH2), 2.36 (3H, s, NCH3); 
13
C NMR δ 
(125.8 MHz, CDCl3) 174.7 (C=O), 155.4 (C), 140.3 (CH), 132.6 (C), 130.2 (CH), 
112.9 (CH), 86.7 (CI), 78.2 (C), 76.2 (CH), 64.6 (CH), 57.1 (CH2), 51.9 (CH3), 38.1 
(CH2), 34.8 (CH3); m/z (ESI+, MeOH) 374 ([M+H]
+
, 100%), 388 (31), 314 (30); 
HRMS (ESI+, MeOH) [M+H]
+
 found 374.0248, C14H17INO3 requires 374.0248. 
 
 




Procedure F, methyl ester 180 (1.51 g, 4.05 mmol) was reacted with NaOH (0.194 
g, 4.86 mmol) in H2O (16 cm
3
) and MeOH (5 cm
3
) to afford carboxylic acid 182 as 
a colourless solid (1.45 g, 97%). 
 
Rf (DCM:MeOH, 99:1) = 0.00; mp 197-198 ºC (dec.); [α]D = −17.1 (c 1.06, aq. 
NaOH); IR (neat) 3409 (OH); 
1
H NMR δ (500 MHz, D2O, pD 14) 7.07 (1H, s, 
ArH), 6.56 (1H, d, J = 8.4, ArH), 6.26 (1H, d, J = 8.4, ArH), 4.16 (2H, s, 
HC≡CCH2), 2.63 (1H, t, J = 6.7, NHCH), 2.35 (1H, dd, J = 13.4, 3.9, CHAHBAr), 
2.11 (1H, dd, J = 13.4, 8.3, CHAHBAr), 1.64 (3H, s, NHCH3); 
13
C NMR δ (125.8 
MHz, D2O, pD 14) 181.7 (C=O), 155.0 (C), 140.6 (CH), 134.7 (C), 131.3 (CH), 
114.5 (CH), 86.8 (CI), 78.8 (CH), 77.8 (C), 67.6 (CH), 57.9 (CH2), 38.3 (CH2), 34.0 
(CH3); m/z (ESI+, MeOH) 795 ([2M-H+2K]
+
, 36%), 785 ([2M-2H+3Na]
+
, 19), 773 
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, 24), 382 ([M+Na]
+
, 32), 360 ([M+H]
+
, 100), 314 (48); 
HRMS (ESI-, MeOH) [M-H]
-








Using General Procedure G, methyl amine 182 (2.06 g, 5.74 mmol) was reacted 
with Fmoc-OSu (1.94 g, 5.74 mmol) and Na2CO3 (1.83 g, 17.2 mmol) in MeOH (45 
cm
3
) and DMF (10 cm
3
) to afford Fmoc-protected methyl amine 184 (2.57 g, 77%). 
Rf (Hexane:EtOAc, 3:1) = 0.07; 
1
H NMR δ (400 MHz, CDCl3) 7.58-7.52 (2H, m, 
ArH), 7.36-7.34 (2H, m, ArH), 7.25-7.18 (2H, m, ArH), 7.18-7.15 (3H, m, ArH), 
7.15-7.10 (2H, m, ArH), 4.85-4.75 (1H, m, CHNMe), 4.62-4.53 (2H, m, 
CH2C≡CH), 4.53-4.49 (1H, m, CH2CHAr), 4.47-4.45 (2H, m, CH2O), 2.93 (3H, s, 
NCH3), 3.02-2.84 (2H, m, CH2NH), 2.56 (1H, s, C≡CH); 
13
C NMR δ (100.6 MHz, 
CDCl3) 172.5 (C=O), 155.3 (C=O), 154.7 (C), 145.2 (2 × C), 138.7 (2 × C), 134.2 
(CH), 132.8 (C), 129.9 (CH), 128.8 (2 × CH), 127.1 (2 × CH), 124.1 (2 × CH), 
122.9 (2 × CH), 113.7 (CH), 87.0 (CI), 80.4 (C), 78.3 (CH), 68.0 (CH2), 59.8 (CH), 
57.7 (CH2), 48.2 (CH), 34.3 (CH2), 32.3 (CH3); m/z (ESI+, MeOH) 604 ([M+Na]
+
, 
87%), 714 (49), 667 (100), 360 (54), 316 (79), 197 (50); HRMS (ESI+, MeOH) 
[M+Na]
+
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Using General Procedure N, phenol 158 (2.33 g, 6.24 mmol) was reacted with 
Boc2O (10.9 g, 49.9 mmol) and Sc(OTf)3 (0.154 g, 0.311 mmol) in DCM (10 cm
3
). 
The crude product was purified by column chromatography (Hexane:EtOAc, 98:2 to 
88:12) to afford tert-butyl ether 163 as a colourless solid (2.07 g, 77%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.39; mp 78-79 °C; [α]D = −47.2 (c 1.17, CHCl3); IR 
(neat) 3368 (NH), 1745 (C=O, ester), 1709 (C=O, carbamate); 
1
H NMR δ (500 
MHz, CDCl3, 323 K) 7.32 (1H, d, J = 2.1, ArH), 7.01 (1H, d, J = 8.3, ArH), 6.96 
(1H, dd, J = 8.3, 2.1, ArH), 4.97 (1H, br s, NHCH), 4.51 (1H, br s, CHNH), 3.69 
(3H, s, OCH3), 3.03 (1H, dd, J = 13.8, 5.7, CHAHBAr), 2.93 (1H, dd, J = 13.8, 6.3, 
CHAHBAr), 1.42 (9H, s, OC(CH3)3), 1.41 (9H, s, OC(CH3)3); 
13
C NMR δ (125.8 
MHz, CDCl3, 323 K) major rotamer (52%) 172.2 (C=O), 155.1 (C=O), 152.6 (C), 
134.3 (CH), 132.4 (C), 128.8 (CH), 123.7 (CH), 119.1 (CBr), 81.4 (C), 80.2 (C), 
54.7 (CH), 52.3 (CH3), 37.8 (CH2), 29.2 (3 × CH3), 28.5 (3 × CH3), minor rotamer 
(48%) 172.5 (C=O), 154.8 (C=O), 152.6 (C), 134.3 (CH), 129.8 (C), 128.8 (CH), 
124.1 (CH), 119.1 (CBr), 81.0 (C), 78.4 (C), 54.7 (CH), 52.3 (CH3), 37.8 (CH2), 
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Using General Procedure O, Boc protected amine 163 (1.35 g, 3.14 mmol) was 
reacted with NaH (60% mineral oil dispersion, 0.188 g, 4.71 mmol) in dry THF (15 
cm
3
) and DMF (4 cm
3
) with MeI (1.6 cm
3
, 25.1 mmol). The crude product was 
purified by column chromatography (Hexane:EtOAc, 100:0 to 85:15) to afford Boc 
protected methyl amine 165 as a colourless oil (1.33 g, 95%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.37; [α]D = +31.8 (c 1.07, CHCl3); IR (neat) 1745 (C=O, 
ester), 1693 (C=O, carbamate); 
1
H NMR δ (400 MHz, CDCl3, 323 K) 7.38 (1H, s, 
ArH), 7.01 (2H, br s, ArH), 4.81 (0.48H, br s, CHNCH3), 4.53 (0.52H, br s, 
CHNCH3), 3.73 (3H, s, OCH3), 3.20 (0.96H, m, CH2Ar), 2.96 (1.04H, m, CH2Ar), 
2.71 (3H, br s, NCH3) 1.57 (9H, s, OC(CH3)3); 
13
C NMR δ (125.8 MHz, CDCl3, 
298 K) major rotamer (52%) 171.5 (C=O), 155.0 (C=O), 152.0 (C), 133.9 (C), 133.7 
(CH), 128.7 (CH), 123.9 (CH), 119.2 (CBr), 81.4 (C), 80.6 (C), 61.5 (CH), 52.4 
(CH3), 34.6 (CH2), 32.3 (CH3), 29.1 (3 × CH3), 28.4 (3 × CH3), minor rotamer 
(48%) 171.8 (C=O), 155.9 (C=O), 152.2 (C), 133.9 (C), 133.8 (CH), 128.5 (CH), 
123.9 (CH), 119.1 (CBr), 81.3 (C), 80.3 (C), 59.7 (CH), 52.4 (CH3), 34.1 (CH2), 





























 found 466.1199, C20H30BrNNaO5 requires 466.1200. 
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Using General Procedure P, Boc protected methyl amine 165 (1.38 g, 3.11 mmol) 
was reacted with TMSOTf (2.30 cm
3
, 12.4 mmol) and 2,6-lutidine (1.80 cm
3
, 15.5 
mmol) in dry DCM (8 cm
3
). The crude product was purified by column 
chromatography (Hexane:EtOAc, 4:1 to 3:2) to afford methyl amine 168 as a 
colourless oil (0.92 g, 86%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.04; [α]D = −14.3 (c 0.98, CHCl3); IR (neat) 3347 (NH), 
1736 (C=O, ester); 
1
H NMR δ (400 MHz, CDCl3, 323 K) 7.34 (1H, s, ArH), 6.98 
(1H, s, ArH), 6.98 (1H, s, ArH), 3.61 (3H, s, OCH3), 3.36 (1H, t, J = 6.8, CHNH), 
2.90-2.75 (2H, m, CH2Ar), 2.34 (3H, s, NCH3), 1.39 (9H, s, OC(CH3)3); 
13
C NMR δ 
(125.8 MHz, CDCl3, 298 K) 174.7 (C=O), 152.1 (C), 133.8 (CH), 133.5 (C), 128.6 
(CH), 123.7 (CH), 119.0 (CBr), 81.2 (C), 64.6 (CH), 51.6 (CH3), 38.5 (CH2), 34.8 













 found 344.0856, 
C15H23
79









Using General Procedure F, methyl ester 168 (0.670 g, 1.94 mmol) was reacted 
with NaOH (0.093 g, 2.33 mmol) in H2O (8 cm
3
) and MeOH (2 cm
3
) to afford 
carboxylic acid 171 as a colourless solid (0.559 g, 87%). 
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Rf (Hexane:EtOAc, 3:1) = 0.00; mp 219-220 ºC (subl.); [α]D = −12.4 (c 1.05, aq. 
NaOH); IR (neat) 3446 (OH); 
1
H NMR δ (400 MHz, D2O, pD 14) 7.26 (1H, d, J = 
1.3, ArH), 6.91-6.89 (2H, m, ArH), 2.94 (1H, t, J = 6.8, CHNH), 2.60 (1H, dd, J = 
12.1, 5.3, CHAHBAr), 2.55 (1H, dd, J = 12.1, 5.3, CHAHBAr), 1.99 (3H, s, NHCH3), 
1.12 (9H, s, OC(CH3)3); 
13
C NMR δ (100.6 MHz, D2O, pD 14) 181.6 (C=O), 151.0 
(C), 136.3 (C), 134.3 (CH), 129.8 (CH), 125.1 (CH), 119.0 (CBr), 83.5 (C), 67.4 





























 found 330.0534, C14H20
81
















Using General Procedure G, methyl amine 171 (0.500 g, 1.51 mmol) was reacted 
with Fmoc-OSu (0.511 g, 1.51 mmol) and Na2CO3 (0.482 g, 4.54 mmol) in MeOH 
(5 cm
3
) and DMF (15 cm
3
) to afford a pale yellow oil which was used as the crude 
Fmoc-protected methyl amine 144 (0.617 g, 74%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.02; 
1
H NMR δ (500 MHz, CDCl3) 7.75-7.73 (2H, m, 
ArH), 7.66-7.61 (1H, m, ArH), 7.52-7.50 (2H, m, ArH), 7.42 (1H, br s, ArH), 7.38 
(2H, br s, ArH), 7.29-7.26 (2H, m, ArH), 7.03-7.00 (1H, m, ArH), 4.55 (1H, br s, 
CHNCH3), 4.34 (2H, m, OCH2CH), 4.20 (1H, br s, OCH2CH), 3.31-3.04 (2H, m, 
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CH2Ar), 2.81-2.77 (3H, m, NCH3), 1.37-1.35 (9H, m, O(CH3)3); 
13
C NMR δ (125.8 
MHz, CDCl3) 172.0 (C=O), 155.3 (C=O), 153.1 (C), 142.9 (2 × C), 137.3 (2 × C), 
134.2 (C), 133.7 (CH), 129.2 (CH), 128.2 (2 × CH), 127.2 (2 × CH), 124.2 (2 × 
CH), 123.8 (2 × CH), 119.3 (CH), 116.2 (CBr), 77.7 (C), 66.9 (CH2), 59.7 (CH), 









, 100), 1347 (15), 663 (25), 274 (22); 











 found 574.1195, C29H30
79









Using General Procedure N, phenol 174 (2.40 g, 5.70 mmol) was reacted with 
Boc2O (9.95 g, 45.6 mmol) and Sc(OTf)3 (0.224 g, 0.456 mmol) in dry DCM (15 
cm
3
). The crude product was purified by column chromatography (Hexane:EtOAc, 
98:2 to 88:12) to afford tert-butyl ether 175 as a colourless solid (1.96 g, 72%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.43; mp 87-89 ºC; [α]D = −45.8 (c 1.18, CHCl3); IR 
(neat) 3440 (NH), 1744 (C=O, ester), 1706 (C=O, carbamate); 
1
H NMR δ (500 
MHz, CDCl3) 7.54 (1H, br s, ArH), 7.00 (1H, dd, J = 8.2, 1.9, ArH), 6.98 (1H, d, J = 
8.2, ArH), 5.02 (1H, br d, J = 7.8, NHCH), 4.51 (1H, br d, J = 7.1, CHNH), 3.69 
(1.65H, s, OCH3), 3.67 (1.35H, s, OCH3), 3.03-2.89 (2H, m, CH2Ar), 1.44 (4.95H, s, 
OC(CH3)3), 1.41 (4.05H, s, OC(CH3)3), 1.40 (4.05H, s, OC(CH3)3), 1.31 (4.95H, s, 
OC(CH3)3); 
13
C NMR δ (125.8 MHz, CDCl3) major rotamer (55%), 172.3 (C=O), 
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155.3 (C=O), 154.5 (C), 140.2 (CH), 132.4 (C), 129.8 (CH), 124.3 (CH), 94.8 (CI), 
81.4 (C), 78.5 (C), 54.5 (CH), 52.4 (CH3), 37.3 (CH2), 29.4 (3 × CH3), 28.4 (3 × 
CH3), minor rotamer (45%), 172.6 (C=O), 155.2 (C), 155.1 (C=O), 140.2 (CH), 
130.9 (C), 129.8 (CH), 121.5 (CH), 94.8 (CI), 80.1 (C), 80.0 (C), 54.6 (CH), 52.2 
(CH3), 37.9 (CH2), 29.4 (3 × CH3), 28.9 (3 × CH3); m/z (ESI+, MeOH) 500 
([M+Na]
+
, 100%), 444 (64); HRMS (ESI+, MeOH) [M+Na]
+
 found 500.0902, 








Using General Procedure O, Boc protected amine 175 (2.18 g, 4.58 mmol) was 
reacted with NaH (60% mineral oil dispersion, 0.275 g, 6.87 mmol) in dry THF (22 
cm
3
) and DMF (5 cm
3
) with MeI (2.28 cm
3
, 36.6 mmol). The crude product was 
purified by column chromatography (Hexane:EtOAc, 100:0 to 85:15) to afford Boc 
protected methyl amine 177 as a colourless oil (2.16 g, 96%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.26; [α]D = +41.7 (c 1.20, CHCl3); IR (neat) 1745 (C=O, 
ester), 1696 (C=O, carbamate); 
1
H NMR δ (500 MHz, CDCl3, 323 K) 7.62 (1H, br 
s, ArH), 7.09-7.03 (1H, m, ArH), 6.97 (1H, d, J = 8.3, ArH), 4.80 (0.45H, br s, 
NHCH), 4.52 (0.55H, br s, NHCH), 3.73 (3H, s, OCH3), 3.19-2.89 (2H, m, CH2Ar), 
2.71 (3H, br s, NCH3), 1.44 (4.95H, s, OC(CH3)3), 1.39 (4.95H, s, OC(CH3)3), 1.37 
(4.05H, s, OC(CH3)3), 1.32 (4.05H, s, OC(CH3)3); 
13
C NMR δ (125.8 MHz, CDCl3, 
323 K) major rotamer (55%), 171.5 (C=O), 155.2 (C=O), 155.1 (C), 139.9 (CH), 
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134.0 (C), 129.5 (CH), 121.5 (CH), 94.8 (CI), 81.3 (C), 78.3 (C), 59.9 (CH), 52.2 
(CH3), 34.4 (CH2), 32.4 (CH3), 29.4 (3 × CH3), 28.5 (3 × CH3), minor rotamer 
(45%), 171.7 (C=O), 155.9 (C=O), 154.4 (C), 139.9 (CH), 132.6 (C), 129.5 (CH), 
124.2 (CH), 94.8 (CI), 80.5 (C), 80.3 (C), 61.6 (CH), 52.2 (CH3), 34.1 (CH2), 32.4 
(CH3), 29.4 (3 × CH3), 29.0 (3 × CH3); m/z (ESI+, MeOH) 514 ([M+Na]
+
, 100%), 
458 (24), 388 (29); HRMS (ESI+, MeOH) [M+Na]
+
 found 514.1064, 
C20H30INNaO5 requires 514.1061. 
 
 




Using General Procedure P, Boc protected methyl amine 177 (2.23 g, 4.55 mmol) 
was reacted with TMSOTf (3.29 cm
3
, 18.2 mmol) and 2,6-lutidine (2.65 cm
3
, 22.7 
mmol) in dry DCM (10 cm
3
). The crude product was purified by column 
chromatography (Hexane:EtOAc, 4:1 to 3:2) to afford methyl amine 179 as a 
colourless oil (1.60 g, 90%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.06; [α]D = −15.9 (c 1.20, CHCl3); IR (neat) 3332 (NH), 
1733 (C=O, ester); 
1
H NMR δ (500 MHz, CDCl3) 7.56 (1H, s, ArH), 7.01 (1H, dd, J 
= 8.2, 2.2, ArH), 6.95 (1H, d, J = 8.2, ArH), 3.62 (3H, s, OCH3), 3.36 (1H, t, J = 6.8, 
CHNH), 2.83 (2H, m, CH2Ar), 2.34 (3H, s, NCH3), 1.42 (9H, s, OC(CH3)3); 
13
C 
NMR δ (125.8 MHz, CDCl3) 174.7 (C=O), 155.0 (C), 139.9 (CH), 133.5 (C), 129.7 
(CH), 121.4 (CH), 94.9 (CI), 81.3 (C), 64.6 (CH), 51.7 (CH3), 38.3 (CH2), 34.8 
(CH3), 29.3 (3 × CH3); m/z (ESI+, MeOH) 414 ([M+Na]
+
, 15%), 392 ([M+H]
+
, 
100), 336 (50), 276 (32); HRMS (ESI+, MeOH) [M+H]
+
 found 392.0712, 
C15H23INO3 requires 392.0717. 
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Using General Procedure F, methyl ester 179 (1.45 g, 3.70 mmol) was reacted 
with NaOH (0.178 g, 4.45 mmol) in H2O (14 cm
3
) and MeOH (4 cm
3
) to afford 
carboxylic acid 181 as a colourless solid (1.22 g, 87%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.00; mp 210-211 ºC (subl.); [α]D = −16.4 (c 1.16, aq. 
NaOH); IR (neat) 3381 (OH); 
1
H NMR δ (500 MHz, D2O, pD 14) 7.22 (1H, s, 
ArH), 6.69 (1H, d, J = 8.3, ArH), 6.52 (1H, d, J = 8.3, ArH), 2.75 (1H, t, J =  6.8, 
CHNH), 2.47 (1H, dd, J = 13.5, 5.3, CHAHBAr), 2.26 (1H, dd, J = 13.5, 8.0, 
CHAHBAr), 1.76 (3H, s, NCH3), 0.89 (9H, s, OC(CH3)3); 
13
C NMR δ (125.8 MHz, 
D2O, pD 14) 181.5 (C=O), 154.3 (C), 140.5 (C), 136.4 (CH), 130.9 (CH), 123.0 
(CH), 95.4 (CI), 83.1 (C), 67.6 (CH), 38.5 (CH2), 34.1 (CH3), 29.6 (3 × CH3); m/z 
(ESI−, MeOH) 775 ([M−2H+Na]
−
, 13%), 376 ([M−H]
−
, 100); HRMS (ESI-, 
MeOH) [M-H]
-
 found 376.0416, C14H20INO3 requires 376.0404. 
 
(R)-3-(4-tert-Butoxy-3-iodophenyl)-2-[(9H-fluoren-9-ylmethoxycarbonyl)methy-
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Using General Procedure G, methyl amine 181 (0.749 g, 1.98 mmol) was reacted 
with Fmoc-OSu (0.670 g, 1.98 mmol) and Na2CO3 (0.631 g, 5.95 mmol) in MeOH 
(15 cm
3
) and DMF (5 cm
3
) to afford a pale yellow oil which was used as the crude 
Fmoc-protected amine 183 (0.819 g, 69%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.07; 
1
H NMR δ (500 MHz, CDCl3) 7.75-7.73 (2H, m, 
ArH), 7.66-7.61 (1H, m, ArH), 7.52-7.50 (2H, m, ArH), 7.42 (1H, br s, ArH), 7.38 
(2H, br s, ArH), 7.29-7.26 (2H, m, ArH), 7.03-7.00 (1H, m, ArH), 4.55 (1H, br s, 
CHNCH3), 4.34 (2H, m, OCH2CH), 4.20 (1H, br s, OCH2CH), 3.31-3.04 (2H, m, 
CH2Ar), 2.81-2.77 (3H, m, NCH3), 1.37-1.35 (9H, m, O(CH3)3); 
13
C NMR δ (125.8 
MHz, CDCl3) 172.0 (C=O), 157.4 (C=O), 155.4 (C), 145.0 (2 × C), 140.0 (CH), 
139.1 (2 × C), 134.6 (C), 129.1 (CH), 127.2 (2 ×CH), 126.3 (2 × CH), 124.5 (2 
×CH), 123.2 (2 × CH), 117.4 (CH), 88.8 (CI), 77.7 (C), 67.0 (CH2), 59.4 (CH), 48.0 
(CH), 34.0 (CH2), 32.7 (CH3), 27.7 (3 ×CH3); m/z (ESI+, MeOH) 622 ([M+Na]
+
, 
100%), 1347 (16), 782 (20), 697 (28), 644 (37), 511 (49), 392 (44), 378 (36), 192 
(33); HRMS (ESI+, MeOH) [M+Na]
+









Using General Procedure A, L-phenylalanine (3.00 g, 18.2 mmol) was reacted 
with acetylchloride (3.9 cm
3
, 54.8 mmol) in methanol (50 cm
3
). The resultant solid 
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was recrystallised from methanol, affording methyl ester 151 as a colourless solid 
(3.91 g, 99%). 
 
Rf (DCM:MeOH, 99:1) = 0.00; mp 156-159 °C, (lit.
153
 158-161 °C); [α]D = +37.1 (c 
1.05, EtOH), [lit.
153
 [α]D +37 (c 2, EtOH)]; IR (neat) 3402 (1º amine), 1748 (C=O, 
ester); 
1
H NMR δ (400 MHz, CD3OD) 7.40 – 7.28 (5H, m, ArH), 4.35 (1H, t, J = 
6.7 Hz, CHNH2), 3.79 (3H, s, OCH3) 3.28 (1H, dd, J = 13.6, 5.8 Hz, CHAHBAr), 
3.23 (1H, dd, J = 13.6, 6.3 Hz, CHAHBAr); 
13
C NMR δ (125.8 MHz, CD3OD), 
170.5 (C=O), 135.3 (C), 130.4 (2 × CH), 130.2 (2 × CH), 129.0 (CH), 55.2 (CH), 













Using General Procedure B, amine hydrochloride 151 (2.00 g, 11.2 mmol) was 
reacted with Boc2O (2.44 g, 11.2 mmol) and NaHCO3 (2.81 g, 33.5 mmol) in 
ethanol (30 cm
3
). The crude product was purified by column chromtography 
(Hexane:EtOAc 9:1 to 3:1) to give Boc protected amine 152 as a colourless 
crystalline solid (2.52 g, 97%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.43; mp 39-40 °C, (lit.
154
 39-41 °C); [α]D = +62.6 (c 
1.22, CHCl3), [lit.
147
 [α]D +60.0 (c 0.8, CHCl3)]; IR (neat) 3435 (2º amine), 3335 (2º 
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amine), 1744 (C=O, ester), 1705 (C=O, amide), 1611 (2º amine); 
1
H NMR δ (400 
MHz, 323 K, CDCl3) 7.30 – 7.12 (5H, m, ArH), 5.00 (1H, br s, NHCH), 4.57 (1H, 
br s, CHNH), 3.69 (3H, s, OCH3), 3.12 (1H, dd, J = 13.6, 5.8 Hz, CHAHBAr), 3.03 
(1H, dd, J = 13.6, 6.0 Hz, CHAHBAr), 1.42 (9H, s, OC(CH3)3); 
13
C NMR δ (125.8 
MHz, CDCl3), 172.4 (C=O), 155.1 (C=O), 136.1 (C), 129.3 (2 × CH), 128.5 (2 × 
CH), 127.0 (CH), 79.8 (C), 54.5 (CH), 52.2 (CH3), 38.3 (CH2), 28.3 (CH3); m/z 













Using General Procedure O, Boc protected amine 152 (2.69 g, 9.62 mmol) was 
reacted with NaH (60% mineral oil dispersion, 0.58 g, 14.4 mmol) and MeI (4.80 
cm
3
, 76.9 mmol), in dry THF (45 cm
3
) and dry DMF (9 cm
3
). The crude product 
was purified by column chromatography (Hexane:EtOAc, 3:1) to give the Boc 
protected methyl amine 153 as a colourless oil (2.82 g, 95%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.56; [α]D = −48.8 (c 1.03, CHCl3), [lit.
155
 [α]D −54 (c 
0.04, CHCl3)]; IR (neat) 1742 (C=O, ester), 1692 (C=O, amide); 
1
H NMR δ (400 
MHz, 323 K, CDCl3) 7.30 – 7.19 (5H, m, ArH), 4.93 (0.45H, br s, CHNMe), 4.75 
(0.55H, br s, CHNMe), 3.74 (3H, s, OCH3), 3.32-3.27 (1H, m, CHAHBAr), 3.03 (1H, 
dd, J = 14.3, 10.6 Hz, CHAHBAr), 2.73 (3H, s, NCH3), 1.37 (9H, s, OC(CH3)3); 
13
C 
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NMR δ (125.8 MHz, 323 K, CDCl3), major rotamer (55%); 171.6 (C=O), 154.9 
(C=O), 137.7 (C), 129.0 (2 × CH), 128.5 (2 × CH), 126.6 (CH), 80.2 (C), 61.7 (CH), 
52.1 (CH3), 35.5 (CH2), 32.6 (CH3), 28.2 (3 × CH3), minor rotamer (45%); 171.9 
(C=O), 155.8 (C=O), 137.4 (C), 128.9 (2 × CH), 128.4 (2 × CH), 126.5 (CH), 79.9 














Using General Procedure D, methyl amine 153 (2.52 g, 8.59 mmol) was reacted 
with TFA (6.60 cm
3
, 86.2 mmol) in DCM (30 cm
3
). The TFA salt 154 was obtained 
as an off-white solid, which was used without further purification (2.49 g, 89%). 
 
Rf (DCM:MeOH, 99:1) = 0.11; mp 73-75 °C, (lit.
156
 75-76 ºC); [α]D = +39.2 (c 
1.25, CHCl3); IR (neat) 1748 (C=O, ester), 1668 (C=O, HO2CCF3); 
1
H NMR δ (400 
MHz, CDCl3) 7.28 – 7.11 (5H, m, ArH), 4.13 (1H, t, J = 6.7 Hz, CHNHMe), 3.69 
(3H, s, OCH3) 3.29 (1H, dd, J = 14.3, 6.2 Hz, CHAHBAr), 3.22 (1H, dd, J = 14.3, 7.3 
Hz, CHAHBAr), 2.72 (3H, s, NCH3); 
13
C NMR δ (125.8 MHz, CDCl3), 168.5 
(C=O), 162.4 (q, J = 35.5 Hz, C=O), 133.9 (C), 129.2 (2 × CH), 129.1 (2 × CH), 
128.0 (CH), 116.6 (q, J = 292.0 Hz, CF3), 62.4 (CH), 53.0 (CH3), 35.9 (CH2), 32.1 
(CH3); m/z (ESI+, MeOH) 194 ([M+H]
+
, 100%), 208 (45). 
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Using General Procedure E, the trifluoroacetate salt of methyl amine 
trifluoroacetate salt 154 (2.14 g, 11.1 mmol) was reacted with NaOH (0.49 g, 12.2 
mmol) in methanol (10 cm
3
) and water (45 cm
3
). The carboxylic acid 155 was 
obtained as a colourless solid (1.77 g, 89%). 
 
Rf (DCM:MeOH, 99:1) = 0.00; mp 255-256 °C (dec.), (lit.
157
 253-254 °C); [α]D = 
+46.7 (c 1.50, aq. NaOH), [lit.
158
 [α]D +47.0 (c 0.5, aq. NaOH)]; IR (neat) 3391 
(OH); 
1
H NMR δ (400 MHz, D2O, pDH 14) 7.36 – 7.02 (5H, m, ArH), 3.11 (1H, t, 
J = 6.4 Hz, CHNHCH3), 2.79 (1H, dd, J = 12.1, 5.0 Hz, CHAHBAr), 2.75 (1H, dd, J 
= 12.1, 6.0 Hz, CHAHBAr), 2.12 (3H, s, NHCH3), 1.82 (1H, s, NHCH3); 
13
C NMR δ 
(125.8 MHz, D2O, pD 14), 182.1 (C=O), 163.6 (q, J = 35.4, C=O), 138.9 (C), 130.0 
(2 × CH), 129.2 (2 × CH), 127.3 (CH), 117.0 (q, J = 291.9, CF3), 67.5 (CH), 39.7 
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Using General Procedure G, methyl amine 155 (2.16 g, 12.0 mmol) was reacted 
with FmocOSu (4.06 g, 12.0 mmol) and Na2CO3 (3.83 g, 36.1 mmol) in DMF (10 
cm
3
) and MeOH (50 cm
3
), which afforded a yellow oil, which was sued as the crude 
Fmoc protected methyl amine 147 as a yellow oil (4.24 g, 88%). 
 
Rf (DCM:MeOH, 99:1) = 0.04; 
1
H NMR δ (400 MHz, CDCl3) 7.79-7.74 (2H, m, 
ArH), 7.64-7.61 (1H, m, ArH), 7.52-7.48 (2H, m, ArH), 7.44-7.37 (2H, m, ArH), 
7.34-7.32 (2H, m, ArH), 7.30-7.26 (2H, m, ArH), 7.24-7.22 (2H, m, ArH), 4.95-4.68 
(1H, br, m , CHNCH3), 4.48-4.44 (“H, m, OCH2CH), 4.32-4.27 (1H, m, OCH2CH), 
3.43-3.10 (2H, m, ArCH2CH), 2.73-2.71 (3H, m, NCH3); 
13
C NMR δ (100.6 MHz, 
CDCl3), 171.4 (C=O), 156.5 (C=O), 144.0 (2 × C), 141.2 (2 × C), 137.3 (C), 129.8 
(2 × CH), 128.8 (2 × CH), 128.7 (2 × CH), 128.6 (2 × CH), 127.9 (CH), 126.9 (2 
×CH), 125.0 (2 ×CH), 67.8 (CH2), 60.3 (CH), 47.4 (CH), 34.7 (CH2), 32.7 (CH3); 
m/z (ESI+, MeOH) 424 ([M+Na]
+
, 100%), 857 (41), 847 (48), 456 (30), 392 (51). 
 





(S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid (220) 
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Using General Procedure B, L-proline (15.0 g, 130 mmol) was reacted with Boc2O 
(28.5 g, 130 mmol) and NaHCO3 (32.9 g, 391 mmol) in ethanol (300 cm
3
). The off-
white solid was purified by column chromatography (Hexane:EtOAc, 9:1 to 3:2) to 
give Boc protected amine 220 as a colourless crystalline solid (26.1 g, 93%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.01; mp 134-136 °C, (lit.
160
 133 °C); [α]D = −111.6 (c 
0.95, CHCl3), [lit.
160
 [α]D −80.0 (c 1.38, CHCl3)]; IR (neat) 3100 (br, C=O), 1749 
(C=O, acid), 1697 (C=O, carbamate); 
1
H NMR δ (400 MHz, CDCl3) 11.38 (1H, s, 
OH), 4.39-4.25 (0.43H, m, CHNBoc), 4.25-4.13 (0.57H, m, CHNBoc), 3.60-3.20 
(2H, m, CH2NBoc), 2.33-1.71 (4H, m, CH2CH2CH2CH), 1.42 (3.87H, s, OC(CH3)3), 
1.37 (5.13H, s, OC(CH3)3); 
13
C NMR δ (125.8 MHz, CDCl3), major rotamer (57%); 
178.4 (C=O), 154.1 (C=O), 80.5 (C), 59.2 (CH), 46.5 (CH2), 30.9 (CH2) , 28.5 (3 × 
CH3) , 23.8 (CH2), minor rotamer (43%); 175.8 (C=O), 156.0 (C=O), 81.1 (C), 59.2 
(CH), 47.0 (CH2), 29.1 (CH2), 28.5 (3 × CH3), 24.4 (CH2); m/z (ESI−, MeOH) 451 
([2M-2H+Na]
−
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Carboxylic acid 220 (0.40 g, 1.86 mmol) was reacted with CDMT (0.392 g, 2.23 
mmol) and NMM (0.613 cm
3
, 5.57 mmol) in THF (5 cm
3
) at room temperature for 1 
h. A colourless precipitate formed and was removed by positive pressure by argon 
through a sintered adapter. CuI (0.354 g, 1.86 mmol) was added, then the reaction 
mixture cooled to 0 ºC (ice bath), and EtMgBr (1 M in THF, 1.86 cm
3
, 1.86 mmol) 
was added slowly. The reaction mixture was stirred for a further 3 h at room 
temperature, before being quenched by NH4Cl (sat. aq. soln., 10 cm
3
). The mixture 
was extracted with Et2O (3 × 15 cm
3
) and the organic layers washed with Na2CO3 
(sat. aq. soln., 15 cm
3
), followed by HCl (1 M, 15 cm
3
), and then brine (15 cm
3
). 
The organic layer was dried (MgSO4), and the solvent removed under reduced 
pressure. The yellow/brown liquid was purified by column chromatography 
(Hexane:EtOAc, 9:1), affording ketone 222 as a colourless oil (0.385 g, 91%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.24; [α]D = −59.1 (c 1.03, CHCl3), [lit.
115
 [α]D −62.7 (c 
1.1, CHCl3)]; IR (neat) 1728 (C=O, ketone), 1694 (C=O, carbamate); 
1
H NMR δ 
(400 MHz, CDCl3) 4.30-4.16  (1H,  m, CHN), 3.48-3.33 (2H, m, CH2N), 2.49-2.29 
(2H, m, CH2CH3), 2.15-2.06 (2H, m, CH2CHN), 1.83-1.73 (2H, m, CH2CH2CH2), 
1.39 (9H, s, OC(CH3)), 1.02-0.97 (3H, m, CH2CH3); 
13
C NMR δ (100.6 MHz, 
CDCl3), 173.5 (C=O), 154.1 (C=O), 80.0 (C), 61.1 (CH), 59.4 (CH2), 46.5 (CH2), 
31.1 (CH2), 28.5 (3 × CH3), 23.8 (CH2), 14.5 (CH3); m/z (ESI+, MeOH) 477 
([2M+Na]
+










(S)-1-tert-Butyl 2-prop-2-ynylpyrrolidine-1,2-dicarboxylate (223) 
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Using General Procedure C, carboxylic acid 220 (2.11 g, 9.80 mmol) was reacted 
with K2CO3 (2.71 g, 19.6 mmol) and propargyl bromide (3.93 cm
3
, 35.3 mmol) in 
DMF (60 cm
3
). The crude product was purified by column chromatography 
(Hexane:EtOAc, 90:10) to afford propargyl ester 223 as a colourless solid (2.38 g, 
96%). 
 
Rf (Hexane:EtOAc, 3:1) = 0.28; mp 53-55 °C, (lit.
161
 52-54 °C); [α]D = –64.6 (c 
1.32, CHCl3), [lit.
161
 [α]D −68.5 (c 1.0, CHCl3)]; IR (neat) 3250 (C≡CH), 2127 
(C≡C), 1748 (C=O, ester), 1697 (C=O, carbamate); 
1
H NMR δ (400 MHz, CDCl3) 
4.72-4.46 (2H, m, HC≡CCH2), 4.28-4.18 (0.38H, m, CHNBoc), 4.18-4.07 (0.62H, 
m, CHNBoc), 3.52-3.16 (2H, m, CH2NBoc) 2.42 (0.62H, t, J = 2.4, CH2C≡CH), 
2.40 (0.38H, t, J = 2.3, CH2C≡CH), 2.24-1.63 (4H, m, CH2CH2CH2Ar), 1.33 
(3.42H, s, OC(CH3)3), 1.29 (5.58H, s, OC(CH3)3); 
13
C NMR δ (125.8 MHz, CDCl3) 
major rotamer (62%), 172.4 (C=O), 153.7 (C=O), 80.0 (C), 77.4 (C), 75.2 (CH), 
58.9 (CH), 52.2 (CH2), 46.3 (CH2), 30.8 (CH2), 28.3 (3 × CH3), 23.6 (CH2), minor 
rotamer (38%), 172.1 (C=O), 154.4 (C=O), 79.9 (C), 77.4 (C), 75.0 (CH), 58.6 
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Boc-L-Prolinamide 185 (2.95 g, 14.0 mmol) was dissolved in dry THF (18 cm
3
), 
then Lawesson’s reagent (2.87 g, 7.00 mmol) was added portionwise. The reaction 
mixture was stirred at room temperature under argon for 3.5 h. The solvent was 
removed under reduced pressure, and column chromatography (DCM:MeOH, 20:1), 
afforded 186 as an off-white solid.(3.01 g, 95%). 
 
Rf (DCM:MeOH, 20:1) = 0.37; mp 190-193 °C, (lit.
130
 192-193 ºC); [α]D = -99.4 (c 
0.90, CHCl3), [lit.
162
 [α]D −103.4 (c 1.0, CHCl3)]; IR (neat) 1672 (C=O, carbamate), 
1167 (C=S); 
1
H NMR 7.71 (2H, br s, NH2), 4.66-4.63 (1H, CHN), 3.48 (2H, br s, 
CH2N), 2.20 (2H, br s,, CH2CHN), 1.87 (2H, m, CH2CH2N), 1.45 (9H, s, 
OC(CH3)3); 
13
C NMR δ (100.6 MHz, CDCl3), 194.3 (C=S), 155.7 (C=O), 80.7 (C), 
62.0 (CH), 47.2 (CH2), 33.4 (CH2), 28.4 (3 × CH3), 24.5 (CH2); m/z (ESI+, MeOH) 
253 ([M+Na]
+
, 100%), 667 (37), 639 (42), 413 (28). 
 






Ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)thiazole-4-carboxylate (187) 
 
 
Thioamide 186 (1.79 g, 7.78 mmol) and NaHCO3 (5.23 g, 62.2 mmol) were 
suspended in DME (40 cm
3
) and stirred at room temperature for 10 minutes. Ethyl 
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, 23.3 mmol) was added dropwise, and the reaction 
mixture stirred at room temperature for 30 minutes before cooling to 0 ºC (ice bath). 
A solution of trifluoroacetic anhydride (4.33 cm
3
, 31.1 mmol) and 2,6-lutidine (7.70 
cm
3
, 66.1 mmol) was added dropwise over 10 minutes. The reaction was stirred at 0 
ºC for 30 minutes, before the solvent was removed under reduced pressure. The 
reaction mixture was partitioned between chloroform (40 cm
3
) and HCl (1 N, 40 
cm
3
). The organic layer was dried (MgSO4), and the solvent removed under reduced 
pressure. The resultant oil was purified by column chromatography (Hexane:EtOAc 
10:1 to 2:1), affording 187 as a yellow solid (1.82 g, 72%). 
 
Rf (DCM:MeOH, 10:1) = 0.70; mp 110-111 °C (lit.
163
 102-104 ºC); [α]D = -78.8 (c 
1.32, DMF), [lit.
163
 [α]D −96.7 (c 0.85, DMF)]; IR (neat) 1734 (C=O, ester), 1699 
(C=O, carbamate); 
1
H NMR δ (400 MHz, CDCl3) 8.06 (1H, s, C=CHS), 5.20 (1H, 
br s, CHN), 4.42 (2H, dd, J = 13.8, 6.7, CH3CH2), 3.66-3.44 (2H, m, CH2N), 2.40-
2.20 (2H, m, CH2CH2N), 1.96-1.85 (2H, m, CH2CHN), 1.40 (3H, t, J = 7.0, 
CH2CH3), 1.31 (9H, s, OC(CH3)3); 
13
C NMR δ (100.6 MHz, CDCl3), 176.4 (C=N), 
160.7 (C=O), 153.6 (C=O), 146.5 (C), 126.3 (CH), 79.8 (CH), 60.7 (CH), 59.0 
(CH2), 46.2 (CH2), 33.7 (CH2), 27.7 (3 × CH3), 22.6 (CH2), 13.8 (CH3); m/z (ESI+, 
MeOH) 349 ([M+Na]
+
, 100%), 675 (23). 
 






Ethyl (S)-2-(pyrrolidin-2-yl)thiazole-4-carboxylate (188) 
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Using General Procedure D, Boc protected amine 187 (2.41 g, 7.38 mmol) was 
reacted with TFA (5.65 cm
3
, 73.8 mmol) in DCM (10 cm
3
). The resultant oil was 
purified by column chromatography methyl amine 188 as a yellow oil (1.25 g, 
98%). 
 
Rf (DCM:MeOH, 10:1) = 0.00; mp 167-169 ºC, (lit
163
 169-171 ºC); [α]D = -15.0 (c 
1.61, DMF), [lit.
163
 [α]D –21.2 (c 1.02, DMF)]; IR (neat) 3523 (NH), 1729 (C=O, 
ester); 
1
H NMR δ (400 MHz, CDCl3) 8.08 (1H, s, C=CHS), 5.20 (1H, br s, CHN), 
4.42 (2H, dd, J = 13.8, 6.7, CH3CH2), 3.63-3.44 (2H, m, CH2N), 2.40-2.22 (2H, m, 
CH2CH2N), 1.96-1.85 (2H, m, CH2CHN), 1.40 (3H, t, J = 7.0, CH2CH3); 
13
C NMR 
δ (100.6 MHz, CDCl3), 176.2 (C=N), 160.7 (C=O), 146.5 (C), 126.3 (CH), 79.8 
(CH), 60.7 (CH), 59.0 (CH2), 46.6 (CH2), 33.7 (CH2), 22.4 (CH2), 13.8 (CH3); m/z 
(ESI+, MeOH) 227 ([M+H]
+
, 100%), 908 (13), 293 (23), 249 (22), 239 (23). 
 










Using General Procedure F, ethyl ester  188 (1.71 g, 7.56 mmol) was reacted with 
NaOH (0.363 g, 9.07 mmol) in H2O (3 cm
3
) and MeOH (3 cm
3
). The resultant solid 
was carboxylic acid 189, a colourless solid (1.34 g, 89%). 
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Rf (DCM:MeOH, 10:1) = 0.00; mp 250-253 °C, (lit.
163
 255-256 ºC); [α]D = -18.8 (c 
1.03, MeOH), [lit.
163
 [α]D -19.3 (c1.08, MeOH)]; IR (neat); 1681 (C=O, acid)
  1
H 
NMR δ (400 MHz, D2O, pD 14) 8.08 (1H, s, C=CHS), 5.18 (1H, br s, CHN), 3.66-
3.47 (2H, m, CH2N), 2.40-2.22 (2H, m, CH2CH2N), 1.96-1.85 (2H, m, CH2CHN); 
13
C NMR δ (100.6 MHz, D2O, pD 14) 176.2 (C=N), 167.7 (C=O), 146.5 (C), 126.3 
(CH), 79.8 (CH), 60.7 (CH), 46.6 (CH2), 33.7 (CH2), 22.4 (CH2); m/z (ESI+, 
MeOH) 221 ([M+Na]
+
, 41%), 1482 (100), 649 (32), 639 (28), 451 (64), 301 (34), 
243 (95). 
 











Using General Procedure G, secondary amine 189 (2.16 g, 12.0 mmol) was 
reacted with FmocOSu (4.06 g, 12.0 mmol) and Na2CO3 (3.83 g, 36.1 mmol) in 
DMF (10 cm
3
) and MeOH (50 cm
3
). The resultant yellow gum, crude Fmoc 
protected methyl amine 150, was purified by column chromatography to obtain a 
colourless solid (1.25 g, 98%). 
 
Rf (DCM:MeOH, 10:1) = 0.00; [α]D = -12.7 (c 1.13, MeOH); IR (neat); 1661 (C=O, 
acid)
  1
H NMR δ (400 MHz, CDCl3) 12.9 (1H, br s, COOH), 8.08 (1H, s, C=CHS), 
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5.18 (1H, br s, CHN), 3.66-3.47 (2H, m, CH2N), 2.40-2.22 (2H, m, CH2CH2N), 
1.96-1.85 (2H, m, CH2CHN); 
13
C NMR δ (100.6 MHz, CDCl3) 176.8 (C=N), 161.2 
(C=O), 157.4 (C=O), 149.0 (C), 144.8 (2 × C), 139.4 (2 × C), 132.3 (C), 128.9 (2 × 
CH), 127.5 (2 × CH), 124.0 (2 × CH), 122.9 (2 × CH), 67.4 (CH2), 52.5 (CH), 48.1 
(CH), 47.1 (CH2), 33.7 (CH2), 25.2 (CH2); m/z (ESI+, MeOH) 349 ([M+Na]
+
, 
100%), 675 (23). 
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PBS (Phosphate buffered saline) solution was made up with 100 PBS tablets in 
distilled H2O (1 L). The PBS solution was stored at room temperature. 
 
PBS-T solution was made up of PBS solution with 0.1% tween-20. PBS-T was 
stored at room temperature. 
 
3% BSA (bovine serum albumin) was made up of BSA (3 g), TBS-tween (99 cm
3
), 
β-glycerophosphate (1 M, 1 cm
3
). It could be stored at 4°C for 3 weeks. 
 
ECL solution 1 was made up of luminol (250 mM, 1 cm
3
) with p-coumaric acid (90 
µM, 440 cm
3
, Tris pH 8.5 (1 M, 10 cm
3
), and made up to 100 cm
3
 with distilled H2O. 
The solution was stored at 4°C,wrapped in foil. 
 
ECL solution 2 30% H2O2 (64 µL), Tris pH 8.5 (1 M, 10 cm
3
), was made up to 100 
cm
3





ELISA with purified AG-2. 
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Each well on a multi-well plate was coated with streptavidin (20 µg mL
-1
) by 
incubation at 37ºC overnight. Wells were then each washed with PBS-T (4 x 200 
µL). Two columns of wells were then incubated with each of the four different 
biotinylated peptides, negative control, positive control BiotinSGSGPTTIYY (30), 
BiotinSGSGPTTIYX (31) and BiotinSGSGPTTIXY (32) (5 µg in 50 µL DMSO) for 
1 h at room temperature, to create duplicate results for each column.  Wells were 
then each washed with PBS-T (6 x 200 µL), before blocking by 1 h incubation with 
3% BSA in PBS-T (200 µL per well). Excess BSA was removed, then wells were 
incubated for a further 1 h at room temperature with purified AG-2 protein at a range 
of concentrations in 3% BSA in PBS-T (50 µL). The relative concentrations used 
were 1, 1/2, 1/4, 1/8, 1/16, 1/32, 1/64 and 0, where 1 = 2.5 mg AG-2 in 1 mL 3% 
BSA in PBS-T, and 0 was 3% BSA in PBS-T. 
After washing all wells with PBS-T (6 x 200 µL), they were incubated for 1 h at 
room temperature with primary antibody α-AG-2 K47 rabbit poly (50 µL, 1:1000 
dilution in 3% BSA in PBS-T). The wells were again washed with PBS-T (6 x 200 
µL) before 1 h incubation at room temperature with the secondary antibody swine 
anti-rabbit (50 µL, 1:1000 dilution in 3% BSA in PBS-T). The wells were washed a 
final time with PBS-T (6 x 200 µL), ECL (50 µL) was added, and the relative 
luminescence measured by a Finstruments Micro-plate reader using Fluoroscan 
Ascent software, giving a relative luminescence value for each well. 
 
 
ELISA with cell lysate. 
 
Each well on a multi-well plate was coated with streptavidin (20 µg mL
-1
) by 
incubation at 37ºC overnight. Wells were then each washed with PBS-T (4 x 200 
µL). Two columns of wells were then incubated with each of the four different 
biotinylated peptides, negative control, positive control BiotinSGSGPTTIYY (30), 
BiotinSGSGPTTIYX (31) and BiotinSGSGPTTIXY (32) (5 µg in 50 µL DMSO) for 
1 h at room temperature, to create duplicate results for each column.  Wells were 
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then each washed with PBS-T (6 x 200 µL), before blocking by 1 h incubation with 
3% BSA in PBS-T (200 µL per well). Excess BSA was removed, then wells were 
incubated for a further hour at room temperature with MCF-7 cell lysate at a range of 
concentrations in 3% BSA in PBS-T (50 µL). The relative concentrations used were 
1, 1/2, 1/4, 1/8, 1/16, 1/32, 1/64 and 0, where 1 = 2.5 mg AG-2 in 1 mL 3% BSA in 
PBS-T, and 0 was 3% BSA in PBS-T. 
After washing all wells with PBS-T (6 x 200 µL), they were incubated for 1 h at 
room temperature with primary antibody α-AG-2 K47 rabbit poly (50 µL, 1:1000 
dilution in 3% BSA in PBS-T). The wells were again washed with PBS-T (6 x 200 
µL) before 1 h incubation at room temperature with the secondary antibody swine 
anti-rabbit (50 µL, 1:1000 dilution in 3% BSA in PBS-T). The wells were washed a 
final time with PBS-T (6 x 200 µL), ECL (50 µL) was added, and the relative 
luminescence measured by a Finstruments Micro-plate reader using Fluoroscan 
Ascent software, giving a relative luminescence value for each well. 
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Appendix 3: Results of ELISA for Peptide Binding to 
AG-2 
 
An ELISA was run of 4 peptides measuring their relative binding to purified AG-2. 




Column 1: Negative control. A random peptide used to measure non-specific binding 
to AG-2. 
Column 2: Duplicate of column 1. 
 
Column 3: Positive control. Commercially supplied BiotinSGSGPTTIYY (30). 
Column 4: Duplicate of column 3. 
 
Column 5: Synthetic Propargylated Peptide. BiotinSGSGPTTIYX (31). 
Column 6: Duplicate of column 5. 
 
Column 7: Synthetic Propargylated Peptide. BiotinSGSGPTTIXY (32). 
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Readout from the “Plate reader” machine, using Fluoroscan Ascent software. 
 
  Conc. 1 (-) 2 (-) 3 (30) 4 (30) 5 (31) 6 (31) 7 (32) 8 (32) 
A 1 9.5 8.8 32.3 32.7 20.0 18.7 32.0 30.9 
B   1/2  3.6 3.6 24.2 26.1 12.3 10.0 21.7 22.7 
C   1/4  1.2 1.8 16.5 17.2 6.6 5.2 17.4 18.1 
D   1/8  0.5 0.6 6.2 6.3 2.0 1.4 6.7 7.7 
E   1/16 0.4 0.5 2.5 2.2 0.5 0.6 2.7 3.8 
F   1/32 0.3 0.4 0.6 0.6 0.4 0.5 1.0 1.1 
G   1/64 0.3 0.3 0.4 0.4 0.3 0.4 0.6 0.8 
H 0 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.6 
 
Average reading over 2 duplicate runs 
 
  Conc. (-) (+) 159 163 
A 1 9.1 32.5 19.4 31.5 
B   1/2  3.6 25.1 11.1 22.2 
C   1/4  1.5 16.9 5.9 17.8 
D   1/8  0.6 6.2 1.7 7.2 
E   1/16 0.5 2.4 0.6 3.3 
F   1/32 0.4 0.5 0.4 1.1 
G   1/64 0.3 0.4 0.4 0.7 
H 0 0.3 0.4 0.3 0.5 
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Appendix 4: Results of ELISA for Peptide Binding to 
AG-2 in MCF-7 Breast Cancer Cell Lysate 
 
An ELISA was run of 4 peptides measuring their relative binding to AG-2 within 
MCF-7 breast cancer cell lysate. Samples were run in duplicate, and averages taken 




Column 1: Negative control. A random peptide used to measure non-specific binding 
to components present in MCF-7 cell lysate. 
Column 2: Duplicate of column 1. 
 
Column 3: Positive control. Commercially supplied BiotinSGSGPTTIYY (30). 
Column 4: Duplicate of column 3. 
 
Column 5: Synthetic Propargylated Peptide. BiotinSGSGPTTIYX (31). 
Column 6: Duplicate of column 5. 
 
Column 7: Synthetic Propargylated Peptide. BiotinSGSGPTTIXY (32). 
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Readout from the “Plate reader” machine, using Fluoroscan Ascent software. 
 
Average reading over 2 duplicate runs: 
 
  Conc. 1 (-) 2 (+) 3 (159) 4 (163) 
A 1       0.061 5.029 0.041 3.759 
B   1/2  0.039 1.266 0.214 1.325 
C   1/4  0.028 0.188 0.025 0.528 
D   1/8  0.030 0.027 0.024 0.024 
E   1/16 0.037 0.028 0.026 0.037 
F   1/32 0.041 0.027 0.024 0.020 
G   1/64 0.038 0.024 0.024 0.022 
H 0       0.031 0.019 0.020 0.015 
 









0 0.2 0.4 0.6 0.8 1 1.2
Relatie Concentration
A
G
-2
 B
in
d
in
g
 (
R
L
U
)
 
